Cervical cancer in Saudi Arabia : trends and regional disparities in incidence and survival by Alkhalawi, E
LSHTM Research Online
Alkhalawi, E; (2021) Cervical cancer in Saudi Arabia : trends and regional disparities in in-





Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
                         
 
Cervical cancer in Saudi Arabia: trends and 
regional disparities in incidence and survival 
 
Dr Eman Alkhalawi, MBBS, MSc 
 
Thesis submitted in accordance with the requirements for the degree of 
Doctor of Philosophy of the 




Department of Non-communicable Disease Epidemiology 
Faculty of Epidemiology and Population Health 
London School of Hygiene and Tropical Medicine 
 
Funded by the Ministry of Education, Saudi Arabia 






I, Eman Alkhalawi, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in 
the thesis.  
Signed:  










 Acknowledgment  
 
First and foremost, I would like to thank my supervisors, Professor Michel Coleman, for 
his tireless dedication and generosity, and Dr. Claudia Allemani, for her guidance, 
encouragement, and support throughout. They have taught me so much beyond the 
science, including the value of kindness and collaboration. 
I would also like to thank my advisory panel, Dr. Mary McCormack for her valuable insight 
as a gynaecology oncologist; and Dr. Ali Al-Zahrani, the director of the Gulf Center for 
Cancer Control and Prevention, for paving the way to this work through years of 
commitment to ensure data access and improve data quality, for his responsiveness to my 
questions, the hours of discussion he has given of his time and support that has gone 
beyond this thesis, opening many doors for me. 
Through this project, I have had the honour to meet some wonderful people: Ms Amal Al-
Madouj, Clinical Research Coordinator at the Gulf Center for Cancer Control and 
Prevention, who’s energy and dedication have been inspiring; Dr. Hind Al-Mutlag, Director 
of the Saudi Health Registries and Ms Wafa Al-Zahrani, who have warmly welcomed me, 
tolerated and accommodated my constant, sometimes strange requests, and whose 
persistence had enabled me to acquire follow-up data. I am also grateful to tumour 
registrars and registry staff, without whom this work would not have been possible; and in 
particular, Sameer Alkaifah, Mohammad Haydar, Zeyad Alshhrani and Ahmed Alrawaji, 
for taking time to answer my questions despite their busy work schedules. 
A special thank you to Dr. Edmund Njeru Njagi, who has very generously helped me with 
the multiple imputation, and to the CONCORD team and other colleagues, who have been 
very helpful and shared their insight and expertise, and last but not least to my fellow PhD 
students and friends, who have been one of the greatest sources of support, and with 







In many countries, recent improvements in cervical cancer survival have mostly been 
modest. However, survival needs to be interpreted in the context of incidence and mortality 
in order to assess progress in cancer control. Further, survival by stage could help 
distinguish whether lower-than-expected survival is due to late-stage diagnosis or sub-
optimal management, and to inform health policy. 
Data on all women diagnosed with invasive cervical cancer during 2005-2016 were 
obtained from the Saudi Cancer Registry. Vital status and date of death if dead were 
ascertained by linking the registry records to vital registration data in the Ministry of Interior. 
Population counts by calendar year, sex, 5-year age group, region and nationality were 
obtained from the General Authority for statistics.  
Age-standardised incidence rates were calculated for women diagnosed during 2005-
2010 and 2011-2016. Age-standardised five-year net survival probabilities were estimated 
for the same periods by region and stage at diagnosis, and by region stratified by stage.  
Incidence rates were lower than in most countries, and changed very little between 2005-
2010 and 2011-2016 (1.66 to 1.76 per 100,000 women per year). Incidence was higher 
among non-Saudi than Saudi women, and in the three most populous regions. 
Age-standardised 5-year net survival did not change in Saudi Arabia between 2005-2010 
(59.2; 95%CI 52.7-65.7) and 2011-2016 (59.7; 54.7-64.6), or in any of the regions, except 
in Makkah, where there was a 19% increase in survival for women diagnosed during 2011-
2016 compared to 2005-2010. Survival for women diagnosed at a distant stage was 
substantially lower in the Eastern Region than in other regions. 
Cervical cancer incidence and survival have remained largely unchanged. Despite very 
low incidence in Saudi Arabia, it is difficult to predict the future burden of cervical cancer. 
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Chapter 1. Introduction 
1.1 Global burden of cervical cancer  
Cervical cancer is the seventh most common tumour in women, with an estimated 601,200 
women newly diagnosed in 2017 and 259,700 women dying of the disease in that year1,2 
It accounts for about 3% of all cancer deaths in women. Age-standardised incidence rates 
(ASIR) range from 4.1 per 100,000 per year in Western Asia to over 40 in Southern and 
Eastern Africa.3 Global variation in the estimates of age-standardised five-year net survival 
from cervical cancer is wide, from less than 40% in some African countries to over 70% in 
Northern Europe for women diagnosed during 2010-2014.4 Consequentially, age-
standardised mortality rates (ASMR) from cervical cancer vary largely across the world, 
ranging from less than 2 per 100,000 per year in North America, Australia and New 
Zealand to 30 per 100,000 per year in Eastern Africa.3  
1.2 Rationale 
Although relatively uncommon in Saudi Arabia and the Middle East in general, future 
projections of cervical cancer incidence are difficult to make because of lack of reliable 
data on past incidence trends and changes in lifestyle, most important being sexual 
behaviour. Based on current estimates of population growth and ageing and assuming 
that current incidence rates will remain constant, the number of cases in the Middle East 
and North Africa are expected to double from 2008 to 2030.5  
Cervical cancer is one of the few cancers with a single predominant cause, namely 
persistent infection with one of several high-risk types of human papillomavirus (HPV).6 
This offers a clear target for preventive public health interventions. Screening methods are 
readily available, affordable and non-invasive. There is a consensus that the majority of 
cervical cancer deaths are preventable,7 leading the WHO Director-General in 2018 to call 
for coordinated action globally to eliminate cervical cancer.8 Following this aim, the WHO 
launched in November 2020 the global strategy to accelerate the elimination of cervical 
cancer as a public health problem, which was defined as achieving an incidence rate of 
less than 4 per 100,000 women per year globally. An interim target was set to be achieved 
by 2030 and sustained thereafter: to fully vaccinate 90% of girls by age 15, to screen 70% 




treat 90% of women with identified cervical pre-cancer and 90% of women with invasive 
cervical cancer.9 
5-year survival for women diagnosed with cervical cancer between 1995 and 2004 in Saudi 
Arabia has been reported in the CONCORD-2 study.10 More detailed analysis by tumour 
stage is important for interpretation of survival data, which is crucial to stimulate change in 
healthcare policy. Moreover, no research has yet been done to identify regional disparities 
in cancer outcomes in Saudi Arabia. Healthcare in Saudi Arabia is provided free of charge 
by different government sectors, but the concentration of oncologists and modern 
treatment facilities in major cities may pose a challenge to equitable access to 
treatment.11,12 
Regional variation and time trends in incidence would provide information about cervical 
cancer risk factors and preventive strategies, while survival and mortality are outcome 
measures that would enable assessment of the effectiveness of the healthcare system in 
treatment and control, reflecting both availability of early diagnosis, thorough investigation 
and effective treatment.13 That said, mortality has a direct relationship with incidence and 
it is a simple rate defined by the number of deaths due to a given cause during a calendar 
year divided by the mid-year population. Survival uses only cases as the denominator and 
is a better reflection of both access to early diagnosis and post-diagnostic management. 
It is important to report all three metrics when describing the burden of cancer.14 Survival 
should be interpreted together with incidence and mortality when assessing progress in 
cancer control.15 Examination of trends in incidence and survival by stage at diagnosis will 
help to determine both the effectiveness of diagnostic activity and the availability and 
efficacy of stage-appropriate treatment.  
1.3 Aim 
To provide up-to-date and detailed incidence, mortality and survival estimates for cervical 
cancer in Saudi Arabia.  
1.4 Objectives 
• To describe trends in incidence and mortality rates, and survival probability, for women 
diagnosed with cervical cancer in Saudi Arabia from 2005 to 2016. 




• To explore regional differences in cervical cancer incidence rates and 5-year net-
survival in Saudi Arabia. 
• To examine whether any regional discrepancies in survival are due to differences in the 




Chapter 2. Cervical Cancer 
2.1 Anatomy of the uterine cervix 
Figure 1: Anatomy of the uterine cervix 
 
 
The cervix is the lower part of the uterus and is a canal leading to the vagina. Its upper 
and lower limits are referred to as the internal and external os, respectively (Figure 1). The 
external os separates the inner part (endocervix), lined by a single layer of glandular 
columnar epithelium, from the outer part (ectocervix), which is covered with non-
keratinizing squamous epithelium. The external os and the ectocervix can be directly 
visualized on vaginal examination with a speculum. The boundary between the two 
epithelia is referred to as the squamo-columnar junction (SCJ). It is located at birth and in 
pre-pubertal girls at or close to the external os but migrates outwards during reproductive 
years to different extents under the effect of various factors, the most important being age 
and hormonal status. The boundary recedes into the endocervix in post-menopausal 
women. Through exposure to the acidic vaginal environment, the columnar epithelium 
undergoes a physiological transformation to squamous epithelium, giving rise to a new 
SCJ where the squamous tissue meets the columnar epithelium. This area between the 
original and the new location of the SCJ and where the columnar epithelium is replaced 
by squamous epithelium is defined as the transformation zone. The squamous cells in the 
transformation zone are susceptible to HPV infection, therefore 90% of cervical cancers 
are squamous cell carcinomas arising from the transformation zone and the remaining 
10% are adenocarcinomas arising from the glandular columnar tissue of the endocervix.7 
Drake, R. L., Vogl, W., & Mitchell, A. W. M. (2012). 





2.2 The role of Human Papillomavirus (HPV) in the development of cervical 
cancer 
Over 170 HPV types have been identified. These are categorised into the alpha and beta 
genus; the alpha genus is further divided into cutaneous and mucosal types. Of the latter, 
epidemiological studies have found 18 types to be associated with cervical cancer (16, 18, 
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82). These are now designated 
high-risk types. HPV16 and HPV18 alone are respectively responsible for an estimated 
50% and 20% of cervical cancers globally.16,17 
There is convincing evidence that HPV infection is not only the strongest risk factor, but is 
in fact a prerequisite for the development of the vast majority of cervical cancer.6,17-19 A 
very strong association is observed between HPV prevalence and the incidence of cervical 
cancer in a particular geographic area.18 In the International Agency for Research on 
Cancer (IARC) survey on prevalence of HPV DNA in invasive cervical cancer, retesting 
HPV-negative cervical cancer specimens with more sensitive methods, while excluding 
histologically inadequate samples, concluded that virtually all samples (99.7%) were 
positive for HPV DNA, in comparison to the initially reported 93% HPV positivity.6,19 This 
was also confirmed in a case-control study in which HPV DNA was detected in 96.6% of 
squamous-cell cervical carcinoma specimens versus 15.6% of controls, yielding the 
extraordinarily high pooled odds ratio (OR) of 158 (95%CI 113-221) for the presence of 
HPV DNA in cases versus controls.17 The small proportion of HPV negative cervical cancer 
has been explained by sample inadequacy and lower sensitivity of methods used (false 
negative), loss of HPV expression, or true HPV independent pathways to the development 
of cervical cancer.20 These HPV-negative tumours tend to be mainly adenocarcinomas of 
gastric or endometroid type and are often diagnosed at later stage and have higher 
metastatic potential.21 
HPV is by far not a sufficient cause for the development of cancer as most infections with 
carcinogenic types are transient and do not progress to cancer.18,22 Different studies have 




2.3 Risk factors for development of Cervical Intraepithelial Neoplasia (CIN) and 
natural history of their progression to cervical cancer  
Persistent infection with high-risk HPV types is the major factor in the development of pre-
cancerous lesions of the cervix. Several viral and host factors that contribute to HPV 
infection and persistence, the development of malignancy, or both, have been identified. 
The number of sexual partners of the woman or her male partner, age at first intercourse 
and co-infection with other sexually transmitted diseases increase risk of infection. While 
immune impairment and HPV type play a role in viral persistence and progression to 
malignancy (HPV16 having the highest risk of persistence). Cigarette smoking, oral 
contraceptive use, parity and lower socioeconomic status have also been associated with 
an increased risk of cervical cancer probably though various pathways.24 The latency from 
carcinogenic HPV infection to development of precancerous lesions is estimated to be 
between 7 and 10 years.25  
The cervical intraepithelial neoplasia (CIN) classification system is based on histological 
diagnosis and takes the natural history of lesions into account. CIN1 describes mild 
dysplasia with koilocytosis (characteristic cellular changes including nuclear enlargement, 
irregular nuclear membranes and perinuclear vacuoles), CIN2 describes moderate 
dysplasia and CIN3 includes severe dysplasia and carcinoma in situ.7 The IARC working 
group on evaluation of carcinogenic risk of human papillomaviruses to humans considers 
CIN3 a surrogate for pre-cancer and CIN2 as a buffer zone.25 Strictly speaking, pre-cancer 
is an intraepithelial lesion destined to progress to invasive cancer. However, non-
oncogenic HPV types can also produce a microscopic picture of CIN2 which is not at risk 
of progression.7 
For screening purposes, however, the WHO Bethesda cytological classification combines 
CIN2 and CIN3 into the broader grouping of high-grade squamous intraepithelial lesions 
(HSIL). This is due to the fact that it is not possible to differentiate the two based on 
cytology alone. Histological evaluation involves taking a tissue biopsy, preferably 
colposcopy-guided, by a trained expert. It is more invasive, and the equipment is not 
frequently available at the primary care level. In the Bethesda classification, CIN1 is 
categorised as low-grade squamous intra-epithelial lesion (LSIL) and the terms atypical 
squamous cells of undetermined significance (ASCUS) and atypical squamous cells in 
which a high-grade squamous intraepithelial lesion cannot be excluded (ASC-H) are 




The majority of CIN2 lesions are transient; only a few progress to CIN3. Although many 
CIN3 lesions also regress, they are considered pre-cancerous and have a much higher 
risk of progression to carcinoma in situ and to a lesser degree, invasive cancer.25 In a 
pooled analysis, the average probabilities of regression of CIN1, 2 and 3 were 57%, 43% 
and 32%, respectively. On the other hand, only 1%, 5% and 12% progressed to invasive 
cancer, respectively.27  
2.4 Screening and treatment guidelines for precancerous lesions 
Screening guidelines vary between countries and resource settings. The WHO 
recommends screening at least once for every woman between 30 and 49 years using 
HPV testing, cytology-based screening (Pap smear or liquid-based cytology) or visual 
inspection of the SCJ after applying acetic acid (VIA).7 The choice of screening method 
depends on available equipment and financial and human resources. Where women are 
unlikely to return for colposcopy, a “screen and treat” approach using VIA and immediate 
treatment of suspicious lesions may be the most appropriate. Cytology-based screening 
has been the mainstay of screening for decades. It is a multi-step process involving sample 
collection, transport to the laboratory, cytological evaluation by pathologists, reporting 
results to healthcare providers and re-call of women with positive results for diagnosis and 
management. HPV testing is becoming more available and less expensive, and offers 
higher sensitivity, especially in settings where there is lack of trained healthcare providers 
and pathologists. Self-collection is also possible, which may be more convenient for both 
women and healthcare providers. In low-risk settings, HPV-testing could be used to reduce 
the number of cytological examinations, allowing them to be analysed centrally by more 
experienced pathologists, leading to improved performance of cytology.28 Diagnostic tests 
include biopsy with or without colposcopy, which provides a magnified view of the cervix; 
or endocervical curettage. They are helpful to confirm and determine the extent of disease, 
but are not always available or appropriate, and should not be used if they are likely to 
cause loss to follow-up or to delay treatment.  
The guidelines published by the Saudi Ministry of Health (MOH) in April 2014 recommend 
universal screening of women, starting three years after marriage up to 65 years of age, 
using HPV testing or cytology, followed by colposcopy and biopsy of positive results.29 The 




Treatment of CIN2 or higher lesions (CIN2+) aims to destroy or remove the abnormal 
tissue. Options consist of cryotherapy, which involves freezing the abnormal areas, Loop 
electrosurgical excision procedure (LEEP), which uses an electrically powered wire to cut 
and coagulate the lesion and the entire transformation zone, or cold knife conisation 
(CKC), involving the surgical removal of a cone-shaped portion of the endo- and ectocervix 
under spinal or general anaesthesia. The choice depends on provider training, availability 
of electricity and anaesthesia, and the need to treat during the screening visit (“screen and 
treat” approach). If cancer is suspected, the woman should not be treated with any of these 
methods, but should have a biopsy taken to confirm or rule out the diagnosis.7 
The Saudi MOH guidelines recommend cryotherapy to treat CIN2+. These guidelines aim 
to reduce variability in clinical practice across the country and to reduce health inequities, 
taking the quality of available evidence as well as acceptability to key stakeholders 
(women, clinicians and policymakers) into account.29 
2.5 Clinical features, diagnosis, staging and treatment of invasive cervical cancer 
Cervical cancer is often asymptomatic in its early stages. Vaginal discharge and post-
menopausal, post-coital or intermenstrual bleeding are the most common first symptoms. 
These might be ignored, especially if the discharge or bleeding is limited, until symptoms 
of more advanced disease manifest as the tumour invades locally (pain, haematuria, 
incontinence, constipation), spreads to lymph nodes (lower limb oedema or flank pain due 
to hydronephrosis) or causes weight loss, fatigue, and various metastatic symptoms.  
Apart from Pap smear-detected disease, diagnosis may take place when visible 
abnormality is seen on examination of an asymptomatic woman attending screening or 
other gynaecological examination. More commonly, women will present with symptoms 
suggestive of cervical cancer. This is also the case in developed countries with free 
healthcare, like the UK. In a retrospective study of 148 women diagnosed with cervical 
cancer over the 4-year period 2007-2010 at the University Hospitals of Leicester, 66.4% 
were already symptomatic at diagnosis. Of those, 37.2% had stage I disease, in contrast 
to 100% of women who were asymptomatic at diagnosis.30  
Following histopathological confirmation, the tumour stage is determined according to the 
International Federation of Gynaecology and Obstetrics (FIGO) classification (Table 1).31 
This is based on tumour size and the extent to which it has spread. Up until 2018, FIGO 




resource settings.32 Pathology and advanced imaging findings could be used to guid 
treatment but not for formal FIGO staging. The 2018 update allowed the incorporation of 
surgical pathological and advanced imaging techniques if available. Diagnosis of stage IA 
disease is made on pathological examination of excised lesions with negative margins. 
For visible lesions (IB and higher), a biopsy confirmation is followed with clinical 
assessment which provides information on tumour size, lymph node status, and local or 
systemic spread. This may include imaging (chest X-ray, ultrasound, CT, MRI or positron 




Table 1: Federation of Gynaecology and Obstetrics (FIGO) staging of cervical cancer (2018) 




Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a 
maximum depth of 5.0 mm measured from the base of the epithelium; vascular 
space involvement, venous or lymphatic, does not affect classification 
   IA1  Measured stromal invasion of≤3.0 mm in depth and ≤7.0 mm in horizontal 
spread 
   IA2  Measured stromal invasion of>3.0 mm and not >5.0 mm, with a horizontal 
spread of≤7.0 mm 
IB Clinically visible lesion confined to the cervix or microscopic lesion greater than 
IA2. 
  IB1  Clinically visible lesion <2.0 cm in greatest dimension 
  IB2  Clinically visible lesion ≥2 cm and <4.0 cm in greatest dimension 
 IB3 Clinically visible lesion ≥4 cm in greatest dimension 
Stage II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the 
lower third of the vagina 
IIA  Without parametrial invasion 
   IIA1  Clinically visible lesion ≤4.0 cm in greatest dimension 
   IIA2  Clinically visible lesion >4 cm in greatest dimension 
IIB  With parametrial invasion 
Stage III  The tumour extends to the pelvic wall and/or involves lower third of the vagina 
and/or causes hydronephrosis or non-functioning kidney 
IIIA  Tumour involves lower third of the vagina, with no extension to the pelvic wall 
IIIB  Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney 
IIIC Involvement of pelvic and/or para-aortic lymph nodes 
   IIIC1 Pelvic lymph node metastasis only 
   IIIC2 Para-aortic lymph node metastasis 
Stage IV  The carcinoma has extended beyond the true pelvis or has involved the mucosa 
of the bladder or rectum.  
IVA  Spread to adjacent organs 





The stage of the disease at diagnosis is the main determinant of treatment. Treatment 
options are also based on patient-related factors, including the woman’s general health 
status and her desire to preserve fertility, and the resources available. For microinvasive 
disease (FIGO stages IA1 and IA2), treatment consists of conisation or hysterectomy 
(abdominal, vaginal or laparoscopic) alone. Radical hysterectomy is reserved for stages 
IB1 and IIA1 (clinically visible lesions ≤4 cm in greatest dimension). Locally advanced and 
grossly invasive cervical cancer (stage IB2–IVA) is treated with platinum-based 
chemoradiation. Palliative chemotherapy or radiotherapy are usually used for distant 
metastatic disease (stage IVB), with some exceptions where curative treatment may be 
appropriate when distant metastasis is limited.33 
2.6 Role of screening and early diagnosis in cervical cancer prevention and 
survival 
Invasive cervical cancer is preceded by years of preclinical precursor changes, which if 
detected early, can be treated by relatively simple procedures.34 The primary aim of 
cervical cancer screening is to reduce the incidence of invasive cervical cancer by 
detection and removal of its precursors. A secondary aim is the early detection of cervical 
cancer that has already become invasive, in order to improve the prognosis and to reduce 
treatment cost and complications.7 Stage at diagnosis is the single most important 
predictor of cervical cancer survival. In a Swedish nationwide population-based cohort, 
both screen-detected cancers and symptomatic cancers that present within screening 
intervals had a more favourable survival than symptomatic cancer overdue for screening, 
and this was largely attributable to FIGO stage at diagnosis.35  
However, achieving high screening coverage may not always translate into improved 
survival on a population level when observing trends over time. High rates of detection 
and removal of slower growing pre-cancerous lesions could lead to the selective 
manifestation of more aggressive cancers, which has probably caused the plateau or even 
decline in survival seen in some countries with established screening programmes.36 
Nevertheless, countries with long-standing organised screening programmes have 




2.7 Role of the HPV vaccine  
Two vaccines targeting the most prevalent HPV types were initially approved by the FDA 
for girls and women 9 to 26 years of age. Gardasil (Merck & Co, Inc., approved in 2006), 
a quadrivalent vaccine covering HPV types 6, 11, 16 and 18; and Cervarix 
(GlaxoSmithKline, approved in 2009), targeting HPV types 16 and 18. In the FUTURE II 
phase 3 randomised double-blinded trial, the quadrivalent vaccine demonstrated 98% 
efficacy in preventing HPV types 16 and 18 related CIN2+ or adenocarcinoma in situ in 
HPV-naïve women 15-26 years of age, with none of the participants in the intervention 
arm developing CIN2+ compared to 28 who developed CIN2+ in the control arm of the 
trial.38 The efficacy of Cervarix was investigated in the PATRICIA trial, a double-blinded 
randomised controlled trial that included more than 18,000 women aged 15-25, which 
showed an efficacy of 92.9% in preventing CIN2+ lesions in HPV-naïve women. It also 
demonstrated some cross-protection against HPV types 31, 33, 45 and 52, and 58.39 Both 
trials had a mean follow-up time of about three years. 
More recently, a nonavalent HPV vaccine (Gardasil9; Merck Sharp & Dohme Corp., 
Whitehouse Station, New Jersey) targeting nine HPV types (6, 11, 16, 18, 31, 33, 45, 52 
and 58) gained FDA approval in December 2014 for females aged 9 to 26 years and males 
aged 9 to 15 years. In an international, double-blinded randomised trial, the nonavalent 
vaccine demonstrated 97.1% efficacy in preventing HPV 31, 33, 45, 52 and 58-related 
high-grade cervical disease (CIN2+) in HPV naïve women after five years of follow-up 
compared to the quadrivalent vaccine.40 
Early population-level data has also shown a significant reduction in the prevalence of 
HPV 16, 18, 31, 33, and 45 among vaccinated girls aged 13-19 and of CIN2+ among 
vaccinated girls aged 15-19 after 5-9 years of vaccination compared to pre-vaccination 
periods.41  
Since population-level vaccination of girls only started in 2008/2009, long-term 
effectiveness data for the prevention of invasive cervical cancer through HPV vaccination 
are just emerging. Up to 10-years of registry-based follow-up of women enrolled in the 
PATRICIA trial resulted in no invasive cervical cancer occurrence in the vaccinated cohort 
while 4 women developed cervical cancer in the control cohort.42 Similarly, 12-years of 
follow-up of the FUTURE II study participants, who have reached 30-37 years of age, 




developing HPV 16 or HPV 18-related CIN2+ in comparison to an expected baseline 
incidence rate of 0.287 per 100 person-years in an unvaccinated cohort, as estimated from 
historical registry data.43 A recent registry-based cohort study, which included over 1.6 
million girls and women living in Sweden, showed an age-adjusted incidence rate ratio of 
0.51 (95% 0.32-0.82) for invasive cervical cancer in vaccinated women compared to 
unvaccinated women. Adjusted for several socioeconomic and family characteristics, the 
incidence rate ratio for women who had been vaccinated before age 17 was 0.12 (95%CI 
0.00-0.34).44 A model-based analysis estimated that the bivalent and quadrivalent 
vaccines would reduce the number of invasive squamous cell carcinomas by 31.9% and 
30.5%, respectively, over 70 years; while the nonavalent vaccine would be expected to 
reduce them by a further 4.8% and 6.6%.45  
Based on available evidence, The WHO recommends universal vaccination of girls aged 
9-14. Many countries have also introduced HPV vaccination of boys with the aims of 






Chapter 3. Literature review 
The aim of the literature review was to identify any similar work that has been done and 
compile what is so far known about cervical cancer epidemiology in Saudi Arabia, and 
about regional differences in cervical cancer incidence, mortality and survival, including 
factors affecting those differences. Because a search for regional differences in cervical 
cancer incidence or mortality or survival in Saudi Arabia yielded no results in different 
databases, two separate search concepts were specified. The search was carried out 
using a combination of free text and subject headings adapted to each database. Where 
possible, language was restricted to English, Arabic and German. 82 Articles were 
included in the final literature review (Figure 2). 
Literature was updated on 23 Sept 2020 in the on EMBASE and MEDLINE databases, 
using the same search terms and restricting results to those published in 2018 onwards. 






1- (cervical OR cervix) AND (cancer OR carcinoma OR neoplasm) AND (Incidence OR 
occurrence OR mortality OR “death rate” OR survival) AND ((Region* or geographic*) AND 
(Disparit* or inequal* or difference*)) 
2- (cervical OR cervix) AND (cancer OR carcinoma OR neoplasm) AND (Incidence OR 
occurrence OR mortality OR “death rate” OR survival) AND "Saudi Arabia" 
Date of search: between 21/2/18 and 26/2/18  
Time frame/ database coverage: no limits. 
Records retrieved from databases: 
BASE =25 
Dissertations & Theses Global =14 
EMBASE =365 
Global Health =162 




Web of Science =400 
WHO Reproductive Health Library =3 




Reasons for full texts exclusion: 
Not reporting geographic disparities (for search 1) =58 
Irrelevant geographic division (based on indigenous population, ethnicity, hospital capabilities, 
or environmental risk factors) =8  
Recommendations, letters, reviews =24 
Repeated studies =2 
Regional differences in cancers with no separate reporting of cervical cancer =3 
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3.1 Cervical cancer incidence, survival and mortality trends and international 
disparities 
Both the incidence of, and mortality from cervical cancer have been declining in most 
countries since the mid-20th century. This decline is mostly attributed to the increased use 
of screening. Some countries in Europe have witnessed an up to-16 fold reduction in 
incidence compared to the pre-screening era, despite a background of changing sexual 
patterns and a cohort-wise increased incidence in younger women.3,47-49 Although some 
decline is seen in the world-wide age-standardised incidence and mortality rates of cervical 
cancer over the past three decades, there has been a 44% increase in the number of 
women diagnosed and a 38% increase in the number of deaths from the disease.50 This 
was equally attributed to both population growth and ageing.51 The decade between 2007 
and 2017 has seen a world-wide average decline of 11.3% in years lost due to disability 
(YLD) rate of cervical cancer, but the absolute number of YLDs has risen by 9.4%.52 
Similarly, there was an estimated 7.2% decline in the rate of years of life lost (YLL) 
worldwide due to cervical cancer but an 18.8% increase in the YLL. 
Not all countries have benefited equally from this decline in incidence and mortality. 
Cervical cancer is one of only three cancers where incidence showed an inverse 
relationship with a country’s Human Development Index (HDI).3,53 A clear increase in age-
adjusted disability-adjusted life years (DALYs) lost due to cervical cancer per 100,000 
population was seen with decreasing HDI among 184 countries.54 Low- and middle-
income countries (LMICs) have disproportionately high cervical cancer mortality rates in 
relation to their incidence, and 80% of cervical cancer deaths worldwide occur in LMICs.55 
The societal burden of cervical cancer is compounded by the relatively young age of its 
occurrence, with death at a young age being the overwhelming contributor to DALYs due 
to this disease.54 In 79% of 185 countries included in the Global Cancer Observatory 2018 
database, it ranked in the top three cancers affecting women younger than 45.3 
Large international variation in cervical cancer standardised incidence ratios (the ratio of 
the observed age-standardised incidence rate in the country to the expected age-
standardised incidence rate in a reference population, in this case the world incidence 
rate) exist, ranging from 13-570. But there is even greater variation in standardised 
mortality ratios, ranging from 16 to 804. It is the cancer with the largest variation in mortality 
between countries. This partially reflects risk factors prevalence but also stark inequalities 




Data from the US indicate that cancers of the uterine cervix and corpus were the only 
common cancers for which survival has remained largely unchanged since the early 
1970s, despite a clear reduction in cervical cancer incidence and mortality.56-58 In England, 
cervical cancer was the only one of six malignancies (oesophagus, stomach, colon, lung, 
breast, and cervix) for which no improvement in 1-year relative survival was observed 
during the period 1991-2006.59 On the other hand, age-adjusted 5-year relative survival in 
Germany showed a 4.7% improvement from 2002 to 2006.13  
International differences in cervical cancer survival remain wide. In about two-thirds of 
countries participating in CONCORD-3, 5-year net survival was between 50% and 70% 
for 2010-2014, while more extreme differences existed, ranging from 52% in Ecuador to 
80% in Iceland. For some African and South American countries, 5-year survival was less 
than 40%, but these estimates were less reliable.10 Although a modest increase in survival 
was seen over the 20 years 1995-2014 in some countries, the interpretation of such 
changes is complex given the potential of screening and early detection to change survival 
estimates in both directions. When cervical cancer is detected at an earlier stage, this 
could lead to more successful treatment and better survival, but also to an artificial 
increase in survival due to the diagnosis being brought forward in time in the absence of 
a true improvement in outcome (lead-time bias). On the other hand, survival may decrease 
when high screening coverage leads to the detection and removal of slower-growing 
precancerous and in situ lesions, leaving more aggressive interval tumours to be 
eventually diagnosed.36 
3.2 Within-country disparities in cervical cancer  
Disparities are seen on every level of the cervical cancer continuum, from risk factors 
exposure to screening, early diagnosis, incidence, survival and mortality. Various factors 
have been reported to influence these disparities. The focus of this literature review is on 
regional disparities, but there is a large body of literature showing socioeconomic and 
ethnic disparities; the three often overlap. 
Incidence of preventable cancers such as melanoma, lung and cervical cancer was higher 
in rural and remote areas of Australia, with the age-standardised incidence rate (ASIR) for 
cervical cancer being 20%, 35% and 26% higher in outer regional, remote and very remote 
areas, respectively, compared to urban areas.60 Cervical cancer was the only female 




Australia.61 Difference in the relative risk of death over five years in cancer patients 
diagnosed between 1992 and 1996 for the most remote (compared to more highly 
accessible) areas in New South Wales was highest for cervical cancer (crude RR=3.22; 
95%CI 1.54–6.75, adjusted for age, sex and stage: RR=2.25; 95%CI 1.06–4.77).62  
In an analysis including 1,594 women with cervical cancer from the New Zealand cancer 
registry, no association was found between rural residence and cervical cancer stage at 
diagnosis or hazard ratio (HR) of death due to cervical cancer during 1994-2005.63 Travel 
time and distance to the nearest general physician (GP) showed no association with ever 
being screened, while showing a statistically non-significant trend towards increased odds 
of later stage diagnosis and HR of cervical cancer mortality during the study period. 
Distance to the nearest cancer centre was not associated with any of the outcomes.64 
An urban excess of cervical cancer incidence has been observed in the Netherlands during 
1989-1991 (RR=1.69; 95%CI 1.47-1.94 in the highest versus lowest level of urbanicity) 
and in Ireland during 1995-2007 (RR=1.48; 95%CI 1.35–1.62 in urban versus rural areas 
after adjusting for socioeconomic status). Organised cervical cancer screening is well 
established in both countries with good access for both urban and rural residents, and 
differences were attributed to higher smoking in urban areas, differences in sexual 
patterns, or migration of people with cancer to urban centres to seek specialised treatment, 
although the latter is unlikely as this urban excess was not seen with many of the other 
cancers examined.65,66 In the period 1978-1982, higher cervical cancer ASIRs were seen 
in urban parts of Umbria region of Italy, while higher ASMRs were seen in rural parts, but 
these differences disappeared in 1998-2002.67 
In Belgium and the Netherlands in the mid-1980s to 1990s, death from cervical cancer 
was the only cause amongst avoidable causes of death showing no difference between 
districts, or where differences were considered fully attributable to differences in 
incidence.68,69 In Switzerland, cervical cancer mortality rates have dropped drastically over 
the 40 years from 1969 to 2010 in all age-groups, with no regional or rural-urban 
differences despite the country’s diverse culture and self-governing cantonal healthcare.70 
Higher mortality due to cervical cancer was seen in urban areas in Colombia after adjusting 
for age, region of residence, type of insurance and educational level. But the authors raise 




moving to urban centres for treatment. Incidence data were not reported, making the 
differences in mortality difficult to interpret.71 
Various studies from the USA showed higher incidence and mortality and poorer survival 
in rural and non-metropolitan areas. An ecological mediation analysis of SEER cervical 
cancer data from 612 counties (2009-2013) found a decrease in cervical cancer incidence 
rates as urbanicity increased. Socioeconomic status and primary care physician density 
were significant mediators, but the relationship remained significant after adjusting for 
them.72 Data from 1950 to 2008 showed a 15% higher cervical cancer incidence and 20% 
higher mortality in rural areas compared to metropolitan areas. Survival differences were 
as wide as those seen between countries (50.8% 5-year survival in black, rural population 
versus 71% in white metropolitan population). Stage at diagnosis could not fully explain 
those differences.73 
A nation-wide analysis of cancer incidence and mortality by the American Cancer Society 
reported that cervical cancer age-standardised mortality rates in the poorest counties were 
2-fold higher than those in the most affluent counties, reflecting the widest between-county 
gap in mortality rates among all cancer types.74  
Geographic clustering of advanced cervical cancer in Texas was explained by age, 
race/ethnicity, and contextual socioeconomic status but not spatial access to primary care 
physicians.75 
For 934 women diagnosed at the University of Alabama at Birmingham during 2005-2015, 
both living in a rural area and distance from the nearest American College of Obstetricians 
and Gynecologists (ACOG) women’s health provider were not associated with a higher 
risk of advanced stage cervical cancer, defined as stage II-IV (OR=1.19; 95%CI 0.91-1.56 
for rural versus urban residence, OR=0.99; 95%CI 0.98-1.01 per mile of shorter distance 
to the nearest provider).76 However, a retrospective cohort which included 390 cervical 
cancer patients diagnosed at the same centre between 1999 and 2011 found that women 
living more than 100 miles from the hospital received less radiotherapy and had worse 
overall survival (HR=1.68; 95%CI 1.11-2.54, unadjusted) despite similar distribution of 
stage and other risk factors.77 
Two large studies from Texas including 7,232 and 11,212 women showed no association 
between rural residence and cervical cancer survival,78 and between primary care 




expected cervical cancer mortality were observed (HR=1.79; 95%CI 1.45-2.22), and these 
did not change much after adjusting for several individual and contextual factors (HR=1.61; 
95%CI 1.31-1.98).79 However, background mortality was not adjusted for, so it is not clear 
whether the clusters of lower survival in the cervical cancer population reflect higher death 
rates in that remote population in general.  
Different results by urban-rural residence or other geographic variables seen between 
countries probably depend on various factors including screening intensity, completeness 
of ascertainment of incidence or mortality and differences in risk factor distribution; and 
probably also reflect complex interactions with other risk factors which are not always 
accounted for including educational level, socioeconomic status and access to high-quality 
healthcare. It seems that rural and remote area residents in the USA and Australia are at 
a disadvantage when it comes to cervical cancer incidence, survival and mortality which 
is not seen in Europe. This may be explained by the larger distances between cities in 
these two countries and differences in transportation systems. Therefore, access to 
healthcare may be more of a challenge for rural populations in the USA and Australia than 
in Europe. 
3.3 Prevalence of HPV in healthy women and in cervical cancer specimens in 
Saudi Arabia 
Prevalence studies of HPV in women from Saudi Arabia showed wide heterogeneity, with 
estimates between 5.9% and 31.6% for any type, 5%-43% for the high and intermediate 
risk types (HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and 9%-
31.6% for HPV16 and HPV18 (3.3%-21.5% HPV16 alone, 1.4-15% mixed and 2.3-5.8% 
HPV18).80-89 The most common type was HPV16, followed by HPV18 and HPV45. The 
variation between studies could be due to difference in settings (gynaecological clinics 
versus family medicine), intensity of cervical examinations in the centre (offering all eligible 
women versus only those who request it, are symptomatic or at high risk), inclusion criteria 
and detection methods (amplification versus hybridization techniques). 
Representativeness was probably an issue in all these studies which took place at a limited 
number of mostly specialised centres in Riyadh and Jeddah. Only one study mentioned 
participation rates, in which 70% of women were excluded. This was mainly due to refusal 




(26%) and technical difficulties in sample collection (1%).84 No population-based 
prevalence studies were found in the literature. 
One study reported the seroprevalence of HPV6, 11, 16 and 18 IgG antibodies in 966 
archived serum samples from healthy male and female blood donor and found it to be very 
low (1.7%). However, there are stringent criteria for blood donation which exclude potential 
donors with risky sexual behaviour. This may lead to an underestimation of HPV 
prevalence. Further, the four tested HPV subtypes are types included in HPV vaccines 
and antibodies in some samples could have therefore been generated by vaccination and 
not by natural infection. History of vaccination was unknown for the donors, many of whom 
were young.85 
HPV was detected in 82% to 96% of cervical cancer specimens in Saudi Arabia. HPV16 
was found in about two-thirds of samples, followed by HPV31, 18, 45 and 33 as a single 
infection. HPV18 was the second most common when considering mixed infection. 
Together, HPV16 and HPV18 comprised 79% of infections.90-92 
3.4 Prevalence of abnormal cervical cytology in Saudi Arabia 
fifteen studies from 12 tertiary and three secondary hospitals have described prevalence 
of abnormal cervical cytology between 1985 and 2017. Seven were located in Jeddah, five 
in Riyadh, two in the Eastern Region and one in the Southern Region. Proportions of 
smears with epithelial cell abnormalities ranged from 1.3% to 17.3%. The median 
proportion of abnormal smears was 4.5% while the median proportion of smears with 
invasive squamous cell carcinomas was 0.17%.88,93-106 In the absence of organised 
population-based screening, it is difficult to draw a conclusion about prevalence of cervical 
cell abnormalities based on these findings, which may suffer biases due to the nature of 
the centre (secondary or oncology centre), reason for contact with a gynaecologist or 
general practitioner and undergoing a Pap smear, hospital eligibility (e.g. Saudi nationals 
or military) as well as study inclusion criteria. The age profile of participants varied widely, 
this is reflected in the up to 15-year difference in mean age at diagnosis of squamous cell 
carcinoma between studies.93,105 Only one author reported excluding repeated smears for 
the same patient.96 Some studies included all smears in the pathology department 
archives, while others were restricted to patients visiting gynaecologists or infertility clinics, 
and the reason for undergoing a Pap smear was not given. In a review of 10,659 Pap 




rate of cervical intraepithelial neoplasia (CIN) was much lower in those presenting for 
routine smears (49 per 100,000) than the total (114 per 100,000).107 This reflects the low 
representativeness of hospital-based studies of cervical abnormalities. 
Very few comparable Middle Eastern countries have population-based cervical cancer 
screening programmes. The screening programme in Turkey yielded 1.83% abnormal 
smears between 2001 and 2010 with a mean age of 45 years (standard deviation=12).108 
More recently, the Emirate of Abu Dhabi has introduced a screening programme starting 
at age 25. From a total of 4,593 screened women with a mean age of 39.5 years, the 
proportion of abnormal smears in the first year (2013) was 4.9%, while 0.05% showed 
malignancy, with a mean age of 45 years.109 
3.5 Cervical cancer epidemiology in Saudi Arabia 
The relative position of cervical cancer has been declining since the first report published 
by the Saudi Cancer Registry (SCR) in 2001, when it was the eighth and second most 
common cancer in Saudi and non-Saudi women of all ages, respectively.110 In the latest 
report published for 2016, it became no longer one of the 10 most common cancers in 
Saudi women, though it remained the seventh most common cancer in non-Saudi women 
and ranked ninth among Saudi women aged 30-59. Cervical cancer made up 1.5% of 
cancers in Saudi women with an ASIR of 1.4 per 100,000 women, and 2.8% of all cancers 
in non-Saudi women, with an ASIR of 2.6 per 100,000 women.111 GloboCan 2018 
estimates for Saudi Arabia reported age-standardised incidence and mortality rates of 2.5 




Figure 3: Number of new cases and age standardised incidence rates (per 100,000) of cervical cancer in Saudi 
females between 1994 and 2016. 
 
 
Data from the Saudi Cancer Registry between 1994 and 2016 (2001-2016 for non-Saudis) 
showed a mean of 94 and 54 new cervical cancer cases per year among Saudi and non-
Saudi females, respectively, the latest published being 111 and 51 cases in 2016.111 The 
ASIR has been slowly declining though the annual number of cases seems to be slightly 
increasing (Figure 3). This is consistent with international trends and reflects the growth 
and ageing of the population. Stage distribution was reported for 2002 only and included 
26.9% localised, 39.8% regional, 10.8% distant and 22.6% unknown stage.113  
3.6 Cervical cancer survival in Saudi Arabia 
Age-standardised 5-year net survival from cervical cancer for women diagnosed during 
the calendar periods 1995-1999 and 2000-2004 was reported in CONCORD-2 at 62.2% 
(95%CI 50.6-73.8) and 65.6% (56.6-74.4) respectively. The SCR did not submit complete 
data for the calendar period 2005-2009.10 There are no population-based stage-specific 
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Four retrospective hospital-based studies of cervical cancer survival have been published. 
The earliest included 504 patients diagnosed and treated at King Faisal Specialist Hospital 
and Research Center (KFSHRC) in Riyadh between April 1975 and December 1993, of 
whom 410 received treatment with curative intent (radical surgery, radiation or a 
combination of both). The 5-year overall survival was 55% for all patients and 61% for 
those treated with curative intent. 5-year survival for stages 0 (in situ), I, II, III and IV, was 
97%, 75%, 70%, 41% and 11% (4-year survival), respectively. While the stage-specific 
survival corresponded to that seen in developed countries, only 20% of patients were 
diagnosed with stage I disease, and 37%, 29% and 14% were diagnosed with stages II, 
III and IV, respectively. This is an unfavourable stage distribution in comparison to 
developed countries and is probably the main contributor to sub-optimal survival.114  
More recently, a study from King Fahad Medical City, Riyadh, included 74 women with 
histologically confirmed locally advanced cervical cancer (66% IIB, 16% IIIA, 9% IIIB, and 
8% IVA) receiving three-dimensional conformal radiotherapy with chemotherapy followed 
by high dose brachytherapy, between 2007 and 2012. 5-year overall survival was 
64.5%.115 
For 60 patients diagnosed between 2004 and 2010 and treated at the radiotherapy 
departments of KFSHRC and King Abdulaziz University Hospital in Jeddah, 4-year overall 
survival was 79%. Stage at diagnosis was 5% IB, 3% IIA, 69% IIB, 5% IIIA, 15% IIIB and 
3% IVA.116  
Between January 1999 and December 2017, 190 women with a mean age of 54 years 
were treated for cervical cancer at King Abdulaziz University Hospital in Jeddah. 19% were 
diagnosed at stage I, 49% at stage II, 18% at stage II and 14% at stage IV. Their 5-year 
overall survival was 32%, but the 18-year period included may mask any changes in stage 
distribution or survival over time.117  
The four studies had different inclusion criteria, and all took place at tertiary referral centres 
often receiving more advanced cases but having the most advanced resources and 




Chapter 4. Healthcare and cancer control in Saudi Arabia 
4.1 Demographics 
The Kingdom of Saudi Arabia covers a total area of 2,149,690 km2, occupying the majority 
of the Arabian Peninsula. It is divided into 13 administrative regions (Figure 4). Two-thirds 
(65.6%) of the population live in the three regions of Riyadh (25.5%), Makkah (25%) and 




The combination of high fertility rates, increased life expectancy and migration has led to 
the population growing from 7 million (89% Saudis) in 1974 to over 34 million (63% Saudis) 
in 2019.119,120 In 2016, the annual growth rate was 2.54% for the total population and 1.1% 
for Saudi nationals. The total fertility rate has declined steadily since the end of the 1970s 
from around 7.3 to 2.5 children per woman in 2016.121 High fertility rates up until the end 
of the 20th century along with low infant mortality rates have led to a large population of 
women now occupying the age group at risk for cervical cancer (20-65 years). 
The sex distribution of Nationals is fairly equal (50.9% female), while a large proportion of 
non-nationals is represented by males 25-44 years of age from Asian and Arab countries 
employed in various sectors (Figure 5).  
 







Figure 5: Population pyramid for Saudis and non-Saudis, 2018 estimates. Data source: General Authority for 
Statistics 
 
4.2 Vital statistics  
Population counts are produced by means of periodic census, with counts for the 
intervening years being estimated by applying growth rates generated from the 
demographic surveys (1998, 2000, 2007, 2016). A comprehensive census has been 
carried out in 1974, 1992, 2004 and 2010. The next census was planned in 2020 but has 
been delayed due to the Covid-19 pandemic. The General Authority for Statistics publishes 
population counts by sex, 5-year age groups, administrative region and nationality 
(Saudi/non-Saudi). 
When a person dies, the death must be certified by a physician and a death notification 
form is filled which includes national ID number, age, sex, the immediate and underlying 
causes of death and any other conditions contributing to the death. A copy of the death 
notification is given to the family of the deceased in order to register the death with the 
Department of Civil Status of the Ministry of Interior within 30 days. A death certificate is 
then issued, which is necessary for inheritance purposes. Burials can take place using 
only a copy of the death notification as burials traditionally take place within one or two 
days of a person's deaths.  
The Ministry of Health (MOH) receives death notifications only from hospitals operating 
under it, and cause of death is coded centrally by the statistical department of the MOH. 
Annual mortality reports are produced by cause of death in crude categories (for example, 
external causes, cardiovascular, perinatal and neoplasms).  
I obtained the complete 2016 MOH mortality database in which 45,686 deaths were 
recorded. Of those, only 2,076 were due to neoplasms (4.5%). The other four most 
commonly mentioned causes of death were “non-specific signs and symptoms” (33.6%), 














































"circulatory system illness" (14.4%), “factors affecting health status” (14.4%) and 
"accidents and external causes" (4.4%). This shows both an under-enumeration of deaths 
in the MOH mortality database compared to those reported from the census (over 80,000 
deaths in 2010) and the low-quality of cause of death certification. This has also been 
reported in the Global Burden of Disease study,2 In which the quality of death certification 
for the period 2010-2017 was rated as 2 on a scale of 0-5, and the percent well certified 
causes of death was 28.8%, completeness of death registration was estimated at 63%, 
and 55% of vital registration deaths were assigned to major garbage codes. Recent efforts 
for improving reporting of deaths and cause of death coding have been taking place though 
the introduction of an electronic reporting system (Balsam) in MOH hospitals in 2018 and 
running ICD-10 coding workshops.  
Besides the MOH, other sources for death counts, include census, the family health 
survey, demographic surveys and municipality burial statistics. The official numbers 
published by the general authority for statistics rely on the first three. Burials tend to be 
largely under-recorded with the total number of those buried being approximately 30% 
lower than the deaths published by the statistical authority, and the number of men buried 
being approximately 70% higher than women. Data on deaths registered with the 
department of civil status are not publicly available. 
4.3 Healthcare 
Free healthcare is available to all Saudi nationals at primary, secondary and tertiary 
healthcare centres operated by the MOH. Several health services are funded and 
managed by government sectors other than the MOH: The Armed Forces medical 
services, Security Forces medical services, National Guard health services, Royal 
Commission for Jubail and Yanbu healthcare services, Saudi Arabian Oil Company 
(ARAMCO) hospitals and Ministry of Education. These are in general only accessible to 
employees of their sectors or by referral or royal decree, which is usually limited to Saudi 
nationals. University hospitals are an exception, in that any patient (including non-
nationals) can be accepted as a teaching case. King Faisal Specialist Hospital and 
Research Center (KFSHRC) also receives separate government funding and is a referral 
centre in the two major cities of Riyadh and Jeddah. About 30% of cancer patients in the 
country are treated in the Riyadh hospital alone. Private hospitals and clinics can be 




Altogether, there are 498 hospitals in the kingdom: 286 MOH, 48 other above mentioned 
government sectors and 164 private hospitals, providing 58%, 17% and 25% of hospital 
beds, respectively.122 The Saudi Health Council was founded in 2002, with the aim to 
oversee and coordinate the various private and government health services, in order to 
increase efficiency and improve healthcare equity. 
Despite the availability of free healthcare and modern facilities, there is inequitable 
distribution of health services between geographic areas,11 which especially impacts those 
in rural and border areas with limited mobility: the elderly, young, disabled, and to an 
extent, women. Until 2018, women were officially banned from driving, which is the main 
mode of transport in the country. Another obstacle to seeking medical care is that even in 
urban centres, waiting times for diagnostic and treatment services in government hospitals 
may be very long.123 
Non-nationals are required to have health insurance. Domestic employees can access 
MOH services as an exception, but cancer treatment may be limited to surgical excision 
and a certain number of chemotherapy cycles. In some cases, royal orders are issued for 
non-nationals to be treated at specialised government centres. There are also some 
charities which help cover their treatment costs. 
The Council of Cooperative Health Insurance was established in 2014. It's role is to 
regulate insurance providers and set minimum coverage requirements, and has mandated 
the private sector to insure employees and their dependents.124 Government employees 
and unemployed citizens will be covered by a national insurance scheme. This scheme 
will also cover health services beyond the private insurance limitations for citizens who 
hold private insurance. 
Insurance companies are not required to reimburse the costs of screening or the HPV 
vaccine. The treatment of sexually transmitted infections is excluded from coverage 
according to the Council of Cooperative Health Insurance regulations.124 Yearly insurance 
coverage limits of 500,000 Saudi Riyals (133,313 USD), and the lack of expensive imaging 
and radiotherapy equipment in private hospitals may pose a special challenge to cancer 
care in the private health sector. This could offset the advantage gained by less waiting 
time in contrast to government hospitals.  
In the context of the national transformation programme, a plan towards corporatisation of 




will be established and will oversee healthcare clusters in their geographic region (Central, 
Eastern, Western, Northern and Southern). Healthcare clusters will afterwards be matured 
to independent Accountable Care Organizations (ACOs). The aim is to improve access to 
health services, increase equity and efficiency and provide more effective primary care. 
Strengthening the role of primary care is expected to increase the utilisation of preventive 
and early diagnostic services, resulting in timelier referral. The ministry of health would 
take on a regulatory and legislative role over healthcare facilities in the country. Healthcare 
clusters will be financed through both a national health insurance scheme and private 
insurance.125  
4.4 The Saudi Cancer Registry 
The Saudi Cancer Registry (SCR) was established in 1992 and now operates under the 
umbrella of the Saudi Health Council. It is a population-based registry with national 
coverage, which started recording incident cancer cases in January 1994. In addition to 
the main office in Riyadh, five regional offices have been set up in the Central, Eastern, 
Western, Northern, and Southern regions. A ministerial decree in 1992 has made 
notification of every cancer diagnosis and death from cancer mandatory for all hospitals, 
clinics and laboratories. Maintaining a database of cancer diagnoses is required for 
hospitals treating cancer patients in order to obtain accreditation by the Saudi Central 
Board for Accreditation of Healthcare Institutions.126 This insures the continued access of 
the registry to cancer patient records. All invasive neoplasms including non-melanoma 
skin cancer, haematological malignancies and cancer of unknown primary site are 
registrable (full list in appendix A).127  
Active case-finding is carried out by trained registrars. It relies primarily on pathology 
reports, with other sources being cytology, radiology, radiotherapy, haematology and 
outpatient departments, as well as hospital death notifications. Many hospitals have 
information systems which are also used to provide a list of patients with a diagnosis of 
cancer. Some pathology departments keep a log of cancer diagnoses to facilitate 
registrars’ access to patients’ pathology reports. Registrars use the medical record number 
to retrieve the patient’s file from which data are abstracted. These include personal details: 
name (first, father, grandfather and family name according to official documents, using 
standardised Latin spelling assigned to each Arabic name), nationality, ID number, date 




of diagnosis defined as date of confirmation on pathology report, primary site, histology, 
behaviour, grade, stage, laterality and basis of diagnosis). Date of last contact, vital status 
and cause of death if dead (cancer or other) are recorded based on information available 
at the time of abstraction and are later updated if other sources for the same patient 
become available, including records from other hospitals, death notifications or death 
certificates.  
Death notifications are usually kept in a dedicated department in hospitals. Cancer 
registrars manually search for death notifications with a mention of cancer. Additionally, 
Death certificates with a mention of cancer have been provided to the SCR by regional 
departments of vital statistics since 2005. These two sources are used to find missed 
cancer cases and to update the vital status of already registered patients. Consequentially, 
the availability of information on death in the registry is mostly limited to those with a 
mention of cancer on their death documents. The completeness of ascertainment is also 
dependent on physicians correctly documenting the cause of death. There is no formalised 
mechanism to follow up all cancer patients. 
When the first mention of cancer is received on a death notification or certificate, the basis 
of diagnosis “death certificate only” (DCO) is assigned, and registry staff attempt to trace 
back the medical record with the first diagnosis after a 6-month wait period. A date of 
diagnosis preceding death is successfully traced within the region in about 80% of cases, 
in which case the basis and date of diagnosis will be updated. If no other source 
mentioning cancer is found from any region, the basis of diagnosis remains DCO and the 
date of diagnosis and date of death remain the same (Sameer Alkaifah, Saudi Cancer 
Registry Western Region senior registrar, personal communication, 13 March 2018). 
The International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) coding for 
tumour topography (anatomical origin) and morphology (histology and behaviour), and 
SEER (Surveillance, Epidemiology and End Results) Summary Stage 2000 have been 
used for tumour coding and staging respectively since 2001. Where stage is recorded as 
TNM or FIGO classification, it is converted to SEER summary stage using the American 
Joint Committee on Cancer (AJCC) manual rules.128 A computerised system (CanReg 4) 
is used to register cancer cases and check quality of the data, including flagging unfilled 
mandatory variables, first name-sex mismatch and invalid or rare combinations such as 
sex-topography. Data from the regional offices are sent to the main office of the registry in 




number of cases from each region with the previous year, checking for duplicates by 
national ID, name and medical record number, as well as checking for duplicates in 
CanReg with at least 70% similarity, then combining any duplicates. Variables are checked 
again for invalid entries or combinations. Any suspected errors are sent back to the 
registrars in regional offices for correction. Finally, the central office checks for duplicates 
over the past five years.  
The registry publishes annual cancer incidence reports describing age and regional 
distribution of cancer diagnosed in each calendar year. Incidence amongst nationals and 
non-nationals is reported separately due to the stark difference in demographic 
characteristics between the two groups. The registry currently publishes cancer incidence 
reports within three years of the registration year and aims to reduce the gap to one year. 
Quality of registry data  
An assessment of the registration process, and of the comparability, completeness and 
validity of the SCR data was carried out in 2013 by the International Network for Cancer 
Treatment and Prevention, which included visits to 16 hospitals across the five regions 
and examining registry data for the period 1994-2009.129  
Completeness 
This refers to the extent to which all of the incident cancer cases are included in the registry 
database. Incidence trends were steadily increasing over time with no significant 
fluctuation. Compared to neighbouring countries, age-standardised incidence rates 
(ASIRs) were the lowest in Saudi Arabia for both men and women for all cancers 
combined, but were similar to ASIRs for Oman and the United Arab Emirates. More 
notably, there were large regional discrepancies in ASIRs for all cancers combined, the 
highest being for Riyadh (117.5 per 100,000 males and 123.6 per 100,000 females) and 
the lowest for Jazan (30.7 per 100,000 males and 46.0 per 100,000 females). Prevalence 
of risk factors may largely vary between urban and rural areas. However, this discrepancy 
may partially result from misclassification of addresses for patients that were diagnosed 
and treated outside of their area of residence.  
The age-specific curves for common cancers generally corresponded to what is expected 
for each site. The proportion of tumours that were morphologically verified (MV%) was 




(91.4%), for which clinical methods of diagnosis and imaging are often used. This might 
point to over-reliance on pathology reports for case finding. 
Childhood cancer incidence is expected to be similar in different parts of the world and is 
therefore often used as an indicator for completeness of registration.130 Age-specific 
incidence rates were within the reference range for boys, and slightly under the reference 
range for girls aged 5-14 years. 
Validity 
Validity points to the proportion of cases with a given characteristic in the registry that truly 
have it. The percentage of morphologically verified (MV%) diagnoses for all tumours has 
been consistently around 93% since 2005, but higher in earlier years. It was lower than 
80% for liver, pancreas, unspecified digestive system cancers and leukaemias. The lowest 
MV% was observed in the age-group older than 80 (79.1% in males and 83.9% in 
females). Some regional variation was observed for MV%, the lowest was in the Northern 
region (80.9% in males and 89.0% in females) and the highest in Makkah region (96.0% 
in males and 97.6% in females). 
The proportion of cases that were registered by death certificate only (DCO) increased 
from 0% in 1994 to 3.3% in 2000, then decreased to 2% in 2009 due to efforts to trace 
back the hospital records of death certificate notified tumours. It ranges from 0% for several 
sites to about 30% for acute undifferentiated leukaemia (C95). The highest percentage of 
diagnoses by DCO was in those older than 80 (9.5%). 
Topography was unspecified for 4% of all registered tumours, the majority of which were 
metastasis of unknown primary. This proportion decreased slightly in the last three years 
examined (2006-2009) and increased with old age, reaching 7% for females older than 80. 
The above-mentioned indices of validity were fairly consistent over time after the first few 
years of registration, and their age patterns seem to reflect diagnostic limitations in older 
age rather than deficits in the abstraction process. However, their values need to be 
interpreted in light of what is expected for the country's diagnostic infrastructure. Lack of a 
standard reference for comparison decreases their usefulness in assessing validity.131  
One way to evaluate the completeness and validity of registry data is through reabstracting 
and recoding records from a given source and comparing them to registered data.131 This 




Riyadh. The reported ascertainment proportion, which at the time relied on medical 
records only, was 68%, and major disagreement was found between the abstracted and 
re-abstracted data for stage (44%) and for histology and behaviour (26%).132 Such issues 
are expected in the early years of a registry and additional sources of case finding have 
been in use since then such as radiology, outpatient clinics and death notifications. 
Timeliness 
When comparing the number of tumours in the 2009 cancer incidence report and tumours 
that were diagnosed during 2009 in the SCR database as of December 2012, a difference 
of 2-9% was observed for various common tumours, which reflects some late reporting. 
The assessment did not include individual cancers, but the number of women who were 
diagnosed with cervical cancer during 2009 as of 30 November 2018 in the SCR database 
(188) was 23.6% higher than the number reported in the 2009 cancer incidence report 
(152).133 This may reflect more delayed reporting for cervical cancer or continued delay 
beyond the first three years. 
4.5 Cancer control 
The Gulf Center for Cancer Control and Prevention (GCCCP) was founded in 2011 and is 
based in KFSHRC in Riyadh. The scope of its work includes introducing cancer control 
strategies and evidence-based guidelines for cancer management, and supporting cancer 
research in the Gulf Cooperation Council (GCC) states (Saudi Arabia, the United Arab 
Emirates, Oman, Kuwait, Bahrain and Qatar). It has published a joint cancer control plan 
for the GCC states for the period 2016-2025 with the aim to reduce the burden of cancer 
and the associated human and financial cost through targeting various elements of the 
cancer control continuum. It states however, that individual states are encouraged to 
produce their national operational action plans according the their unique needs and 
resources.134 
Primary prevention 
The Gulf cancer control plan sets targets for several known cancer risk factors (overweight, 
physical activity, infections, environmental factors, diet and smoking). Tobacco 
consumption has increased by 12% in Saudi Arabia between 1996 and 2012,135 but 




smoking ban, plain packaging, health warnings, ban on advertising, cessation services 
and a large increase in tobacco tax in since 2017.136  
Screening and early detection  
The Saudi MOH has published screening guidelines for breast, colorectal and cervical 
cancer,29,137,138 but there are currently no organised population-based screening 
programmes. The current fragmented health system and weak primary care mean there 
is often no clear path for individuals to seek the appropriate care they need. The efficiency 
and timeliness of cancer diagnosis and referral are also adversely affected by the 
complexity of this system. 
Treatment and palliation 
Ten governmental oncology centres provide specialised comprehensive care for cancer 
patients in Saudi Arabia:139 five in Riyadh (King Faisal Specialist Hospital and Research 
Center, King Abdulaziz Medical City of the National Guard Hospital, King Fahad Medical 
City, Prince Sultan Medical Military City, and King Saud Medical City); three in Jeddah, the 
largest city of the Western Region (King Faisal Specialist Hospital and Research Center, 
King Abdulaziz Cancer Center (since 2010, the oncology centre was transferred to King 
Abdullah Medical City in Makkah and Jeddah), and Princess Noorah Oncology Center of 
the National Guard Hospital); and one in the Eastern Region (King Fahad Specialist 
Hospital). More recently, oncology centres have been launched in Makkah (King Abdullah 
Medical City, 2010) and Madinah (King Fahad Hospital, 2017). 
Other major hospitals like ARAMCO hospital and some university and private hospitals 
provide treatment for cancer patients, but may lack services such as radiotherapy and 
palliative care.  
Cancer care in rural areas is provided by general practitioners or non-specialised 
gynaecologists and surgeons. Patients who are referred to more specialised care may 
face logistical challenges such as in transport and housing. In a geographic information 
system analysis which mapped the city of residence for 45,532 individuals with registered 
cancers that were diagnosed between 1998 and 2004, approximately 40% lived more than 
a three-hour drive from the nearest city containing a specialist cancer centre, the median 
travel time was estimated to be 212 minutes. Those living in the Northern and Southern 




Palliative care is mainly provided at the above-mentioned oncology centres. A recent pilot 
project carried out under the MOH model of care project provided primary health centre-
based palliative care to 200 cancer patients and showed higher adherence to treatment 
and very high patient satisfaction.140 The MOH plans to roll out the project over the next 
decade to cover more geographic areas. 
An additional challenge cancer patients face is cancer treatment shortages, which has 
been reported to occur at least occasionally at all oncology centres in the country, and has 
led to treatment failure or relapse due to treatment delay or substitution.139 
Rehabilitation and mental health services within the formal healthcare system are limited. 
Charities, civil society organisations and patient groups provide various types of material, 
psychological and spiritual support to cancer patients and cancer survivors. 
Cervical cancer prevention and control 
In 2013, the Saudi MOH introduced a 2-dose HPV vaccine schedule into its national 
immunisation programme, to be administered to girls at ages 11 and 12; and a 3-doses 
catch-up schedule given at 0, 1-2 and 6 months for females aged 15-26. However, 
availability of the vaccine has been limited mostly to private clinics and hospitals with high 
levels of resources such as KFSHRC and National Guard Hospitals (Dr. Fadia Albuhairan, 
personal communication, 15 November 2020). Of 450 Saudi women aged 18 to 57 who 
were randomly selected from gynaecology and primary care clinics in Riyadh, less than 
1% had an HPV vaccine. Almost half the women were younger than 30 when the survey 
was conducted in 2018. Therefore, at least some of them belong to a cohort that was 
eligible for vaccination.141 There are no published government data so far on HPV vaccine 
coverage in eligible girls and women.  
Although the Saudi MOH recommends universal screening for ever-married women, there 
are no existing organised programmes for cervical cancer screening to date in Saudi 
Arabia. It's up to the healthcare provider to offer Pap smears and most smears take place 
opportunistically if eligible women present to a gynaecologist. Primary physicians have a 
limited but increasing role in offering and performing Pap smears. In a survey of 500 
eligible women in Jeddah in 2008 with a median age of 42 years (range 18-66), only 16.8% 
had ever had a Pap smear and a little over half of those stated that their physician offered 
it. It does not mention how many had undergone it routinely versus as an investigation due 




26% had ever undergone a Pap smear test.141 Of 200 eligible female physicians surveyed 
in 2009, (70 gynaecologists and 130 non-gynaecologists), only 28.5% had undergone Pap 
smears themselves and only 61.4% of gynaecologists reported ever recommending it to 
patients.143 In the nationally representative World Health Survey Plus conducted in Kuwait, 
Oman, Saudi Arabia and the UAE in 2008, only 7% of 2,746 eligible women in Saudi Arabia 
received a Pap smear within recommended intervals for their age (within the past 3 years 
for women 25-49 years and within the past 5 years for women 50-64 years).This was the 
lowest among the included countries. Women living in urban areas were twice as likely to 
have had a Pap smear within the recommended interval. Higher educational level was 
also associated with Pap smear uptake while wealth was the strongest predictor: 10% of 
women in the high wealth category and 2.5 % of women in the low wealth category 
received a Pap smear within the recommended interval.144 
Barriers to prevention and early diagnosis  
While some women prefer or insist on being examined by a female physician, this wish 
can usually be granted. Shame and shyness from discussing symptoms like vaginal 
bleeding, especially with a male relative, lack of awareness about the potential significance 
of such symptoms and of the availability and benefits of screening might delay presenting 
to a healthcare provider.142 The belief that cancer is an incurable disease, and superstition 
that “seeking out or speaking of such serious diseases” could attract ill fate, may also lead 
women to ignore their symptoms and reject the offer of a Pap smear. In the case of cervical 
cancer, the fact that the causative agent is a sexually transmitted virus makes it 
challenging to educate women in order to make an informed decision about HPV 
vaccination and screening, especially in a conservative society where it is generally 
assumed that premarital and extramarital sexual relations are rare. The lack of adolescent 
health platforms may pose a challenge to reach high coverage for the HPV vaccine.145 
Changing risk factors 
The number of lifetime sexual partners is the most important predictor of persistent high-
risk HPV infection.25 In a survey of 400 women who have been ever married (married, 
divorced or widowed) attending family medicine or gynaecology clinics between November 
2013 and November 2015, 12% reported having had more than one lifetime sexual 
partner. Due to cultural sensitivity, never married women could not be included in this 




some men in Saudi Arabia. In the same survey, 30% of the women were smokers.87 
However, in the nationally representative Saudi Health Information Survey conducted in 
2014, only 1.5% of women older than 15 were current smokers, with an average of 3.7 
cigarettes consumed a day among those who smoked.146 Age of marriage in Saudi Arabia 
has been increasing. In the 2016 demographic survey, over 30% of ever-married women 
aged 45 and more reported that their first marriage was before age 19, while only 17% of 
ever-married women aged 25-35 were married by age 19. Previous marriages of the 
husband may also play a role in risk of exposure to HPV. Of the ever-married surveyed 
population, only 3% of women, but 13% of men, were married more than once.147 It is 
unknown whether delaying marriage could lead to an increase in premarital sex. Women 
are delaying pregnancy and having less children on average,121 which may reduce the risk 




Chapter 5. Principles of cancer incidence, survival and mortality 
Incidence, survival and mortality are complementary indicators that help to assess the 
cancer burden in a given population. In order to reach a comprehensive understanding of 
the effectiveness of cancer control measures, any change, or lack thereof, in survival 
should be interpreted together with incidence and mortality. 
5.1 Incidence 
Cancer is unique among major chronic diseases in that data on the occurrence of disease 
have been available from population-based registries for many countries, in some cases 
for more than 60 years. These datasets enable the calculation of incidence rates and 
trends.  
The incidence rate is defined as the number of new cases occurring over a given period, 
typically a year, in a defined population, divided by the person-years at risk:  
𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑒𝑤 𝑐𝑎𝑠𝑒𝑠 𝑜𝑓 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑖𝑛 𝑎 𝑝𝑒𝑟𝑖𝑜𝑑
𝑝𝑒𝑟𝑠𝑜𝑛 𝑦𝑒𝑎𝑟𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘
 
In a stable population, the mid-year population can be used as an approximation for the 
person-years at risk. Cancer incidence rates are usually expressed per 100,000 persons 
per year. In the case of cervical cancer, the population at risk is the general female 
population. 
Incidence rates are important in identifying risk factors for a disease and allocating 
preventive services. Monitoring trends in incidence help to plan for future healthcare 
demands.  
5.2 Survival 
In longitudinal studies where subjects are followed-up from a defined starting point (for 
example, diagnosis) up to the event of interest (for example, death or loss to follow-up), 
survival analysis allows for the estimation of event rates that may not be constant over 
time.  
Survival can be expressed in terms of the hazard h(t), the instantaneous rate at time t, or 
the survivor function S(t), which is the probability that an individual will survive up to a 




gives the hazard function, also known as the cumulative hazard H(t), which has a direct 
mathematical relationship with the survival function:  
 𝑆(𝑡) = 𝑒−𝐻(𝑡)    or equivalently: 
 𝐻(𝑡) = − log(𝑆(𝑡))  
If a person is known to have survived up to a certain point in time, but whose survival past 
that point is unknown, they are censored, i.e., they only contribute their follow-up time to 
the point when they are censored. This occurs when the person is lost to follow-up, 
experiences a competing event that precludes the event of interest from being observed, 
or does not experience the event of interest by the end of the follow-up time. Censoring is 
said to be non-informative if the probability of being censored is independent from the 
probability of experiencing the event of interest. 
Because the risk of death usually varies with time since diagnosis, it is useful to display a 
survival curve graphically in a step function where there is a drop every time an event is 
observed. Patients who are censored do not cause a drop in the curve, but are removed 
from the population at risk in the next interval. As a summary statistic, survival is reported 
as a proportion surviving for a defined duration (usually 1 or 5 years).  
Survival is classically estimated using the Kaplan-Meier method, which is a non-parametric 
method calculating the probability of surviving up to a given time (for example, 5 years) as 
the product of the conditional probabilities of individuals surviving over successive small-
time intervals, given that they survived up until that time. 
Population-based cancer survival 
Examining cancer survival on a population level enables the assessment of the overall 
performance of the healthcare system in managing cancer, including timely diagnosis and 
effective treatment. It relies on having high quality registry data covering the whole 
population of a defined geographic area. The population at risk is those diagnosed with 
the cancer of interest. The date of diagnosis is the starting point for follow-up. 
In terms of years of follow-up used to estimate cancer survival, two main approaches are 
used: the cohort approach uses the actual observed survival experience of a cohort of 
patients until the end of the desired follow-up (for example, 5 years), and only cohorts with 
a potentially full follow-up time are included in the analysis. A variation of this approach is 




without the full follow-up experience are censored. An alternative "period" approach was 
proposed to predict survival when not all cancer patients have been followed for the 
desired time (for example, at 5 years since diagnosis). This approach uses the most up-
to-date data and draws on the survival experience of individuals diagnosed in earlier years 
who are still alive in the calendar period of interest and for whom the full follow-up time 
has been observed. Thus, the conditional survival probabilities from individuals diagnosed 
during successive years are multiplied. Survival in this case is observed for a 5-year period 
of follow-up rather than a 5-year cohort. This has the advantage of including the most 
recent years of diagnosis and it was argued by the authors that this "period" analysis 
produces estimates closer to the true survival experience than the complete approach 
when the cohort is eventually followed for the full duration of interest.148  
In registries where follow-up is obtained by passive linkage to the death index, it is often 
the case that the follow-up is more recent than the available years of cancer registration, 
especially when cancer registration is carried out manually. In this case a "hybrid" 
approach can be used, which includes elements of the cohort and period analysis.149  
Net survival 
In population-based cancer survival, we are interested in isolating the hazard of death due 
to cancer in order to compare the survival experience between different settings or monitor 
progress over time, whilst taking account of background mortality in the population. This 
can be estimated in two different settings: “Cause-specific” and “relative”.  
In a cause-specific survival setting, deaths attributable to cancer are the event of interest, 
while deaths due to any other cause are censored. Survival is usually estimated using the 
Kaplan-Meier method. It requires both the correct attribution of cause of death by the 
reporting physician and appropriate coding of the underlying cause of death. Determining 
whether the cause of death in a cancer patient is their cancer is challenging and may be 
subjective, since cancer and its treatments can affect many of the body's systems and 
cancer often occurs in elderly people with pre-existing comorbidities. Moreover, it cannot 
account for the informative censoring by other causes of death which is problematic when 
it differs between populations being compared. This informative censoring also increases 
in older age groups. 
The relative survival setting compares the survival experience of the cancer population to 




aiming to estimate the excess deaths in the cancer population compared to the age- and 
sex-matched general population. However, because cancer is not the only cause of death 
in cancer patients and death from other causes precludes death from cancer (competing 
risks), and because the hazard of death from other causes varies between populations 
and increases with age, the ratio of survival observed in the cancer population to that of 
the general population, known as the relative survival ratio, is not an appropriate measure 
to compare survival between populations or over time. Therefore, an estimator must be 
used that addresses these issues.  
Net survival is the cumulative probability of surviving up to a given time since diagnosis, 
after correcting for background mortality. The population background mortality is given by 
life tables of all-cause death rates by a set of covariables, usually single year of age, sex, 
and calendar year, which are available from government census data. For this purpose, 
the Pohar-Perme estimator is used. It is a non-parametric estimator which gives an 
unbiased estimate of net survival because it takes account of differences in mortality due 
to causes other than the cancer of interest (background mortality) between the populations 
being compared, and of the increase in competing risks of death in older age. It achieves 
this by giving individual weights to each failure and censoring time which are equal to the 
inverse of the expected probability of surviving up to this time.150 In other words, it is the 
cumulative product of the partial probabilities of survival, weighted by the inverse 
probability of an individual being alive in the population. 
Estimation of net survival requires the following assumptions:150 
1- Time to death due to the disease and time to death in the population are 
conditionally independent, given a set of covariables (age, sex). i.e., within each 
demographic stratum, time to death in the cancer population does not depend on 
time to death in the population. 
2- Non-informative censoring.  
3- That the disease is rare. Since the life tables are derived from the general population 
including individuals with the cancer of interest, the assumption is that their effect 
on the overall all-cause mortality rates is negligible. 
5.3 Mortality  
Cancer mortality data are obtained from cause of death certification where the underlying 




by the ministry of health in a country or region. Mortality rate refers to the number of deaths 
due to a given cause divided by the mid-year population at risk.  
𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒 =  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠 𝑑𝑢𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑑𝑖𝑠𝑒𝑎𝑠𝑒 𝑖𝑛 𝑎 𝑝𝑒𝑟𝑖𝑜𝑑
𝑝𝑒𝑟𝑠𝑜𝑛 𝑦𝑒𝑎𝑟𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘
 
As with incidence, the denominator for cervical cancer mortality is the general female 
population. The mortality rate is usually expressed per 100,000 population per year. 
Mortality has the advantage of not being affected by biases caused by changes in 
diagnostic procedures in the same way that incidence and survival are.  
Although reducing mortality is the ultimate goal of cancer control strategies, mortality rates 
per se are not the best indicator of progress in cancer control. First, because mortality for 
many cancers, including cervical cancer closely mirrors incidence patterns. Incidence is a 
reflection of risk factors which a person is exposed to years or decades earlier. Due to long 
latency, preventive measures are only expected to manifest years later. Second, mortality 
is affected by survival of patients diagnosed in previous years, and this backscatter in time 
varies with time, and increases as survival improves. Thus, it is difficult to interpret, and it 
is not as sensitive to changes in diagnosis and treatment. 
5.4 Age standardisation 
For many cancers, incidence and mortality rates increase by 100-fold or more over the 
adult age span. Because the age profile of populations varies geographically and over 
time, it is necessary to age-standardise these metrics to enable meaningful comparisons. 
For cervical cancer, incidence rates change less markedly with age, but standardisation 
for age is still required to enable comparison of all-ages rates over time and between 
populations. 
For incidence and mortality, we use the direct standardisation method applying the weights 
from the Segi-Doll world standard population to the age-specific rates.151 The world 
standard population was introduced by Segi (1960)152 and then modified by Doll et al. 
(1966) for the first volume of Cancer Incidence in Five Continents (Table 2).151 The Segi-
Doll world standard population is still used in order to enable continuous comparison 




Table 2: Age distribution of the Segi-Doll world standard population 




















For survival, it is necessary to use cancer population weights because we estimate survival 
within a cancer population, for which the age profile differs markedly from that of the 
general population. The International Cancer Survival Standard (ICSS) weights have been 
derived from analysing over one million adult cancer patients included in the EUROCARE-
2 study, using multivariable methods to derive the smallest number of sets of standard 
weights. Three broad cancer age-incidence patterns were identified: (1) cancers for which 
incidence increases with age; (2) cancers for which incidence is fairly constant with age; 
(3) cancers mainly affecting young adults. For cervical cancer, ICSS group 2 is used (Table 
3).153  
Table 3: International cancer survival standard (ICSS) weights, group 2 
Age group 
Standard cancer patient population 











Chapter 6. Methods 
6.1 Data sources 
Registry data 
Cervical cancer records for the whole period of data availability (1994-2016), including in 
situ cancer were obtained from the Saudi Cancer Registry (SCR) (n=4,071; 1,841 
diagnosed in 1994-2004 and 2,330 in 2005-2016) via the CONCORD file transmission 
utility.154 The dataset included full date of birth, date of diagnosis, date of last known vital 
status, administrative region and city/town of residence, diagnosis and referral; as well as 
nationality, tumour stage (SEER Summary Stage 2000) grade, morphology, behaviour and 
cause of death if a death notification or death certificate was received (cancer, other or 
unknown). 
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine 
prior to data transfer (Appendix D. Ethical approval). 
Population counts and life tables 
The general authority for statistics provided death counts and mid-year population counts 
for the years 2004, 2007, 2010 and 2016 by nationality (Saudi/ non-Saudi), 5-year age 
groups (0-4 to 80+) and administrative region. These data were collected during the 2004 
and 2010 census and the 2007 and 2016 demographic surveys. Death counts rely on 
recall of deaths which occurred in the household over the past 12 months. Based on the 
census and demographic surveys, the SCR produced population counts for the years 
2005-2016 by 5-year age groups, which I used to estimate incidence and mortality.   
I calculated all-cause mortality rates by age group and administrative region for Saudi and 
non-Saudi females. However, the mortality rates were irregular especially for non-Saudis, 
older age groups and for regions with smaller populations. 
The United Nations Population Division (UNPD) publishes population and mortality 
estimates in the World Population Prospects. The same above-mentioned sources for 
Saudi Arabia were utilised but estimates were adjusted for under-enumeration of the 
population and for under-5 and old age mortality. Internal consistency by age and sex and 




and migration) and the population. Some years were prioritised due to fluctuation in the 
reported data. 
The Institute of Health Metrics and Evaluation (IHME) also publishes life tables in the 
context of the Global Burden of Disease study (GBD).155 In order to produce life tables for 
Saudi Arabia, it uses various data sources including the Ministry of Health mortality 
database, United Nations Statistics Division (UNSD), census data from the Central 
Department of Statistics and Information (now the General Authority for Statistics) 
demographic bulletin. It corrects for lower completeness of death ascertainment in women 
and extremes of age, employing complex modelling methods.  
I used UNPD life tables in the net survival estimation because, apart from the adjustment 
for under-enumeration at extremes of age, the age-specific mortality rates were similar to 
those I calculated from the census data. The death rates from the GBD study were lower 
especially in younger age groups. The CONCORD Central Analytic Team obtained life 
tables of all-cause mortality rates by single calendar year, sex and 5-year age groups for 
Saudi Arabia from the UNPD and interpolated them and extended them to age 99 years 
with the Elandt-Johnson method in order to have mortality rates by single year of age.156 
6.2 Linkage to death records 
For the purpose of survival analysis, a passive follow-up method was used to obtain a 
woman’s vital status and date of death if dead. Based on women's unique national 
identification (ID) numbers, registry records were linked to the vital registration database 
of the National Information Centre of the Ministry of Interior (NIC) on 29 August 2019.  
Non-nationals are a group largely made up of those working on limited contracts. Many 
return to their home countries after a diagnosis of cancer due to visa and medical treatment 
restrictions, making follow-up difficult. Also, obtaining accurate life table data for this 
population is challenging given their unsteady in- and out-migration. Therefore, I limited 
the survival analysis to Saudi nationals.  
I further restricted the analysis to women diagnosed during 2005-2016 because ID number 
was not a mandatory field in the cancer registry before 2005, and it was only available for 
32% of women diagnosed during 1994-2004. 
Of 1,477 records, 1,199 (81%) had at least one complete (10-digit) national ID number. 31 




finding more than one ID number in a woman’s medical record, one of which probably 
belongs to an accompanying husband or relative. All available ID numbers were submitted 
to the NIC. Vital status and date of death if dead were requested, as well as sex, date of 
birth and complete name (the first name of the woman and of her father and grandfather, 
and the family name) in order to cross-check with registry records. All name checks were 
carried out by registry staff in order to protect the identities of the women. Linkage was 
successful for 1,193 ID numbers corresponding to 1,191 registry records. Eighty-three of 
the ID numbers belonged to males in the NIC. This eliminated 29 of the second ID numbers 
in records with two IDs. For the remaining two records, the correct ID number was selected 
based on matching names and dates of birth. The remaining 54 IDs belonging to males 
were therefore considered to be wrong ID numbers (Figure 6). For women with missing, 
incomplete or wrong ID numbers, date of last known vital status from the registry was used 
in the survival analysis. There were 20 women who were dead according to registry follow-
up but alive in NIC records. I used NIC follow-up for these women in order for the method 
to remain consistent. 
Six further records had names that partially or completely did not match between registry 
and NIC records. Registry follow-up was used if more that one of the four names did not 
match (n=4). There was a much higher proportion of mismatch in dates of birth between 
registry and NIC records, ranging between 1 day and 24 years (Figure 7). Only 44% had 
perfectly matching dates of birth, while 67% had differences within 2 days, 86% within 1 
year and 97% within 5 years. Many of the elderly in Saudi Arabia do not know their dates 
of birth or only know them roughly, therefore the mid-year date was assigned to the 
majority of those born in the 1970s and earlier. In addition, the conversion from the locally 
used Hijri lunar calendar to the Gregorian calendar could lead to differences of a few days. 










Figure 7: Correlation between dates of birth recorded in the Saudi Cancer registry and the Ministry of Interior 
 
6.3 Data quality 
A total of 1,470 records were checked for CONCORD eligibility criteria. Patients were 
eligible for survival analysis if they had a complete date of birth, diagnosis and death if 
dead, were 15-99 years of age at diagnosis and if they had an invasive primary tumour 
with an eligible morphology and topography code. Further, patients were excluded from 
the analysis if registered based on death certificate only, or had inconsistent age, sex, 
morphology or site combinations, including age less than 20 for cervical cancer (Appendix 
B, Annex table 1 for full exclusion table). Of the 1,242 women eligible for survival analysis, 
1,219 were included in the survival analysis (98.1%) (Figure 6).  
Further quality indicators were examined according to the CONCORD protocol (Annex 
table 2).4,157 Of the women included in the survival analysis, 99.7% had microscopically 
verified tumours and 1.2% had non-specific morphology. Follow-up was censored within 
5 years of diagnosis for 34% of women. Two percent had died within 30 days of diagnosis. 
The distribution of the day and month of birth showed around a 15% excess of women 
having their day of birth documented as the first of the month and their month of birth as 
July. The first of July is assigned by the government to those who's date of birth is 




last known vital status clustered on the 29th of August, which was the date of record 
linkage (29 August 2019) (Appendix figure 1). 
For calculation of incidence, non-Saudis and women with unknown vital status, women 
registered by death certificate only, and records with invalid date of death or an invalid 
date sequence which involved date of death were included. Women with carcinoma in situ 
were excluded (n=306). Eight women were excluded for incomplete date of birth or date 
of diagnosis, 8 for age younger than 15 or older than 99 years, 2 for age-morphology 
mismatch (Embryonal rhabdomyosarcoma) 11 for site-morphology mismatch (for 
example, Papillary serous cystadenocarcinoma, Papillary transitional cell carcinoma, 
Large-cell carcinoma) and one because the date of diagnosis preceded her date of birth. 
Seventeen duplicate registrations were combined, and 21 non-Saudi women were 
excluded because they were international patients, leading to a total of 1,957 women. For 
10 women, the region of residence was unknown (6 Saudi and 4 non-Saudi women), and 
these were excluded from regional analysis. 
6.4 Statistical analysis  
Incidence rates 
Incidence rates by five-year age group were calculated for the two calendar periods 2005-
2010 and 2011-2016 by region of residence and by stage at diagnosis. Age-standardised 
incidence rates were then derived for each period and region/stage as the sum of the 




Where the subscript i indicates age group, di is the number of women diagnosed in age 
group i, yi is the number of person-years at risk (approximated by sum of the mid-year 
female populations over the period in age group i), and wi is the weight given to age group 
i, i.e. the proportion of individuals in that age group in the world standard population.  
Estimation of net survival  
Five-year net survival probabilities and their 95% confidence intervals were estimated for 
women diagnosed during the two calendar periods 2005-2010 and 2011-2016, both for 
the whole population and for each of the three main administrative regions (Riyadh, 




that enough women were available for robust estimation of survival in each category, given 
the small population of these ten regions.  
Probabilities were estimated with the Pohar-Perme estimator150 in Stata IC 16 version 1, 
using the program stns.158 Life tables of all-cause mortality rates in the Saudi Arabian 
female population were utilised to correct for background mortality. Death due to any 
cause was the event of interest. Women who were alive on 31 December 2018 were 
censored. For the 291 (24%) women for whom ID number was not available, their follow-
up time was censored at the last known vital status recorded by the registry, if they were 
known to be alive at that date. The date of death in the registry, obtained from the death 
notification or death certificate, was used for women known to be dead.  
A cohort approach was followed for the period of diagnosis 2005-2010 for which at least 5 
years of potential follow-up were available for all women. For the period 2011-2016, a 
complete approach was used, where those diagnosed in calendar years for which 5 years 
of follow-up are not available (2014-2016) were censored at the closing date (Figure 8). 
One- and five-year net survival was estimated for each calendar period, and by region of 
residence and stage at diagnosis. Where at least 10 women were available for analysis in 
each age group, estimates were produced for each of five age groups (15–44, 45–54, 55–
64, 65–74, and 75-99 years) and an age-standardised summary estimate was derived 
using the International Cancer Survival Standard (ICSS) group 2 weights.153 If fewer than 
10 women were at risk for a single age group, they were combined with the women in the 
adjacent age group and the resulting survival estimate was assigned to both age groups, 
which were then used for age standardisation. If fewer than 10 women were at risk in two 
or more age groups, I only present the unstandardised estimate for all ages combined. 
Survival estimates for all women were not age-standardised if fewer than 50 women were 
at risk in a given analysis stratum. Further, estimates were not age-standardised if, for at 
least one of the age groups with 10 or more women, the last event occurred before 6 
months for 1-year estimates or before 3 years for 5-year estimates, and some women are 
still alive at the end of follow-up. This was done in order to obtain robust estimates, based 





Figure 8: Structure of survival analyses 
 
Imputation of missing data on stage 
Data on stage at diagnosis were missing for 11.3% of the women included in the survival 
analyses. This proportion was relatively low, but the option to impute missing stage was 
explored, because missing data can reduce efficiency and may introduce bias in the 
estimation of survival.  
In order to address missing data appropriately, the mechanism of missing data, and any 
associations between the variable with missing data and other variables in the data set 
that may be predictive of its values should be explored.  
The mechanisms that underlie missing data fall into three conventional categories. In 
situations where the data are considered to be missing completely at random (MCAR), the 
probability that an observation is missing is not dependent on any other variables in the 
data set, or on the outcome. In this case, the exclusion of observations (in this case, 
tumour records) with missing data will not bias estimates of the outcome, but they may 
lead to loss in statistical power, because of the smaller number of records that can be 
included in the analyses. 
Data are described as missing at random (MAR) when cases with incomplete data (here, 
data on stage at diagnosis) do differ in respect to the distribution of their values from those 
with complete data, but the chances of stage data being missing are independent of the 
underlying value, which is unknown, given other variables that are fully observed, or the 
outcome. An example is when records of elderly patients are more likely to have missing 
stage information and these patients are also more likely to have advanced stage, but the 
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
2005 0 1 2 3 4 5 6 7 8 9 10 11 12 13 2005
2006 0 1 2 3 4 5 6 7 8 9 10 11 12 2006
2007 0 1 2 3 4 5 6 7 8 9 10 11 2007
2008 0 1 2 3 4 5 6 7 8 9 10 2008
2009 Cohort analysis 0 1 2 3 4 5 6 7 8 9 2009
2010 0 1 2 3 4 5 6 7 8 2010
2011 0 1 2 3 4 5 6 7 2011
2012 0 1 2 3 4 5 6 2012
2013 0 1 2 3 4 5 2013
2014 complete analysis 0 1 2 3 4 2014
2015 0 1 2 3 2015
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true distribution of stage amongst those with missing values for stage is similar to that in 
patients in the same age group for whom stage is fully observed. 
Under the assumption that data for a given variable (in this case stage) are missing at 
random, multiple imputation of the missing values is a practical way to address the 
problem, by “filling the gaps” in the records with missing data. The approach is to obtain a 
value for the missing variable in a given record from the distribution of observed data for 
that variable, conditional on data from other variables. Thus, the stage at diagnosis in a 
woman of a given age, region of diagnosis and with a tumour of given grade can be 
imputed from the distribution of stage among women whose records are complete for 
these variables. 
The observed data are then combined with the imputed data to construct a complete 
dataset, in which there are no longer any missing data. This process is repeated several 
times, typically 5-20 times, to obtain a number of complete datasets. 
Data are missing not at random (MNAR) when the chance of data being missing depends 
on their unseen value, even given observed variables,159 for example if the main reason 
for missing stage was that women were directly referred to palliative care, typically with 
very advanced disease, but without investigation to determine the stage. Exclusion of 
these women could bias the estimation of survival for women with advanced disease, and 
thus for all women combined. Estimation under a MNAR assumption is complex and 
requires specifying the selection mechanism or how the distribution of the variable with 
missing data given fully observed variables differs between observations that do and do 
not have missing data.159 
The mechanism of missing data cannot be formally proven, but the association between 
missingness of stage and observed data for other variables can provide some indication 
of the mechanism.  
Missing data on stage are often not missing completely at random: missing data are more 
likely in women with advanced disease, in women who are medically unfit for staging or 
where investigation to determine the stage are deemed irrelevant for treatment decisions 
because the woman is receiving palliative care.160 
Missing stage in these data was associated with age older than 75, Region of residence 




diagnosis (Regions other than Riyadh and the Eastern Region), shorter follow-up time and 
less death during the follow-up period (Table 4, Table 6).  
Table 4: Association between missingness of stage and observed variables (univariable) (n=1,219) 
Variable Odds Ratio 95% CI P-value 
Age (years) 1.02 (1.00 - 1.03) 0.016 
20-44 1     
45-54 0.98 (0.60 - 1.58) 0.921 
55-65 1.00 (0.58 - 1.71) 0.988 
65-74 1.39 (0.78 - 2.45) 0.264 
75+ 2.18 (1.20     - 3.96) 0.010 
Region of residence      
Riyadh 1     
Makkah 1.43 (0.83 - 2.46) 0.203 
Eastern 1.04 (0.54 - 2.02) 0.908 
Other 3.10 (1.87 - 5.15) <0.001 
Region of diagnosis      
Riyadh 1     
Makkah 2.32 (1.45 - 3.73) <0.001 
Eastern 1.42 (0.70 - 2.90) 0.336 
Other 9.78 (5.88 - 16.24) <0.001 
Follow-up time (days) 0.9998 (0.9997 - 0.9999) 0.023 
Vital status (dead) 0.75 (0.38 - 0.85) 0.006 
Grade (n=878)      
I  reference     
II 0.57 (0.28 - 1.15) 0.118 
III 0.74 (0.36 - 1.49) 0.497 
IV 1.23 (0.77 - 2.92) 0.702 
 
The strongest determinant of missing stage was being diagnosed in regions other than the 
three main regions of Riyadh, Makkah or the Eastern Region, followed by living in one of 
those regions.  
Where stage at diagnosis was known, advanced stage (regional spread with lymph node 
involvement, with or without direct extension or distant metastasis) was associated with 
region of residence, region of diagnosis, older age at diagnosis and higher grade (Table 




Table 5: Association between advanced stage at diagnosis and other observed variables (univariable) 
(n=1,081) 
Variable Odds Ratio    P-value 
Age (years) 1.02 (1.00 - 1.02) 0.002 
20-44 reference     
45-54 0.91 0.66 - 1.26) 0.578 
55-65 1.23 (0.86 - 1.77) 0.249 
65-74 1.80 (1.20 - 2.72) 0.005 
75+ 1.65 (1.01 - 2.72) 0.045 
Region of residence      
Riyadh reference     
Makkah 0.60 (0.43 - 0.84) 0.003 
Eastern 1.17 0.81 - 1.69) 0.405 
Other 1.21 (0.86 - 1.70) 0.269 
Region of diagnosis      
Riyadh reference     
Makkah 0.54 (0.40 - 0.72) <0.001 
Eastern 0.85 (0.57 - 1.25) 0.407 
Other 0.26 (0.14 - 0.48) <0.001 
Grade (n=799)       
I  reference     
II 1.81 (1.05 - 3.12) 0.033 
III 2.50 (1.44 - 4.32) 0.001 
IV 3.12 (1.35 - 2.93) 0.007 
 
Given the observed data, being diagnosed in Makkah or “other” regions was associated 
with higher odds of missing data on stage at diagnosis (OR=2.32 for Makkah and 9.78 for 
other regions, p<0.001) but also lower odds of advanced stage among women for whom 
the data were available (OR=0.54 for Makkah and 0.26 for other regions, p<0.001). This 
suggests that women for whom data on stage were missing may have been those with 





Table 6: Characteristics of women and tumour grade by stage at diagnosis 
 Early stage Advanced stage Unknown stage 
 N  % N  % N  % 
Age       
15-44 217 59.62 110 30.2 37 10.2 
45-54 223 61.6 103 28.5 36 9.9 
55-64 131 55.3 82 34.6 24 10.1 
65-74 70 45.2 64 41.3 21 13.6 
75-99 44 43.6 37 36.6 20 19.8 
Region of residence 
Riyadh 183 57.4 113 35.4 23 7.2 
Makkah 237 65.7 88 24.4 36 10.0 
Eastern 115 53.7 83 38.8 16 7.5 
Other 147 46.1 110 34.5 62 19.4 
Region of diagnosis 
Riyadh 295 53.2 229 41.3 31 5.6 
Makkah 241 62.0 101 26.0 47 12.1 
Eastern 79 55.6 52 36.6 11 7.8 
Other 69 52.7 14 32.5 48 36.6 
Period of diagnosis  
2005-2010 317 58.8 166 30.8 56 10.4 
2011-2016 368 54.1 230 33.8 82 12.1 
Grade  
 I  66 67.4 20 20.4 12 12.2 
II  237 60.0 130 32.9 28 7.1 
III  177 51.6 134 39.1 32 9.3 
IV  18 43.9 17 41.5 6 14.6 
Unknown 187 54.8 95 27.9 59 17.3 
 
The marked difference in the odds ratio of missing stage between women living in one of 
the peripheral regions and women who were diagnosed in them can be explained by the 
large proportion of women living in these regions who were diagnosed in Riyadh. While 
virtually all women living in Riyadh and Makkah region were diagnosed in the same region 
they lived in, almost half of the women living in the ten peripheral regions were diagnosed 
in Riyadh and 10% were diagnosed in Makkah region. Further, over one third of women 
living in the Eastern Region were diagnosed in Riyadh (Figure 9). This is not surprising 





Figure 9: Proportion (%) of women diagnosed with invasive cervical cancer in each of the four regions for 
each region of residence 
 
Of all women diagnosed in the ten peripheral regions, 37% did not have information on 
stage. This proportion was reduced to 20% when women had a second referral hospital 
documented by the registry (Table 7), but the proportion of missing stage was only reduced 
in women who were referred to Makkah or Riyadh (none were referred to the Eastern 
Region) and remained at 39% for women referred within the ten peripheral regions. 
Table 7: Proportion of women with missing stage for each region of diagnosis for all women and for women 
with a second referral hospital 






(%)   Missing 
stage 
 (%) 
Riyadh 555 31 (5.6)  357 11  (3.1) 
Makkah 389 47 (12.1)  225 19 (8.4) 
Eastern 142 11 (7.8)  85 3  (3.5) 
Other 131 48 (36.6)  59 12 (20.3) 
Total 1,217 137 (11.3)  726 45 (6.2) 
 
Conventionally, multiple imputation and estimation of the outcome are carried out in a one-
step approach using parametric methods. Multiple imputation of missing values for 

















































been frequently addressed. I used a multinomial logistic model to impute stage where it 
was missing. I generated five imputed datasets, using a model that included the Nelson-
Aalen estimate of the cumulative hazard, the event indicator (death), and dummy variables 
for grade, age group and region of diagnosis161. The five resulting complete datasets had 
very similar stage distributions (Table 8).  
Table 8: Stage distribution in the imputed datasets 
Imputation localised regional distant Total 
 N   (%) N   (%) N   (%) N 
Complete observations 378  (34.97) 480 (44.40) 223 (20.63) 1,081 
1 437 (35.88) 534 (43.84) 247 (20.28) 1,218 
2 433 (35.55) 536 (44.01) 249 (20.44) 1,218 
3 442 (36.29) 528 (43.35) 248 (20.36) 1,218 
4 448 (36.78) 519 (42.61) 251 (20.61) 1,218 
5 441 (36.21) 533 (43.76) 244 (20.03) 1,218 
 
I estimated age-standardised net survival for each of the complete datasets by stage and 
calendar period of diagnosis, at one and five years after diagnosis. We then combined the 
point estimates of survival and their variance, using Rubin's rule,162 to obtain a single 








where i indexes the imputation up to k, the number of imputations. This represents the 
mean of the survival estimates from the k complete data sets after imputation.  
The mean of the variances of these survival estimates, the “within-imputation” variance 








where SE is the standard error of the survival estimate from each imputed dataset. 
Further, the between-imputation variance (B) is calculated as: 
𝐵 =







This accounts for the extra uncertainty in the variance of the pooled estimate that arises 
from the missing data. 
The total variance is the sum of B and W corrected for the number of imputations: 




The 95% confidence intervals of the pooled estimate after multiple imputation are then 
derived conventionally for a normal distribution as: 𝑁𝑆̅̅ ̅̅ ± 1.96√𝑉𝐴𝑅 
Effect of stage on variation in survival by region of residence  
I estimated net survival for women of all ages by region of residence and stage at diagnosis 
without age standardisation, in order to avoid small numbers in older age groups. Although 
older women tended to be diagnosed at a more advanced stage (Figure 10), the 
comparability of estimates between regions is not expected to be compromised since the 
age distribution between regions was similar (p for chi2=0.64, 12 degrees of freedom) 
(Figure 11). 
Figure 10: Age distribution (%) of Saudi women diagnosed with cervical cancer between 2005 and 2016, by stage 





Figure 11: Age distribution (%) of Saudi women diagnosed with cervical cancer between 2005 and 2016, by 
region of residence (n=1,213) 
  
Sensitivity analysis 
In order to explore whether censoring the follow-up time for women without an available 
ID number could bias the survival estimates, net survival was estimated while restricting 
the analysis to women with NIC follow-up, which required an ID number. 
In order to explore whether the complete approach used for women diagnosed during 
2011-2016, who were followed up to 31 December 2018, could bias the evaluation of 
survival trends, survival was also estimated for women diagnosed during 2005-2010 while 
censoring the follow-up at 31 December 2012, i.e., restricting the follow-up duration to be 
the same as that used for women diagnosed during 2011-2016. 
Net survival estimates using life tables produced by the Global Burden of Disease study 
were compared to those obtained using UNPD life tables. 
Mortality rates 
Given the clear under-enumeration of deaths that were attributed to cervical cancer in the 
MOH mortality database, I instead used deaths due to cancer in women registered with 
cervical cancer as the numerator for mortality. These were obtained primarily from death 




update the vital status of women already existing in the registry or as a primary source for 
case finding, and can therefore be considered an independent source of cervical cancer 
mortality data.  
I included women who were diagnosed with invasive cervical cancer from 1994 onwards 
and had died from cancer between 2005 and 2016 (n=326). I further excluded two women 
who were younger than 20 at the time of death and one who was an international patient. 
I calculated mortality rates by age at death (five-year age groups) for the two calendar 
periods 2005-2010 and 2011-2016, and separately for Saudi and non-Saudi women. I 
derived age-standardised mortality rates in the same way as age-standardised incidence 
rates. I did not estimate mortality by region because there were too few deaths and 
because the region a woman lived in at the time of diagnosis may differ from the one she 




Chapter 7. Results 
7.1 Study population characteristics 
During the period 2005-2016, 2,313 women were diagnosed with cervical cancer (1,470 
Saudis and 843 non-Saudis) of whom 1,957 had invasive disease eligible for inclusion in 
incidence calculation and 1,219 were included in the survival estimation. A further 306 
women were registered with carcinoma in situ.  
The mean age at diagnosis for invasive cancer was 51.4±13.3 years. Non-Saudis were 
four years younger on average (Table 10). This may partially reflect the population 
distribution of non-Saudi women who are mostly of employment age (Figure 5), but the 
proportion of non-Saudi women diagnosed at younger age tends to be higher than that of 
Saudi women (Figure 12, Table 10). The age-specific incidence rates for non-Saudi 
women were higher at every age group than those for Saudi women (Error! Reference 
source not found.). The unusually high incidence rates in women aged 75-79 may reflect 
an under-enumeration of the non-Saudi population in that age group or misclassification 
of women aged 75-79 as being over 80 in the census (Table 9). Given the more plausible 
age distribution of women diagnosed in the registry (Figure 12), it seems the registry 
documents age more accurately than the census.  
While 26% of Saudi women lived in Riyadh region, 45% were diagnosed there and only 
about half the proportion living in one of the ten peripheral regions were diagnosed in those 
regions. These large differences between region of residence and region of diagnosis were 
not apparent in non-Saudi women. Non-Saudi women had a smaller proportion of in situ 
tumours (10.2%) than Saudi women (14.9%). A higher percentage of non-Saudi women 
were diagnosed at localised stage, but they had almost double the proportion of unknown 
stage (23% versus 12%). This difference was larger in the earlier period 2005-2010. The 
proportion of women registered as dead by registry follow-up was much lower for non-
Saudi women. Ninety-nine percent of women had a histologically verified diagnosis. 
Characteristics of the women included in the survival analysis did not differ from those of 










































































Figure 13: Age-specific incidence rates for invasive cervical cancer in Saudi and non-Saudi women (n=1,957), 




Table 9: Population counts and number of women diagnosed with invasive cervical cancer in each 5-year age 
group 
 Saudi  non-Saudi 
  2005-2010   2011-2016     2005-2010   2011-2016   
Age group Population n Population n  Population n Population n 
20 - 24 5,091,022 1 5,553,048 6  723,479 0 1,082,624 1 
25 - 29 5,042,146 10 5,487,974 7  1,466,043 6 2,193,810 10 
30 - 34 4,561,534 28 4,965,737 21  1,457,582 28 2,181,149 24 
35 - 39 3,970,635 59 4,320,091 65  1,873,654 67 2,803,776 46 
















































































45 - 49 2,740,968 77 2,985,082 120  917,396 56 1,372,803 75 
50 - 54 2,183,876 73 2,378,254 94  344,896 33 516,101 63 
55 - 59 1,654,520 52 1,801,606 76  225,444 20 337,351 45 
60 - 64 1,220,986 52 1,329,560 60  161,286 24 241,343 28 
65 - 69 838,538 48 911,118 43  99,494 28 148,894 16 
70 - 74 593,181 24 645,016 42  64,254 10 96,161 10 
75 - 79 382,194 24 414,449 34  15,818 11 23,679 13 
80+ 480,750 20 522,207 27  22,277 3 33,351 4 





Table 10: Characteristics of women diagnosed with invasive cervical cancer during the calendar period 2005-
2016 (n=1,957) 
  Saudi  Non-Saudi 
  2005-2010  2011-2016  All periods  2005-2010  2011-2016  All periods 
  mean SD  mean SD  mean SD  mean SD  mean SD  mean SD 
Age 52.5 13.7  53.3 13.6  52.9 13.6  47.97 12.4  49.3 12.1  48.7 12.2 
 n %  n %  n %  n %  n %  n % 
Region of residence                  
Riyadh 145 26.4  173 25.3  318 25.8  92 27.2  88 22.7  180 24.8 
Makkah 157 28.6  204 29.9  361 29.3  187 55.3  202 52.2  389 53.7 
Eastern 94 17.1  123 18.0  217 17.6  25 7.4  50 12.9  75 10.3 
Other 150 27.3  180 26.4  330 26.8  32 9.5  45 11.6  77 10.6 
Unknown 3 0.6   3 0.4   6 0.5   2 0.6   2 0.5   4 0.6 
Region of diagnosis                  
Riyadh 249 45.4  305 44.7  554 45.0  97 28.7  98 25.3  195 26.9 
Makkah 171 31.2  218 31.9  389 31.6  186 55.0  205 53.0  391 53.9 
Eastern 57 10.4  87 12.7  144 11.7  22 6.5  47 12.1  69 9.5 
Other 71 12.9  72 10.5  143 11.6  31 9.2  37 9.6  68 9.4 
International 1 0.2  0 0.0  1 0.1  0 0.0  0 0.0  0 0.0 
Unknown 0 0.0   1 0.2   1 0.1   2 0.6   0 0.0   2 0.3 
Stage                  
Localised 153 27.9  226 33.1  379 30.8  114 33.7  194 50.1  308 42.5 
Regional 234 42.6  245 35.9  479 38.9  91 26.9  84 21.7  175 24.1 
Distant 98 17.9  127 18.6  225 18.3  43 12.7  32 8.3  75 10.3 
Unknown 64 11.7  85 12.5  149 12.1  90 26.6  77 19.9  167 23.0 
Grade                                   
Grade I 38 6.9  60 8.8  98 8.0  20 5.9  32 8.3  52 7.2 
Grade II 192 35.0  205 30.0  397 32.2  99 29.3  141 36.4  240 33.1 
Grade III 136 24.8  206 30.2  342 27.8  100 29.6  95 24.6  195 26.9 
Grade IV 23 4.2  18 2.6  41 3.3  20 5.9  25 6.5  45 6.2 
Unknown 160 29.1   194 28.4   354 28.7   99 29.3   94 24.3   193 26.6 
Basis of diagnosis                  
Pathology 532 96.9  673 98.5  1,205 97.8  336 99.5 0 384 99.3  720 99.3 
Clinical/imaging 2 0.4  2 0.3  4 0.3  1 0.3 0 1 0.3  2 0.3 
Death certificate only 10 1.8  4 0.6  14 1.1  0 0  1 0.3  1 0.1 
Unknown 5 0.9  4 0.6  9 0.7  1 0.3  1 0.3  2 0.3 
Proportion dead by 
registry follow-up 
124 22.6  110 16.1  234 19.0  22 6.5  30 7.75  52 7.2 
Total 549     683     1,232     338     387     725   






Table 11: Characteristics of Saudi women included in the survival analysis (n=1,219) 
 2005-2010  2011-2016  All periods 
 Mean SD  Mean SD  Mean SD 
Age 52.7 13.59  53.73 13.47  52.8 13.52 
 n %  n %  n % 
Region of residence 
 
   
 
   
  
Riyadh 145 26.90  174 25.59  319 26.17 
Makkah 157 29.13  204 30.00  361 29.61 
Eastern 92 17.07  122 17.94  214 17.56 
Other 142 26.35  177 26.03  319 26.17 
Unknown 3 0.56  3 0.44  6 0.49 
Region of diagnosis 
 
   
 
   
  
Riyadh 249 46.20  306 45.00  555 45.53 
Makkah 171 31.73  218 32.06  389 31.91 
Eastern 55 10.20  87 12.97  142 11.65 
Other 63 11.69  68 10.00  131 10.75 
Unknown 1 0.19  1 0.15  2 0.16 
Stage 
 
   
 
   
  
Localised 153 28.39  225 33.09  378 31.01 
Regional 234 43.41  246 36.18  480 39.38 
Distant 96 17.81  127 18.68  223 18.29 
Unknown 56 10.39  82 12.06  138 11.32 
Grade 
 
   
 
   
  
I 38 7.05  60 8.82  98 8.04 
II 191 35.44  205 30.15  396 32.49 
III 136 25.23  207 30.44  343 28.00 
IV 23 4.27  18 2.65  41 3.36 
Unknown 151 28.01  190 27.94  341 27.97 
Basis of diagnosis 
 
   
 
   
  
Pathology 533 98.89  674 99.12  1,207 99.02 
Clinical/imaging 2 0.37  2 0.29  4 0.33 
Unknown 4 0.74  4 0.59  8 0.66 
Censored within 5 years 
of diagnosis 
130 24.1  284 41.7  414 34.00 
Total 539    680    1,219   





The proportion of women who were found to be dead after linkage to the National 
Information Center (NIC) records was consistently higher than the proportion who were 
registered as dead by the Saudi Cancer Registry (SCR) in every region and period, and 
was more than double the proportion previously captured by the SCR (Table 12). 
Table 12: Proportion of Saudi Women included in survival analysis who were dead by linkage to the National 
Information Center (NIC) and by registry follow-up for each calendar period of diagnosis and region of 
residence (n=1,213) 
NIC  Registry 
Period  Period 
 2005-2010  2011-2016  2005-2010  2011-2016 
Region n dead  n dead  n dead  n dead 
  n %   n %   n %   n % 
Riyadh 102 43 42.2  144 59 41.0  145 33 22.8  174 31 17.8 
Makkah 108 58 53.7  175 64 36.6  157 30 19.1  204 38 18.6 
Eastern 67 36 53.7  102 53 52.0  92 20 21.7  122 24 19.7 
Other 100 49 49.0  139 56 40.3  142 31 21.8  177 16 9.0 





Regional distribution of stage 
The proportion of women diagnosed at localised stage increased from 2005-2010 to 2011-
2016 in the three main regions. This increase in localised stage was minimal in the 10 
other regions where more women were still being diagnosed at regional stage in 2011-
2016. Of women with a documented stage at diagnosis, Makkah had the highest 
proportion of localised stage and the lowest proportion of distant stage. A higher 
percentage of women had an unknown stage in the other 10 regions compared to the three 
main regions (Figure 14, Figure 15). The regional distribution of stage in the imputed 
datasets was similar to that of known stage, with Makkah having the highest proportion of 
localised stage and lowest proportion of distant stage in both periods (Figure 16).   
Figure 14: Stage distribution of invasive cervical cancer (2005-2016) for women living in Riyadh, Makkah, 








































Figure 15: Stage distribution of invasive cervical cancer (2005-2016) for Saudi women included in survival 
analysis and living in Riyadh, Makkah, Eastern or one of the 10 remaining administrative regions (n=1,213) 
(region was missing for 6 women) 
 
Figure 16: Stage distribution of invasive cervical cancer (2005-2016) for Saudi women included in the survival 
analysis and living in Riyadh, Makkah, Eastern or one of the 10 remaining administrative regions using the 








































































Time trend of stage at diagnosis 
Over the 12 years examined, there has been an increase in the proportion of women 
diagnosed at localised stage and a decrease in those with unknown stage. After 2012, 
localised overtook regional as the most common stage at diagnosis (Figure 18). A similar 
trend was seen for Saudi women included in the survival analysis (Figure 18) 
 
 
Figure 18: Stage distribution by year of diagnosis for Saudi women included in the survival analysis (n=1,219) 
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Figure 17: Stage distribution by year of diagnosis for all women diagnosed with invasive cervical cancer in 




7.2 Age-standardised incidence rates 
The age-standardised incidence rate (ASIR) for invasive cervical cancer in women of all 
nationalities was 1.66 and 1.76 per 100,000 women per year in 2005-2010 and 2011-2016, 
respectively. 
By region of residence 
The ASIR of invasive cervical cancer varied between regions and was higher in the three 
main regions than the ten peripheral regions. Makkah region had the highest ASIRs in 
both periods. There was no remarkable change in ASIR between the two periods (Table 
13). 
Table 13: Crude and age-standardised incidence rates (ASIRs) for invasive cervical cancer by region for all 
nationalities (n=1,947). 
By nationality and stage 
ASIRs of invasive cervical cancer in non-Saudi women were higher for each stage of 
invasive cancer than those in Saudi women, and especially for unknown stage. ASIR for 
cervical carcinoma in situ was slightly lower for non-Saudis. There was no remarkable 
change between the two periods 2005-2010 and 2011-2016 (Table 14, Figure 19). 
2005-2010  2011-2016 
 N crude ASIR 95% CI  N crude ASIR       95% CI 
All  902 1.37 1.66 (1.55 - 1.78)  1,076 1.40 1.76 (1.65 - 1.87) 
Riyadh 237 1.51 2.10 (1.78 - 2.41)  261 1.41 1.93 (1.66 - 2.20) 
Makkah 344 2.04 2.32 (2.05 - 2.58)  406 2.01 2.42 (2.17 - 2.68) 
Eastern 119 1.25 1.68 (1.34 - 2.01)  171 1.57 2.20 (1.84 - 2.57) 
Other 182 0.75 0.88 (0.75 - 1.02)  223 0.82 0.98 (0.84 - 1.11) 
Asir 32 0.63 0.73 (0.47 - 0.99)  45 0.79 0.97 (0.68 - 1.27) 
Baha 10 0.88 0.81 (0.29 - 1.33)  9 0.72 0.67 (0.22 - 1.12) 
Hail 9 0.57 0.75 (0.22 - 1.27)  16 0.90 1.17 (0.56 - 1.78) 
Jazan 13 0.36 0.39 (0.17 - 0.60)  18 0.45 0.48 (0.25 - 0.71) 
Jouf 12 1.10 1.52 (0.62 - 2.42)  17 1.38 1.92 (0.95 - 2.90) 
Madinah 46 1.02 1.14 (0.79 - 1.49)  52 1.00 1.18 (0.85 - 1.52) 
Najran 13 1.01 1.33 (0.56 - 2.10)  12 0.82 1.04 (0.41 - 1.67) 
Northern 3 0.36 0.59 (0.00 - 1.27)  7 0.75 0.96 (0.22 - 1.71) 
Qassim 27 0.91 1.14 (0.68 - 1.61)  34 1.01 1.25 (0.79 - 1.71) 




Table 14: Crude and age-standardised incidence rates of invasive cervical cancer by calendar period, 
nationality and stage (n=2,262) 
  2005-2010   2011-2016 
  n crude ASIR 95% CI  n Crude ASIR 95% CI 
Saudi In situ 59 0.21 0.20 (0.17 - 0.24)  61 0.19 0.19 (0.15 - 0.22) 
 All invasive 549 1.04 1.28 (1.17 - 1.40)  683 1.19 1.47 (1.36 - 1.60) 
 Localised 153 0.29 0.33 (0.28 - 0.39)  226 0.39 0.46 (0.40 - 0.52) 
 Regional 243 0.44 0.54 (0.47 - 0.61)  245 0.43 0.53 (0.46 - 0.60) 
 Distant 98 0.19 0.25 (0.20 - 0.31)  127 0.22 0.29 (0.24 - 0.35) 
 Unknown 64 0.12 0.15 (0.11 - 0.19)  85 0.15 0.19 (0.14 - 0.23) 
Non-Saudi In situ 17 0.31 0.22 (0.14 - 0.29)  20 0.23 0.22 (0.14 - 0.31) 
 All invasive 338 2.74 4.38 (3.71 - 5.05)  387 2.04 3.48 (3.00 - 3.96) 
 Localised 114 0.91 1.48 (1.07 - 1.89)  194 1.02 1.56 (1.25 - 1.86) 
 Regional 91 0.75 1.19 (0.86 - 1.53)  84 0.45 0.88 (0.63 - 1.13) 
 Distant 43 0.34 0.68 (0.39 - 0.97)  32 0.17 0.29 (0.16 - 0.43) 
 Unknown 90 0.73 1.02 (0.72 - 1.31)  77 0.40 0.78 (0.53 - 1.03) 
 








































































Linkage to death records 
Seventy-six percent of women included in the survival analysis had a valid national ID 
number enabling NIC follow-up. The proportion of women with information on national ID 
number increased over the study period (Figure 21), but women living in the 10 peripheral 
regions had the least increase, leading to a lower proportion of available ID numbers in 
the period 2011-2016. In both periods, less than half the women diagnosed in those 10 
regions had an ID number (Table 15). More women diagnosed at localised stage and 
women with unknown stage had missing ID numbers. The age difference between women 
with and without NIC follow-up was not statistically significant (mean age was 53 for 
women with, and 54.2 for women without NIC follow-up, p=0.17). 
Table 15: Number and proportion (%) of women included in survival analysis who had NIC follow-up data by 
calendar period, region of residence, region of diagnosis and stage at diagnosis. 
    2005-2010     2011-2016     All periods 
   NIC follow-up    NIC follow-up    NIC follow-up 
 n n %  n n %  n n % 
Region of residence 
Riyadh 145 102 70.3  174 144 82.8  319 246 77.1 
Makkah 157 108 68.8  204 171 83.8  361 279 77.3 
Eastern 92 66 71.7  122 100 82.0  214 166 77.6 
Other 142 99 69.7  177 133 75.1  319 232 72.7 
Total 536 375 70.0  677 548 81.0  1,213 923 76.1 
Region of diagnosis 
Riyadh 249 190 76.3  306 267 87.3  555 457 82.3 
Makkah 171 121 70.8  218 182 83.5  389 303 77.9 
Eastern 55 36 65.5  87 69 79.3  142 105 73.9 
Other 63 30 47.6  68 32 47.1  131 62 47.3 
Total 538 377 70.1  679 550 81.0  1,217 927 76.2 
Stage at diagnosis 
Localised 153 93 60.8  225 177 78.7  378 270 71.4 
Regional 234 182 77.8  246 216 87.8  480 398 82.9 
Distant 96 70 72.9  127 110 86.6  223 180 80.7 
Unknown 56 32 57.1  82 48 58.5  138 80 58.0 





Age-specific net survival 
Net survival decreased with increasing age at diagnosis for women diagnosed at 55 or 
older, and especially for those 65 and older (Figure 21, Table 16). Survival at one year 
since diagnosis was very similar in each age group for women diagnosed during 2005-
2010 and 2011-2016, but was difficult to compare at five years due to the small number of 
women in older age groups (Table 17). 
Figure 21: Age-specific net survival probabilities using ICSS (international Cancer Survival Standard) age 




























































Table 16: 1- and 5- year net survival by ICSS age groups for Saudi women diagnosed with cervical cancer 
during 2005-2016 (n=1,219) 
Age N 1-year net survival   5-year net survival 
15-44 364 89.2 ( 85.8 - 92.6 )  68.7 ( 62.9 - 73.7 ) 
45-54 362 88.9 ( 85.5 - 92.3 )  63.6 ( 57.2 - 68.6 ) 
55-64 237 81.2 ( 75.8 - 86.5 )  52.8 ( 45.9 - 60.7 ) 
65-74 155 67.5 ( 59.7 - 75.3 )  39.1 ( 28.5 - 46.3 ) 
75+ 101 57.8 ( 47.3 - 68.2 )  30.1 ( 22.7 - 43.5 ) 
 
Table 17: Number of women at risk at the beginning of each year of follow-up in each ICSS age group 
 Year of follow-up 
age group 1 2 3 4 5 
15-44 364 282 239 196 171 
45-54 362 281 235 187 153 
55-64 237 158 119 102 76 
65-74 155 88 64 44 36 
75+ 101 48 32 23 19 
Total 1219 857 689 552 455 
 
Time trends in age-standardised net survival 
From 2005-2010 to 2011-2016, age-standardised net survival did not change for all Saudi 
women and all stages combined. Women living in Makkah region moved from having the 
lowest 5-year net survival during 2005-2010 (49.9%; 95%CI 39.4-60.3) to the highest 
during 2011-2016 (69.1; 60.1-78.0), while survival of women living in Riyadh, the Eastern 
Region and the other 10 regions remained the same or decreased slightly. There was a 
small increase in 5-year net survival for localised and regional stage and decline for distant 
stage and unknown stage. Survival for women with unknown stage was similar to that for 
women diagnosed at a localised or regional stage. Stage-specific net survival did not 




Table 18: Age-standardised 1- and 5-year net survival estimates, with 95% confidence intervals (CI), by region 
of residence and stage at diagnosis, in 2005-10 and 2011-16. 
 Calendar period n  1-year net survival  5-year net survival 
 
2005-10 539  81.0 ( 76.8 - 85.2 )  59.2 ( 52.7 - 65.7 ) 
  2011-16 680  79.4 ( 75.8 - 83.0 )  59.7 ( 54.7 - 64.6 ) 
Region of residence                
Riyadh 2005-10 145  84.5 ( 77.4 - 91.6 )  59.0 ( 48.6 - 69.3 ) 
 
2011-16 174  77.1 ( 70.1 - 84.2 )  55.8 ( 47.3 - 64.2 ) 
                 
Makkah 2005-10 157  80.5 ( 72.9 - 88.1 )  49.9 ( 39.4 - 60.3 ) 
 
2011-16 204  84.6 ( 78.7 - 90.4 )  69.1 ( 60.1 - 78.0 ) 
                 
Eastern 2005-10 92  79.6 ( 70.7 - 88.6 )  52.9 ( 42.4 - 63.4 ) 
 
2011-16 122  79.1 ( 71.0 - 87.3 )  53.4 ( 42.8 - 64.0 ) 
                 
Other 2005-10 142  78.2 ( 71.3 - 85.1 )  64.8 ( 53.8 - 75.9 ) 
  2011-16 177  74.1 ( 66.8 - 81.3 )  57.6 ( 48.8 - 66.4 ) 
Stage 
 
               
Localised 2005-10 153  88.1 ( 80.3 - 95.8 )  67.4 ( 57.3 - 77.5 ) 
 
2011-16 225  90.0 ( 84.1 - 95.9 )  73.8 ( 63.5 - 84.1 ) 
                 
Regional 2005-10 234  86.4 ( 81.0 - 91.8 )  59.4 ( 49.7 - 69.0 ) 
 
2011-16 246  83.5 ( 78.0 - 89.0 )  66.5 ( 58.8 - 74.3 ) 
                 
Distant 2005-10 96  61.9 ( 52.1 - 71.8 )  32.1 ( 22.2 - 42.0 ) 
 
2011-16 127  55.6 ( 46.5 - 64.7 )  25.2 ( 16.6 - 33.8 ) 
                 
Unknown 2005-10* 56  84.8 ( 73.1 - 96.4 )  72.0 ( 56.7 - 87.4 ) 
  2011-16 82  70.4 ( 58.6 - 82.2 )  63.4 ( 49.9 - 77.0 ) 
Stage (Imputed) §                
Localised 2005-10 879  88.2 ( 80.7 - 95.8 )  69.6 ( 59.3 - 79.9 ) 
 2011-16 1304  89.9 ( 84.2 - 95.7 )  74.3 ( 64.9 - 83.6 ) 
                 
Regional 2005-10 1282  85.8 ( 80.5 - 91.1 )  60.8 ( 51.3 - 70.3 ) 
 2011-16 1376  84.3 ( 78.9 - 89.6 )  68.2 ( 60.5 - 75.9 ) 
                 
Distant 2005-10 529  61.7 ( 52.2 - 71.3 )  32.0 ( 22.0 - 41.9 ) 
 2011-16 720  54.3 ( 45.1 - 63.6 )  24.9 ( 16.3 - 33.4 ) 
*unstandardised 





Figure 22: Age-standardised 1- and 5-year net survival trends by stage at diagnosis and region of residence 
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Net survival by region and stage 
Unstandardised stage-specific net survival for women diagnosed during the 12-year period 
2005-2016 was similar between regions except for distant stage, for which 5-year net 
survival in the Eastern region was remarkably lower than that in all other regions (Table 
19, Figure 23). When including unknown stage as a category using the unimputed dataset, 




Table 19: Stage-specific 1- and 5-year unstandardised net survival estimates, with 95% confidence intervals 
(CI), by region of residence for women diagnosed with invasive cervical cancer during 2005-2016. 
   N 1-year net survival      5-year net survival 
Region         
 Riyadh 319 84.0 ( 79.8 - 88.2 )  57.6 ( 51.5 - 63.7 ) 
 Makkah 361 84.8 ( 80.9 - 88.7 )  57.8 ( 51.9 - 63.8 ) 
 Eastern 214 80.1 ( 74.5 - 85.8 )  50.0 ( 42.4 - 57.7 ) 
 Other 319 79.3 ( 74.4 - 84.1 )  60.2 ( 54.1 - 66.3 ) 
              
Region and stage              
Riyadh Localised 96 93.0 ( 87.7 - 98.4 )  71.6 ( 60.8 - 82.5 ) 
 Regional 138 88.8 ( 83.5 - 94.1 )  62.1 ( 53.4 - 70.9 ) 
 Distant 62 58.1 ( 45.7 - 70.5 )  23.1 ( 11.8 - 34.4 ) 
 Unknown 23 94.1 ( 83.3 - 105.0 )  77.2 ( 54.9 - 99.5 ) 
         
 
     
Makkah Localised 142 87.9 ( 82.2 - 93.7 )  62.2 ( 52.4 - 72.1 ) 
 Regional 128 92.4 ( 87.6 - 97.2 )  59.9 ( 50.3 - 69.5 ) 
 Distant 55 62.4 ( 49.1 - 75.7 )  34.1 ( 20.3 - 47.9 ) 
 Unknown 36 79.3 ( 64.8 - 93.8 )  68.1 ( 51.2 - 85.0 ) 
         
 
     
Eastern Localised 65 98.2 ( 94.6 - 101.7 )  75.4 ( 63.2 - 87.6 ) 
 Regional 87 86.2 ( 78.7 - 93.7 )  52.7 ( 40.9 - 64.6 ) 
 Distant 46 48.3 ( 33.5 - 63.1 )  7.0 ( 0.0 - 14.8 ) 
 Unknown 16 68.8 ( 44.4 - 93.1 )  58.9 ( 32.4 - 85.5 ) 
         
 
     
Other Localised 72 98.1 ( 94.5 - 101.7 )  89.4 ( 80.7 - 98.2 ) 
 Regional 127 83.4 ( 76.7 - 90.0 )  62.7 ( 53.8 - 71.5 ) 
 Distant 58 59.9 ( 47.4 - 72.5 )  32.1 ( 19.5 - 44.8 ) 
 Unknown 62 70.5 ( 56.5 - 84.5 )  57.0 ( 40.6 - 73.4 ) 
Region and imputed stage             
Riyadh Localised 100 93.6 ( 88.1 - 99.1 )  75.1 ( 63.7 - 86.5 ) 
 Regional 152 89.5 ( 84.1 - 94.9 )  64.9 ( 55.7 - 74.2 ) 
 Distant 67 59.0 ( 46.4 - 71.6 )  23.9 ( 11.9 - 35.9 ) 
              
Makkah Localised 156 88.9 ( 83.1 - 94.7 )  70.5 ( 59.6 - 81.3 ) 
 Regional 142 93.2 ( 88.3 - 98.1 )  62.6 ( 52.2 - 72.9 ) 
 Distant 63 63.7 ( 50.1 - 77.3 )  38.9 ( 23.4 - 54.4 ) 
              
Eastern Localised 74 98.7 ( 95.1 - 100.0 )  79.1 ( 66.4 - 91.7 ) 
 Regional 93 87.2 ( 79.5 - 94.8 )  56.2 ( 43.6 - 68.7 ) 
 Distant 47 49.6 ( 34.4 - 64.8 )  7.9 ( 0.0 - 16.6 ) 
              
Other Localised 104 98.7 ( 95.1 - 100.0 )  94.2 ( 85.0 - 100.0 ) 
 Regional 147 84.2 ( 77.4 - 90.9 )  67.8 ( 58.2 - 77.4 ) 
  Distant 68 60.6 ( 47.9 - 73.2 )  34.3 ( 20.8 - 47.7 ) 






Figure 23: 1- and 5-year unstandardised net survival estimates by region of residence and stage at diagnosis 
for women diagnosed with invasive cervical cancer during 2005-2016. 
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Restriction to women with NIC follow-up 
Restricting the analysis to the 928 women with NIC follow-up did not change the results 
for any of the regions, with the largest difference being a 3.6% absolute increase for Riyadh 
in 2005-2010 (Table 20, Figure 24). 
Table 20: 1- and 5-year age-standardised net survival estimates, with 95% confidence intervals (CI), by region 
of residence and stage at diagnosis for women with NIC follow-up (n=928). 
 Calendar period n  1-year net survival  5-year net survival 
 
2005-10 377  80.5 ( 76.8 - 85.2 )  58.6 ( 51.8 - 65.5 ) 
 
2011-16 551  79.2 ( 75.8 - 83.0 )  59.6 ( 54.5 - 64.8 ) 
Region of residence                
Riyadh 2005-10 102  87.6 ( 82.3 - 92.9 )  62.6 ( 52.6 - 72.6 ) 
 
2011-16 144  78.0 ( 71.6 - 84.4 )  57.0 ( 49.0 - 65.0 ) 
                 
Makkah 2005-10 108  80.5 ( 72.7 - 88.2 )  48.5 ( 37.7 - 59.2 ) 
 
2011-16 171  83.7 ( 77.5 - 89.8 )  68.8 ( 59.6 - 77.9 ) 
                 
Eastern 2005-10* 66  79.4 ( 69.5 - 89.3 )  56.2 ( 43.6 - 68.8 ) 
 
2011-16 100  78.3 ( 69.7 - 86.8 )  51.9 ( 41.0 - 62.9 ) 
                 
Other 2005-10 99  77.2 ( 69.5 - 84.8 )  62.7 ( 50.6 - 74.7 ) 




      
 
      
Localised 2005-10* 93  91.2 ( 85.1 - 97.3 )  78.0 ( 68.2 - 87.8 ) 
 
2011-16 177  90.4 ( 84.2 - 96.6 )  74.2 ( 63.6 - 84.8 ) 
                 
Regional 2005-10 182  86.2 ( 80.1 - 92.2 )  60.4 ( 50.3 - 70.4 ) 
 
2011-16 216  83.2 ( 77.5 - 88.8 )  66.5 ( 58.6 - 74.4 ) 
                 
Distant 2005-10* 70  63.9 ( 52.5 - 75.3 )  33.5 ( 22.1 - 45.0 ) 
 
2011-16 110  54.0 ( 44.3 - 63.6 )  23.3 ( 14.8 - 31.8 ) 
                 
Unknown 2005-10* 32  81.6 ( 68.2 - 95.0 )  67.5 ( 50.9 - 84.1 ) 






Figure 24: Age standardised 5-year net survival, with 95% confidence intervals (CI). (a) using NIC follow-up 




















































Censoring survival time at 31 December 2012 for women diagnosed during 2005-2010 
Using a complete approach for women diagnosed during 2005-2010 while censoring 
follow-up until 31 December 2012 did not change the survival estimate for all ages 
combined compared to the cohort approach, but was 5% higher for women diagnosed at 
a distant stage (Figure 25). 
Figure 25: Effect of censoring survival time at 31/12/2012 on 5-year age-standardised survival estimates for 
women diagnosed during 2005-2010 
 
Cohort: 5 years follow-up for all women 















































































Age-standardised net survival using Global Burden of disease life tables 
One and 5-year age-standardised net survival estimates were slightly lower when using 
life tables for Saudi Arabia obtained from the Global Burden of Disease study. The 
difference was less than 1% for all 1-year net survival estimates and the largest difference 
was 3.3% for women diagnosed at localised stage during 2005-2010 (Table 21). 
Table 21: Age-standardised 1- and 5-year net survival, 95% confidence intervals (CIs), for women 
diagnosed with invasive cervical cancer in Saudi Arabia during 2005-2011 using Global Burden of 
Disease life tables (n=1,219) 
         N 1-year net survival 
 
5-year net survival   
               
 
2005-10 539 80.6 ( 76.5 - 84.8 ) 56.5 ( 50.7 - 62.4 ) 
  2011-16 680 79.1  ( 75.5 - 82.7 ) 58.2 ( 53.5 - 62.9 ) 
Region of residence 
             
Riyadh 2005-10 145 84.2 ( 77.1 - 91.2 ) 58.2 ( 48.3 - 68.2 )  
2011-16 174 76.9 ( 70.0 - 83.9 ) 55.2 ( 46.9 - 63.4 ) 
               
Makkah 2005-10 157 80.2 ( 72.7 - 87.8 ) 47.9 ( 38.3 - 57.5 ) 
 
2011-16 204 84.1 ( 78.4 - 89.9 ) 66.6 ( 58.2 - 75.0 ) 
               
Eastern 2005-10 92 79.3 ( 70.4 - 88.2 ) 52.4 ( 42.1 - 62.7 ) 
 
2011-16 122 78.9 ( 70.8 - 87.0 ) 52.3 ( 42.1 - 62.5 ) 
               
Other 2005-10 142 77.9 ( 71.0 - 84.8 ) 61.3 ( 51.3 - 71.2 ) 
  2011-16 177 73.9 ( 66.7 - 81.1 ) 57.0 ( 48.4 - 65.5 ) 
Stage 
              
Localised 2005-10 153 87.6 ( 80.0 - 95.3 ) 66.9 ( 56.9 - 76.8 ) 
 
2011-16 225 89.6 ( 83.8 - 95.4 ) 71.1 ( 61.8 - 80.4 ) 
               
Regional 2005-10 234 86.2 ( 80.8 - 91.6 ) 56.1 ( 47.4 - 64.7 ) 
 
2011-16 246 83.2 ( 77.8 - 88.6 ) 65.3 ( 57.9 - 72.7 ) 
               
Distant 2005-10 96 61.6 ( 51.9 - 71.4 ) 31.7 ( 21.9 - 41.5 ) 
 
2011-16 127 55.4 ( 46.3 - 64.4 ) 24.5 ( 16.1 - 32.9 ) 
               
Unknown 2005-10* 56 84.7 ( 73.1 - 96.3 ) 71.6 ( 56.4 - 86.9 ) 
  2011-16 82 70.1 ( 58.4 - 81.9 ) 62.9 ( 49.4 - 76.3 ) 
*unstandardised 





7.4 Age-standardised mortality rates 
A total of 323 women were included in mortality estimates. The mean age at death was 
58±14.4. The number of women dying of cervical cancer was very similar over the periods 
2005-2010 and 2011-2016 for both Saudi and non-Saudi women. Crude and age-
standardised mortality rates were also similar over the two calendar periods of mortality 
(Table 22). 
Table 22: Crude and age-standardised mortality rates (ASMR) from invasive cervical cancer (n=323) 
 2005-2010  2011-2016  
 N Crude ASMR 95% CI   N Crude ASMR 95% CI  
     upper lower      upper lower 
Saudi 134 0.25 0.34 ( 0.28 - 0.40 )  135 0.23 0.32 ( 0.27 - 0.38 ) 







Chapter 8. Discussion 
In this thesis, I have described the characteristics of women diagnosed with cervical 
cancer in Saudi Arabia during 2005-2016 and examined incidence and survival trends by 
stage at diagnosis and region of residence; I have also explored age-standardised 
mortality rates over the same period. I have included both Saudi and non-Saudi women 
with registered cervical malignancies in the incidence and mortality rates, but since it was 
not possible to obtain data on follow-up for vital status for non-Saudi women, survival 
analyses have been restricted to Saudi women.  
Stage at diagnosis has moved over time towards a more favourable distribution with 
localised becoming the predominant stage after 2012. With 39% of women diagnosed at 
localised stage in 2016, this is still somewhat lower than the proportion seen in high-
income countries with established screening programmes, such as the UK (Northern 
Ireland) during 2010-2017 (54% localised) and the US during 2010-2016 (44% 
localised).163,164 A similar increase in localised stage over time was seen in the United Arab 
Emirates (UAE) from 15.6% during 2003-2007 to 38.3% in 2008-2012. For other countries 
of the Gulf Cooperation Council (GCC), a large proportion of missing stage made it difficult 
to observe trends.165 Between 2000 and 2013, 43% of women diagnosed with cervical 
cancer in Jordan were diagnosed at localised stage, but stage was unknown for 28%.166  
The shift from regional to localised stage over time was minimal in the ten peripheral 
regions of Saudi Arabia. The proportion of women whose stage at diagnosis was unknown 
also remained high in these regions, suggesting that women living in those regions did not 
benefit as much as women in more populous regions from improved timeliness and 
thoroughness of diagnosis. This may be due to a lower degree of awareness among 
women living in these regions or a lack of clinical resources. Women's educational 
attainment is positively associated with higher cervical cancer screening uptake and earlier 
stage diagnosis.78,167,168 In a nationally representative survey of women in Kuwait, Oman, 
Saudi Arabia and the UAE, women with secondary and college education were more likely 
to have a Pap smear within recommended intervals.144 While 49%, 50% and 52% of 
females aged 10 years and older in Riyadh, Makkah and the Eastern region have a 
secondary school education or a higher level of attainment, only 42% had the equivalent 
educational level in the other ten regions. In almost all regions, the most frequently given 




household.169 However, these statistics include girls aged 10 to 17 who have not yet had 
the chance to complete secondary education. They also include cohorts of women who 
did not have access to formal schooling, which only became widely available for girls in 
the early 1960s. The age distribution is very similar between regions, with girls in the age 
group 10-19 years making up 25-26% of the female population and women 65 years or 
older making up only 3-4%. The reported figures therefore underestimate the proportion 
of women who have completed secondary education, but they are still useful for 
comparison between regions. 
Early-stage diagnosis is the most important determinant of cervical cancer survival, but 
early diagnosis can also allow young women diagnosed with stage I cervical cancer to be 
offered the option of fertility-sparing surgery. Preserving fertility is a crucial outcome to 
consider, especially with a disease that affects relatively young women in societies that 
value having children very highly. In this study population, half the women were in what is 
considered child-bearing age (younger than 50). Desire to spare fertility may pose a 
challenge to effective treatment for gynaecological cancers, and it is a source of 
psychological stress for the woman. Additionally, diagnosis at an early stage is even more 
crucial in settings with less access to specialised treatment centres that offer radiotherapy, 
since radiotherapy is part of the treatment of choice (chemoradiation) for locally advanced 
tumours.33 
Incidence rates of cervical cancer 
The patterns of age-specific incidence rates are consistent with those seen in low-resource 
settings, where they continue to rise up to age 69 years. In high-resource countries, 
incidence rates tend to peak around age 40, which may reflect the removal of pre-
cancerous (dysplastic) or pre-invasive (in situ) lesions detected at screening. The higher 
prevalence of hysterectomy in some high-income countries may also contribute to the 
lower incidence in older age.3 
Age-standardised incidence rates (ASIR) remained similar throughout the period 2005-
2016. The annual incidence rates for all Saudi and non-Saudi women combined (1.66 and 
1.76 per 100,000 women during 2005-2010 and 2011-2016, respectively) derived from 
these data are similar to those reported in Cancer Incidence in Five Continents for 2008-
2012, which only included data from Riyadh.170 These rates are about 30% lower than the 




not yet published data for 2018 and the estimates are projections, based on a range of 
assumptions and use the incidence data for 2003-2012, applied to the 2018 United Nations 
resident population estimates.171 
The age-standardised incidence rates for cervical cancer in Saudi Arabia are similar to 
those in neighbouring countries such as Jordan, Palestine, Egypt, Iran, Iraq and 
Yemen.166,171 The ASIRs for Saudi nationals are lower than the incidence rates among 
nationals of other GCC states.165 Low ASIRs in Saudi Arabia and the region in general are 
most likely attributable to the low prevalence of premarital and extramarital sex, for 
religious and cultural reasons. Very little is known about the prevalence of extramarital sex 
in Saudi Arabia and whether it is increasing, or the number of life-time sexual partners for 
women and men. A survey of 225 male preparatory college students aged 15-20 years in 
2012 revealed that 31% had engaged in premarital sexual activity at least once.172 Of 
5,377 men and women presenting to primary care with symptoms suggestive of sexually 
transmitted infections during 2009, only 8.6% reported having sex outside marriage. 
However, the questionnaires were completed at the primary health centre and were not 
anonymous, which may have led to under-reporting.173 Of 400 women aged 22-80 years 
who attended routine cervical examination in Riyadh from November 2013 to November 
2015, only 12% reported having had more than one life-time sexual partner, and only 4% 
had more than three.87 The prevalence of high-risk HPV strains is also difficult to determine 
in the absence of population-based prevalence studies, or HPV testing in the context of 
screening programmes. Despite lack of empirical evidence, it is generally believed that 
sexual behaviours that would increase the risk of HPV infection are now being more 
frequently adopted among Saudi women due to globalisation, increased travel, and 
internet and social media use.174 However, later age at marriage, delayed childbearing 
and decreasing parity are also factors that could reduce the risk of cervical cancer,175 along 
with increasing uptake of Pap-testing. There is evidence of increasing age of first marriage 
and celibacy among women in Arab countries, including Saudi Arabia, since the second 
half of the 20th century. While this trend is associated with a reduction in early childbirth 
and multiparity, the interval between menarche and marriage could increase the risk of 
pre-marital sex without access to sexual health services.176,177 Male circumcision also 
plays a protective role in HPV transmission and is very widely practiced in Saudi Arabia 




For all nationalities combined, Riyadh, Makkah and the Eastern Region had higher ASIRs 
than the ten other regions, and ASIRs were the highest in Makkah in both periods, 2005-
2010 and 2011-2016. Makkah has the largest non-Saudi population in the country (48% 
of women according to the 2010 census),118 and the proportion of non-Saudis among 
women with cervical cancer was higher than in other regions (52%). The ASIR among 
Saudi women living in Makkah was similar to that in Riyadh. 
Non-Saudi women had higher incidence rates than Saudi women in every age group, and 
higher ASIRs at every stage of invasive cervical cancer. Lower socioeconomic status is 
associated with increased risk of cervical cancer, and many of the non-Saudi residents are 
working in unskilled, low-paying jobs (for example, domestic helpers). Countries with lower 
Human Development Index also generally have higher cervical cancer incidence rates.53 
The 746 non-Saudi women in this study population held 50 different nationalities, but half 
of them came from the Philippines, Indonesia, Yemen and Somalia, followed by smaller 
numbers from Syria, Sudan, Ethiopia, Eritrea, Nigeria, Chad, Sri Lanka, Pakistan, India 
and Palestine. This reflects a mix of the numbers of resident women from these countries 
and the risk profile of the countries the women come from. For example, the estimated 
ASIRs for cervical cancer for the Philippines, Indonesia and Somalia for 2018 are 14.9, 
23.4 and 24.0 per 100,000 women respectively, while the estimated ASIR is low in Yemen 
(1.9 per 100,000). But Yemeni nationals constitute one of the largest group of expatriates 
and migrants in Saudi Arabia. Employment-related migration has been recognised as 
increasing the risk of sexually transmitted infections due to several factors. These include 
demographics, since many migrant workers are young and single, or move to the host 
country alone; lack of skills and restrictive employment policies, which may push women 
towards sex work; and loss of social pressure to conform to the sexual norms in their 
society of origin.178 Further, studies of sexual networks have shown clustering of sexual 
relations by ethnicity.179 This could mean that women born in Saudi Arabia but who identify 
with high-risk ethnicities could carry a similar risk of cervical cancer to those ethnic 
backgrounds. Data from the United Kingdom suggest that young women living in deprived 
areas are less likely to be vaccinated against HPV or to attend cervical screening, which 
may compound inequalities in cervical cancer incidence.180 
Net survival 
Age-standardised net survival at one and five years since diagnosis for all Saudi women 




Survival was similar for women diagnosed during these two periods in all regions except 
Makkah, where the 5-year net survival probability increased by 19%, from the lowest 
survival among regions during 2005-2010 (49.9%) to the highest survival during 2011-
2016 (69.1%). There was a small decline in survival in 2011-2016 compared to 2005-2010 
in Riyadh and in the ten peripheral regions.  
Five-year survival was lower than that reported for Saudi Arabia in CONCORD-2 for 
women diagnosed during 1995-1999 (62.2%; 95%CI 50.6-73.8%) and 2000-2004 (65.6%; 
56.8-74.4%).10 However, those estimates were flagged as being less reliable due to the 
very high proportion of women with censored survival times (75.9%). The data submitted 
for CONCORD-2 contained “registry follow-up” (page 40), which is obtained through a mix 
of active methods (search in patient records) and passive methods (receipt of death 
notifications and death certificates with a mention of cancer). The registry aims to capture 
deaths of all registered patients, regardless of the cause of death, but the method is 
inherently biased towards finding deaths that have been attributed to cancer, while follow-
up is censored at the date of last contact at which a woman was known to be alive. This 
is often a short time after diagnosis, which is why the proportion of women with a censored 
survival time was so high. By contrast, linkage to the National Information Center (NIC) 
mortality records, although it was only achieved for 74% of women, substantially reduced 
the proportion of women with censored survival time, to 24% for those diagnosed during 
2005-2010 and 42% for 2011-2016. 
The age-standardised 5-year net survival estimates for cervical cancer in Saudi women 
were similar to those in countries in Western Asia reported in CONCORD-3, such as 
Turkey during 2005-2009 (59.2%; 95%CI 56.5-61.9) and 2010-2014 (60.7%; 58.1-63.3), 
Jordan during 2010-2014 (56.4%; 48.2-64.6), Kuwait during 2010-2014 (56.6%; 44.2-
69.0), Qatar during 2005-2009 (55.5%; 35.3-76.0) and 2010-2014 (63.5%; 44.2-82.8). 
Survival estimates were also similar to those in some Eastern European countries, but 
lower than estimates for most countries in Western and Northern Europe.4 
A lack of improvement or even a decline in cervical cancer survival has been seen in some 
countries after the introduction of widespread cervical cancer screening, due to the 
removal of slower-growing precancerous lesions. More aggressive lesions, some of which 
carry a worse prognosis, selectively form and progress to invasive cancer within screening 
intervals. However, this is unlikely to be why survival has not improved in Saudi Arabia, 




has been quite low, with only about 7.6% of women aged 25-49 having had a Pap smear 
within the recommended intervals for their age.144  
Interpreting survival estimates in the light of the stage distribution could help understand 
changes, or lack thereof, in survival patterns. The proportion of women diagnosed at a 
localised stage increased, while the proportion diagnosed at a regional stage declined. 
However, there was no change in the proportion of women diagnosed at a distant stage in 
all regions combined. The probability of surviving up to five years was similar for women 
diagnosed at a localised or regional stage, while women diagnosed at a distant stage had 
much lower survival. 
The large improvement in survival in Makkah, in contrast to the lack of improvement in 
other regions, cannot be explained by discrepancies in follow-up between regions, or a 
deficit in follow-up in Makkah Region during the later calendar period (2011-2016). A 
decline in the proportion of women with missing ID numbers was seen in all regions, but 
women living in Makkah Region had the highest proportion of missing ID numbers in 2005-
2010 and the lowest during 2011-2016 (Table 15). Also, the proportion of women who had 
died in Makkah, as determined by registry follow-up (Table 12), was similar to that in other 
regions, which makes it unlikely that the registry was failing to capture deaths in Makkah 
during 2011-2016. Finally, the increase in survival in Makkah, and lack thereof in all other 
regions, was not much altered when the analysis was restricted to women with more 
complete (NIC) follow-up (Table 20). Among women with a known stage at diagnosis, the 
proportion diagnosed at a localised stage was the highest in Makkah in both periods, and 
there was very little change in the stage distribution, whereas the increase in localised 
stage was much larger for Riyadh and the Eastern region (Figure 14). Thus, the increase 
in survival in Makkah Region cannot be attributed to improvements in early detection. 
There have been no changes to treatment guidelines during 2005-2016, and such changes 
would be expected to apply to all regions. The oncology centre at King Abdulaziz hospital 
in Jeddah was moved in 2010 to the newly founded King Abdullah Medical City, with 
treatment centres in Jeddah and Makkah. This led to the availability of more advanced 
treatment and an increased treatment volume. The oncology centre at the King Abdullah 
Medical City became the first specialised cancer centre in the Western Region functioning 
under the Ministry of Health (MOH), and in 2015, became the first of three centres of 
integrated oncology and palliative care in Saudi Arabia designated by ESMO (European 




Research Center in Riyadh (2018) and the King Fahad Specialist Hospital in the Eastern 
Region (2019). The presence of this oncology centre at King Abdullah Medical City under 
the Ministry of Health (MOH) may have led to more equitable access, efficient referral and 
timely treatment, translating into improved survival. 
A small decrease in survival was seen in Riyadh and the ten peripheral regions. The 
complete approach used to estimate 5-year net survival during 2011-2016 could give rise 
to lower survival estimates due to censoring the follow-up of women diagnosed in 2014, 
2015 and 2016.181 However, the lower survival seen in Riyadh and the ten peripheral 
regions was also seen for 1-year survival, for which a cohort approach was possible for all 
years of diagnosis. The sensitivity analysis limiting follow-up until 31 December 2012 for 
women diagnosed during 2005-2010, and thus making the estimates comparable to those 
for women diagnosed during 2011-2016, did not show any consistent difference from the 
cohort analysis. Higher availability of national ID numbers in the SCR records during later 
years has probably led to improved death ascertainment, but restricting the analysis to 
women with NIC follow-up did not alter the findings. Improvement in completeness and 
timeliness of death reporting to the department of civil status may offer a better explanation 
for this reduction in survival. A fine was imposed in 2015 for failure to notify deaths within 
30 days, and electronic death notification was also introduced in MOH hospitals in 2016, 
and is now being rolled out to other hospitals. In the data with imputed stage, there was 
no change in the proportion of distant stage, except for Riyadh, where it increased by 4%, 
which may also explain the observed decrease in survival in that region. 
Age-standardised five-year net survival increased slightly between 2005-2010 and 2011-
2016 for localised and regional stage, but fell for women diagnosed at a distant stage, both 
before and after imputation of unknown stage. Together with the lack of improvement in 
survival for all stages combined, despite the increase in the proportion of localised stage, 
this pattern could be attributable to stage migration, or the so-called "Will Rogers 
phenomenon".182 When staging practices improve over time, some tumours that have 
intermediate survival and were previously classified as localised are later classified as 
regional, leading to an apparent improvement in survival for both stages. This possibility 
is supported by the increase from 7% to 18% in the proportion of women with lymph node 
extension among women diagnosed at a regional stage. Stage migration was shown to 
occur for cervical cancer in a study that compared stage distribution before and after 




Improvements in the detection of lymph node extension was stated as the main reason for 
stage migration in cervical cancer, while the detection of occult metastasis accounted for 
a small increase of distant stage. The authors did not observe any improvement in survival 
for women with distant metastasis after upstaging of tumours found to have occult 
metastasis. This suggests that distant metastasis, even when clinically occult, has a poor 
prognosis.183 
There was an increase in the ratio of localised to regional stage during the period 2011-
2016. This is not consistent with stage migration, which would produce a shift in the 
opposite direction. It is possible, however, that for women who were diagnosed at a 
localised stage during 2011-2016, better documentation of stage more than compensated 
for the shift towards more regional stage that may have arisen from improved diagnostics, 
leading to a net increase in the proportion of women with localised stage. The category 
“unknown stage” comprises a mixture of women diagnosed at various stages. Therefore, 
if more women who had a localised underlying stage, and who would not previously have 
been assigned a stage, were appropriately assigned to their correct stage at diagnosis in 
2010-2016, this would lead to an increase in the proportion of women diagnosed at 
localised stage and a reduction of that sub-set of women in the pool of women with 
unknown stage. This could also explain the decline in survival for women with unknown 
stage during 2011-2016. 
Compared to stage-specific relative survival reported by the US National Cancer Institute 
for the period 2010-2016 and net survival by stage reported by CONCORD-3 for US 
women diagnosed during 2009-2014,184 net survival was lower in Saudi women diagnosed 
at a localised stage but higher for women diagnosed at a regional and distant stage (Table 
23). The proportion of women with unknown stage was higher among Saudi women than 
US women, and survival for women with unknown stage was higher among Saudi women 
than US women. This, together with the lower survival for Saudi women diagnosed at a 
localised stage, may point to some of the women with unknown stage having a localised 
underlying stage with a good prognosis. However, imputation of missing stage in the Saudi 






Table 23: Stage distribution (%) and stage-specific age-standardised 5-year survival (%) in the US (SEER 
registries: Surveillance, Epidemiology and End Results program and CONCORD-3) and in Saudi Arabia 
Stage-specific unstandardised 1- and 5-year net survival was similar between regions 
except for the Eastern Region, where 5-year net survival for distant stage was substantially 
(16% to 27%) lower than that in all other regions. However, this was based on 46 
observations only. Five-year net survival for women living in the Eastern Region, who were 
diagnosed at regional stage, also was between 6.4% and 11.6% lower than in Riyadh, 
Makkah and the ten peripheral regions. 
Restricting the analysis to the 928 women with National Information Center (NIC) follow-
up did not change the results for any of the regions or for any stage at diagnosis.  
When comparing the proportion of women who have died as ascertained through registry 
follow-up and through linkage to the NIC records, among women for whom data on both 
are available, it is clear that more than half of the deaths are not captured by registry follow-
up. Of the women with NIC follow-up, 44.3% were dead, according to government records. 
However, when including all women, i.e. those with and without NIC follow-up, and 
complementing the follow-up data with information available from the registry for women 
who could not be followed up at NIC because of a missing or incorrect ID number, the 
proportion of women known to have died fell to 36.8%, because only 13% of women for 
whom registry follow-up was used were known to be dead. However, these women only 
contributed their follow-up time until the date of their last known vital status, which was 
often the date when their data were abstracted for the registry. This amounted to 272 of 
4,456 years of follow-up (for 5 years survival), only 6% of the total follow-up time. 
Therefore, using registry follow-up in this context does not seem to bias the results. 
It is not clear what proportion of follow-up can be complemented using registry follow-up 
without compromising validity. In total, 24% of women only had registry follow-up. But there 
was variation by region and stage, with 27.3% of women living in the ten peripheral regions 
 US-SEER 2010-16*  US-CONCORD 2009-14§  Saudi Arabia 2011-16 
 






 Stage (%) 5-year net 
survival (%) 
Localised 44 91.8  43 86.9  33 73.8 
Regional 36 57.6  37 56.4  36 66.5 
Distant 16 16.8  14 18.7  18 25.2 
Unknown 4 49.7  6 55.0  12 63.4 
All stages  66.1   62.4   59.7 
* Based on data from SEER 18, 18 population-based registries covering 27.8% of US population. 




and 58% of women with unknown stage only having registry follow-up. The proportion of 
women for whom only registry follow-up was available fell from 30% during 2005-2010 to 
19% during 2011-2016. 
Using Global Burden of Disease (GBD) life tables gave slightly lower net survival 
estimates. This is because the modelled mortality rates for the general female population 
were lower than those produced by the United Nations Population Division (UNPD). Data 
sources for the GBD study were less clear and partially relied on the Ministry of Health, 
which only collects mortality data from its own hospitals. In their census data, the General 
Authority for Statistics groups the population 80 years and older in a single age group. 
Mortality rates up to age 99 years are therefore extrapolated, and may vary between 
estimations.  
Data on stage at diagnosis were imputed for the 11% of women for whom they were 
missing. This is a relatively small proportion, and neither the stage distribution nor the 
stage-specific survival estimates changed from the complete-case analysis. Because 
between-imputation variance was taken into account, in addition to within-imputation 
variance, the gain in precision from the increased number of observations in each stratum 
of age, stage and calendar period after the imputation of missing stage was offset by the 
addition of the between-imputation variance.  
A limitation of exploring the missing data mechanism and the process of multiple 
imputation in the current dataset is the lack of data on comorbidity and treatment. 
Comorbidity may partially explain the association between age and stage missingness but 
could also be an independent determinant of missing stage if a person's health status 
makes them unfit for clinical procedures that are used to determine stage.185  
The strongest predictor of missing stage in this context was region of diagnosis. Thirty 
seven percent of women diagnosed in one of the ten peripheral regions had an unknown 
stage. This proportion was only 20% for the subset of women who had a second referral 
hospital as a source of information, but the proportion of women with missing stage only 
became lower for women who were referred to Riyadh or Makkah regions. This suggests 
that missing information on stage is strongly related to the access a woman has to more 




Being diagnosed in one of the ten peripheral regions was also associated with less 
advanced stage. This may be caused by under-staging due to lack of advanced imaging 
modalities. If true, this could bias the multiple imputation results. 
Mortality rates of cervical cancer 
Age-standardised mortality rates for Saudi women (0.34 and 0.32 per 100,000 women per 
year in 2005-2010 and 2011-2016, respectively) and non-Saudi women (0.59 and 0.15 per 
100,000 women per year in 2005-2010 and 2011-2016, respectively) were lower than the 
Global Cancer Observatory estimates for 2018 (2.1 per 100,000 women) and Global 
Burden of Disease estimates for the years 2005-2016 (about 1.3 per 100,000 women per 
year).51,171 
I used what I believe to be the most reliable and most complete source of mortality data 
currently available in Saudi Arabia. The stability of the number of deaths over the two 
periods 2005-2010 and 2011-2016 indicates consistent collection of these data, and the 
lack of change in mortality rates is in line with the unchanged incidence and survival over 
the period 2005-2016. But given the known shortcomings of cause of death reporting in 
Saudi Arabia, the numbers reported may nevertheless underestimate the true mortality, 
especially for non-Saudi women. The ratio of the number of Saudi women to non-Saudi 
women who died of cervical cancer was more than double that seen for incidence. Such 
under-ascertainment of deaths among non-Saudis is expected, given that many of them 
return to their countries upon diagnosis. 
Deaths available in the Saudi Cancer registry (SCR) were from women diagnosed since 
1994, the first year of registration, which is 12 years earlier than the first year included in 
mortality estimates. Any deaths that occurred in 2005 or later among women diagnosed 
earlier than 1994 would not be captured. Of the 323 women who died of cervical cancer 
during 2005-2016, 15.5% had been diagnosed before 2005 but none had been diagnosed 
in 1994 or 1995, suggesting that capturing deaths among women diagnosed since 1994 
is sufficient for estimating cervical cancer mortality. 
Additional considerations 
The utilisation of a population-based cancer registry with national coverage, and statutory 
cancer registration, theoretically ensures access to every single cancer patient’s record 
and gives a picture of the true survival of women with cervical cancer in Saudi Arabia, 




women who were treated in tertiary centres. However, low numbers of registry staff may 
pose a challenge to timely and complete registration. The active nature of case finding 
also relies on the meticulousness of tumour registrars. There is no system in place for the 
SCR to ensure complete ascertainment of cases.  
The overall incidence of cancer in Saudi Arabia is low. Under-registration cannot be 
excluded, but the assessment carried out in 2013 by the International Network for Cancer 
Treatment and Research (INCTR) did not detect any major issues pointing towards low 
completeness.129 Assuming near-complete registration, the low incidence of all cancers 
could be due to two causes. First, the number of cancers may be truly low. Cancers 
generally take decades to develop (induction period) and the incidence rates we see today 
are to a large degree arising in a generation that was not exposed to the same set of risk 
factors that exist today. Smoking prevalence is moderate in men (23.7%) and extremely 
low in women (1.5%), with an overall prevalence of 12%. It is even lower (6.5%) in the 
those over the age of 65 years.186 Alcohol consumption is increasingly recognised as a 
major contributor to cancers of the breast, colorectum and upper gastrointestinal tract. Of 
all cancers worldwide, 3.6% were attributable to alcohol consumption and this proportion 
is even higher in Europe,187 while only 0.5% of cancers in Saudi Arabia were attributable 
to alcohol.188  
The second reason for low incidence may be under-diagnosis. Many cancers have a long 
pre-clinical phase (latent period), and when a person becomes symptomatic, their health-
seeking behaviour may be affected by cultural, psychological and logistical factors, 
including ease of access to healthcare. Competing health issues may divert both the 
patient’s and the physician's attention away from seemingly trivial complaints like 
perimenopausal bleeding, and the person may die of other causes before being diagnosed 
with cancer. This is less likely to occur for solid tumours that arise in non-vital organs and 
are not rapidly lethal, and these patients may be expected to present to a physician in due 
course unless they die of another cause prior to diagnosis. For example, the age-
standardised mortality rate from transport accidents in 2015 was 28 per 100,000 
population, significantly higher than in most high-income countries. Since autopsies are 
rarely carried out in Saudi Arabia, tumours that have not come to medical attention during 
a person's lifetime would not be captured. The lower age-standardised incidence rates 




The effect of any incompleteness in cancer registration on survival estimates would 
depend on the underlying reason for under-registration. The high percentage of 
morphologically verified tumours in the SCR may point to over-reliance of registrars on 
pathology reports. Since cervical cancer is a pathological diagnosis at any disease stage, 
it is unlikely that this preferential use of pathology reports would lead to selective detection 
of one stage over another and that it might therefore bias survival estimates for all stages 
combined. Under-staffing of regional offices has been an issue that may affect 
thoroughness of case-finding, because it has led to less frequent visits to remote areas 
and smaller clinics. Cervical specimens from smears or cone biopsies that are performed 
in private clinics and polyclinics are usually sent to larger laboratories or hospitals. It is 
thus very likely that they would be captured, even if registrars did not visit these clinics and 
the women were not referred to a hospital. 
Completeness of registration should be evaluated by independent ascertainment of cases 
from a sample of sources for a defined period of diagnosis, and comparison to those cases 
with the registry’s records. Quantification of death certificate-initiated cancers for which no 
information was received within the following six-month waiting period and for which trace-
back was initiated, leading to a previously missed hospital record, would also give an 
indication of thoroughness of routine case-finding.130  
The mortality-to-incidence ratio is a metric that has been used to assess the completeness 
of cancer registration by comparing the number of deaths from a given cancer in a given 
year or period, obtained from the vital registration system, with the number of new 
registrations of the same cancer in that period. However, this was not possible in Saudi 
Arabia, because the cause of death is often given only as “cancer”, and there is a major 
deficiency in the documentation of specific cancers as a cause of death. For example, in 
the 2016 MOH mortality database, only eight deaths were attributed to cervical cancer, 
and a further 47 to malignant neoplasm of the uterus, part unspecified. In contrast, 29 
deaths due to cancer were identified from the registry data in the same year among women 
diagnosed with cervical cancer at some point since 1994. In such a setting, the mortality-
to-incidence ratio is likely to be an indicator of the completeness of death registration, or 
the accuracy of certification or coding of the underlying cause of death, rather than an 
indicator of the completeness of cancer registration.189 
During 2005-2016, around 120 and 160 women were diagnosed yearly with a cancer of 




registered yearly as “uterus, not otherwise specified (NOS)”. Due to the anatomic proximity 
of the two topographies, some clinical misclassification of stage II or higher cervical cancer 
(extending to the body of the uterus) as uterine cancer is possible. However, squamous 
cell morphology was recorded in only 1% and 3%, respectively, of tumours registered as 
cancer of the uterine corpus (C54) or uterus NOS (C55). This indicates that the vast 
majority of tumours at both these sites are indeed of uterine, and not cervical origin. 
However, it is more difficult to assess whether adenocarcinomas of the cervix are 
sometimes misclassified as uterine cancer. In many cases, the origin of adenocarcinomas 
with unclear topography can only be determined by immunohistochemistry. Such testing 
is not always performed, and the registry does not collect information on it. 
Adenocarcinomas generally have a worse prognosis, especially if they are HPV-
negative.21 However, any misclassification of these tumours as uterine cancer is unlikely 
to affect survival estimates, because HPV- negative cervical cancers are rare,20 and the 
morphological distribution of cervical cancer in the dataset (69.2% squamous cell 
carcinoma, 21.6% adenocarcinoma 9.2% other or unspecified) is in line with what is 
expected (adenocarcinomas make up 10-25% of cervical cancers in developed countries 
with established screening programmes).190 
About a quarter of tumours registered as uterus NOS were diagnosed at a distant stage, 
and another quarter had an unknown stage, compared to only 13% at distant stage and 
12% with an unknown stage for cancer of the uterine corpus. Only 80% of tumours 
registered as uterus NOS were diagnosed by histology of the primary tumour, compared 
to 98% for uterine corpus cancers. Most notably, 11% of uterus NOS tumours were 
registered based on death certificate only. These characteristics are likely to lead to 
ambiguity and probably contributed to assigning some of the tumours to the NOS category. 
Therefore, the topography code uterus NOS may include women with both cancer of the 
uterine corpus and cervix who have a worse prognosis. 
A major advantage of net survival for population-based survival estimates is that 
information on the cause of death is not required, because it is often unavailable or 
unreliable. However, it relies on the completeness of death registration. There are no 
formal estimates of the completeness of death reporting to the Department of Civil Status. 
Since hospital death notifications are sufficient for burial, and it is the responsibility of the 
relatives of the deceased to report the death to the Department of Civil Status in order to 




common observation in statistics published from census and survey data and from burial 
statistics in Saudi Arabia is the lower numbers of deaths that are reported for women than 
men, even in Saudis, for whom the sex distribution is fairly equal. This discrepancy may 
be due to counting non-Saudis as Saudis, given the large excess of non-Saudi men. 
Additionally, deaths in women and children may go unreported because they are less likely 
to have assets or money in bank accounts that would require a death certificate to be 
distributed as inheritance. Neglecting to report deaths can also occur due to lack of 
knowledge, difficult access to a reporting centre, or may even be deliberate in order to 
continue to collect pension money. Efforts to counteract late and non-reporting of deaths 
have included media campaigns to increase awareness of the necessity and process of 
notification, introducing fines for late reporting and an electronic death reporting system in 
MOH hospitals. This would theoretically guarantee the immediate notification of all deaths 
if they occur in hospital, or if the deceased is taken to hospital. Fifty-four percent of deaths 
in the 2016 MOH mortality database occurred out of hospital, which suggests that such 
deaths are regularly captured by the MOH.  
Twenty women were reported as alive from the NIC records but dead in the registry 
records, despite matching names in the two databases. Eleven of these women were 
diagnosed at a distant stage, one of whom was 90 years old at the closing date, having a 
survival time of 14 years since diagnosis. Two women were diagnosed at localised stage 
and were aged 96 and 98 years at the closing date, with a survival time of 8 and 13 years, 
respectively. It is possible that some or all of these women have died and that their deaths 
were not notified to the Department of Civil Status. Another possible explanation is that 
non-Saudi women who were uninsured have used other women's IDs in order to receive 
medical care. Not all women in Saudi Arabia hold a photo ID, and a family card with the 
name and national ID number is sufficient for hospital use. In order to keep the method 
consistent, the vital status from linkage to the NIC was used when available, provided that 
the name and sex matched between the SCR and NIC records. 
Survival time was censored for 34% of women. Censoring in the context of this study 
involves two mechanisms: the first is that the ID number is missing from the patient’s 
record, leading to censoring at the date of last contact. According to registry staff, a missing 
ID number is more common among women treated in private hospitals, which do not 
require patients to present identification. In this case, ID numbers would be missing at 




also not be requested to show identification. In this scenario they would be expected to 
present with more advanced disease, but in fact, there was a higher proportion of localised 
stage among women with missing ID numbers (37%) than women with available ID 
numbers (29%), which supports the suggestion that many of them had early disease that 
could be treated in private hospitals. Some ID numbers were invalid due to recording 
errors, which occur randomly. Attempts to trace back missing IDs were unsuccessful, due 
to the workload of registry staff. Like stage, missing ID number is strongly associated with 
being diagnosed in regions other than Riyadh, Makkah and the Eastern Region, which 
may indicate that a missing ID number is related to poorer documentation practices in 
patient records in peripheral regions, and is not due to patient or disease characteristics 
that are relevant to survival. The second reason for censoring is that the woman was alive 
at the date of record linkage, and with less than five years of follow-up. This was the case 
for women diagnosed in 2014, 2015 and -2016, and is a form of non-informative censoring. 
I used life tables for Saudi Arabia that have been published by the UNPD because high-
quality death rates were not available. These life tables are for all nationalities, and they 
may therefore inaccurately reflect the background mortality of the women included in the 
survival analyses, which include only Saudi citizens. They are also not region-specific. 
Although every attempt was made to acquire death counts by sex, age, region and 
nationality from the government vital registration records, this was not possible due to the 
lack of a process for researchers or individuals to request data from the Ministry of Interior 
or Department of Civil Affairs. The SCR was also unsuccessful at requesting these data. 
Despite this shortcoming, the relative survival setting has been shown to be more robust 
to violations in the assumptions of life tables than the cause-specific setting is to 
misclassification in the cause of death.191 
Region of diagnosis may be a more important determinant of survival than region of 
residence. However, exploring survival by region of diagnosis was not feasible because 
fewer women were diagnosed in one of the ten peripheral regions, especially in the older 
age strata. While 319 (27%) women lived in one of these regions, only 131 women (11%) 
were diagnosed there. Moreover, for over half the women who were diagnosed in the ten 
peripheral regions, only registry follow-up was available. This would probably have led to 
overestimation of their survival due to the high proportion of women for whom follow-up 
time is censored in registry follow-up. The region to which a woman is referred, which may 




Therefore, survival could not be compared between regions of referral. Whether 
centralised cancer care leads to better cancer outcomes than in decentralised care 
settings is an important question that has produced different results in various countries. 
Cancer survival by region of diagnosis and region of referral in Saudi Arabia could be 
usefully explored with other, more common tumours. 
Estimating survival by stage at diagnosis is valuable in explaining survival differences 
between regions and over time. However, advances in diagnostic methods or differences 
in the available technology between regions could lead to some women who would have 
been diagnosed in earlier years or in lower-resource regions at a less advanced stage 
being classified later or in higher-resource regions at a more advanced stage. This may 
be falsely interpreted as progress in stage-specific survival (due to the stage migration 
phenomenon) or may mask differences in the stage distribution between regions, and 
consequentially, in stage-specific survival between regions. Diagnostic criteria that were 
used at the time of diagnosis or the diagnostic procedures a particular woman had 
undergone are not available from the registry records and therefore cannot be accounted 
for.  
Survival was one of the variables used in the multiple imputation model to predict stage. 
A higher proportion of women living in the ten peripheral regions only had registry follow-
up. If survival for these women was overestimated due to higher loss to follow-up, some 
of them would have been assigned to a lower stage than their true (but unknown) stage. 
The resulting stage distribution, and therefore, the stage-specific survival by region, may 
be biased. Estimating survival by region and stage using unimputed data and restricting 
to NIC follow-up was not possible due to small numbers. 
Although it has not been possible to examine patterns of survival from cervical cancer in 
non-Saudi women, some understanding of their experience with the disease can be 
obtained by exploring other characteristics. Incidence rates are much higher in each age 
group than for Saudi women, which reflects the patterns of incidence in many of the 
countries from which these women have immigrated into Saudi Arabia. For cervical 
cancers of known stage, the tumours in non-Saudi women are more often diagnosed at a 
localised stage and less often at a regional or distant stage than for Saudi women. 
However, the proportion of cervical cancers with unknown stage in non-Saudi women 
(23%) is almost double that in Saudi women (11%). Unknown stage was imputed for Saudi 




model. This was not possible for non-Saudi women due to lack of follow-up data. The 
resulting complete stage distribution for Saudi women leads us to believe that unknown 
stage is to a large extent missing completely at random. However, it is possible that 
unknown stage has a different mechanism in non-Saudis. For example, women with early-
stage cancer who are fit to travel may leave the country as soon as they receive the 
diagnosis and before their tumour can be fully staged. But it is also generally observed 
that stage is more likely to be missing for those with advanced tumours and comorbidities 
making them unfit for staging.160,185 
The proportion of in situ tumours in non-Saudi women was half of that in Saudis, indicating 
that they may have less access to early diagnostic tests, or less awareness of their 
availability and importance. Several studies from Saudi Arabia have described women's 
knowledge and awareness of cervical cancer, its risk factors and its prevention, but none 
of these studies reported results separately for non-Saudis, and some were restricted to 
Saudi nationals.142,143,192-194  
A large proportion of Saudi women living in the Eastern region and the ten peripheral 
regions were diagnosed in Riyadh or Makkah. Non-Saudi women living in those regions 
appear to be less likely to travel to Riyadh or Makkah for diagnosis. This may reflect a 
discrepancy in mobility among non-Saudi women, due to economic factors or lack of the 
social and family support which would enable them to move to other regions for medical 
care. Movement from smaller towns or villages to larger cities within a given region is not 
explored here because the small number of women diagnosed with cervical cancer 
disables any such comparison on a more granular scale. 
Non-Saudis make up about one third of the general population and of the population of 
women with cervical cancer, but little is understood about their experience with healthcare 
and with cancer care specifically. In a multi-centre study of patients who presented with 
acute coronary syndrome, non-Saudi patients had a significantly longer median symptom-
to-door time (175 versus 130 minutes), were less likely to undergo percutaneous coronary 
interventions and suffered higher hospital mortality, cardiogenic shock and heart failure, 
after adjustment for age and sex.195 Of 335 women with breast cancer who were treated 
at King Abdulaziz University Hospital in Jeddah between 2009 and 2017, Non-Saudi 
women had double the odds of Saudi women for undergoing mastectomy versus breast-
conserving therapy after adjusting for age and several tumour characteristics (e.g. size, 




follow-up to estimate survival for non-Saudi women would not have been a feasible option 
because it is generally incomplete, and could be especially low for non-Saudi women. This 
is reflected in the low proportion of non-Saudi women who are known to be dead from 
registry follow-up, especially during the period 2005-2010 (Table 10). Therefore, survival 
for Saudi and non-Saudi women cannot be usefully compared, even if the analysis were 
restricted to registry follow-up for both groups. Loss to follow-up could be due to those 
women returning to their home country after being diagnosed. In contrast, migration 
among Saudis is rare, and despite some Saudis seeking treatment for cancer in other 
countries, citizens who die abroad will in most cases be buried in Saudi Arabia, which 
ensures that their death is registered. Loss to follow-up by the registry could also be 
caused by a woman abandoning her treatment. Various factors may put non-Saudi women 
at risk of treatment discontinuation, including lack of social support, limited insurance 
coverage or the requirement to cover part of the treatment cost in government hospitals. 
I explored the possibility of deriving mortality estimates from deaths due to cancer that 
occurred among women who were diagnosed with cervical cancer and whose death was 
captured by the registry. The registry held more records of women certified as having died 
of cervical cancer than the cause-specific mortality database at the Ministry of Health. 
Even so, as for incident cases, the completeness of ascertainment of deaths from cancer 
by the registry cannot be ensured. Regardless of the data sources, the completeness of 
mortality estimates can only be as good as the quality of cause of death attribution by the 
reporting physician, which has been documented as quite low in Saudi Arabia, even 




Chapter 9. Summary and recommendations 
Summary 
Monitoring population-based cancer survival is crucial to evaluate the effectiveness of 
cancer care in a country or region and thus to support cancer control planning. Population-
based cancer registries with national coverage provide data on all malignant neoplasms 
diagnosed in the country. They reflect the real-world population experience and outcomes 
of a cancer diagnosis, irrespective of the inclusion criteria applied in clinical studies and 
stringent treatment regimens. 
Net survival provides a robust method which enables comparison of cancer survival 
between populations and over time, whilst taking due account of differences in the risks of 
death from competing causes (background mortality), which increase in older age. 
Estimating net survival was made possible by linking cancer registry records to information 
on each woman’s vital status in the Ministry of Interior records, which ensures virtually 
complete ascertainment of all-cause mortality. Although linkage could not be achieved for 
one-quarter of women included in the survival analysis, more than double the number of 
deaths were captured through this method compared to registry follow-up alone. This 
halved the proportion of women with censored survival time compared to CONCORD-2.  
I examined cervical cancer incidence rates and net survival probabilities by stage for 
women diagnosed with cervical cancer in Saudi Arabia between 2005 and 2016. I also 
explored regional differences in cervical cancer incidence and survival, and examined 
stage-specific survival by region of residence. 
Age-standardised incidence rates (ASIRs) for cervical cancer in Saudi Arabia are generally 
very low on a global scale, but are higher in non-Saudi women and women living in the 
three most populous regions of Saudi Arabia: Makkah, Riyadh and the Eastern Region. 
No change in incidence was observed over the twelve years 2005-2016. There was a shift 
towards a higher proportion of women being diagnosed at a localised stage during the 
calendar period 2011-2016 compared to 2005-2010 in the three most populous regions, 
but not in the other ten peripheral regions. 
Age-standardised 5-year net survival probabilities are similar to those in other countries in 
Western Asia for which survival estimates are available. No change was seen in age-




Makkah Region, where 5-year net survival increased by 19%, from the lowest among 
regions in 2005-2010 to the highest in 2011-2016. There was a small increase in age-
standardised 5-year net survival among women diagnosed at a localised or regional stage, 
and a decrease in survival for women diagnosed at a distant stage and among women 
with an unknown stage. This pattern may indicate more accurate staging practices in 
recent years, leading to stage migration. Stage-specific survival estimates during the 12-
year period 2005-2016 were similar in all regions except for the Eastern Region, where 
survival for distant stage was substantially lower. 
Restricting the survival analysis to women with available ID numbers, which enabled their 
records to be linked to the National Information Centre database to ascertain their vital 
status, did not change the survival patterns by stage at diagnosis or by geographic region; 
neither did using alternative life tables obtained from the Global Burden of Disease study. 
Recommendations 
Public health recommendations 
The availability of HPV vaccines in Saudi Arabia has been limited, despite their licensing 
since 2013. Further, a large cohort of unvaccinated women is entering the age group at 
risk for cervical cancer. Raising awareness of early signs and symptoms of cervical cancer 
could increase the proportion of tumours detected at an earlier stage, allowing for surgical 
management, which is more widely accessible than chemoradiation. Increasing the uptake 
of cervical screening through high-quality organised screening programmes with national 
coverage would help reduce the incidence of invasive cervical cancer. It could also further 
increase the proportion of women who are diagnosed at a localised stage by detection of 
pre-symptomatic cancer. This would ultimately reduce morbidity and mortality from the 
disease, and help to achieve higher survival levels as seen in many other high-income 
countries.  
Implementing a systematic screening programme entails inviting women who are eligible 
according to the Ministry of Health (MOH) guidelines. Home HPV testing may offer a 
culturally sensitive, accessible and feasible screening option given the low HPV 
prevalence in Saudi Arabia and the wide geographic spread of cities.199 This would, 
however, require a system for swab transport and collection, and recall of women with 
positive tests. Any planned screening programme should be preceded by a pilot 




decision to participate should be encouraged through clear and honest communication, 
which addresses the misconceptions about cancer and screening. It may be useful to 
identify higher-risk groups of women who would benefit from more frequent screening, for 
example migrant workers coming from high-incidence countries. 
The limited availability of HPV vaccines, primarily in private and high-resource government 
settings, raises concerns about equity. Uptake of Pap smears is higher among those 
women in Saudi Arabia with higher income and education,144 which may further compound 
inequities in cervical cancer incidence and outcomes. National guidelines for preventive 
and early diagnostic programmes should be developed, and led by the MOH, along with 
mechanisms to ensure equitable access and allocation of resources. 
Research recommendations 
It is difficult to predict the future burden of cervical cancer in Saudi Arabia from existing 
data. Studies are needed to shed light on current patterns of sexual behaviour, and on the 
uptake of HPV vaccines and Pap smears. HPV prevalence studies should be 
representative of the general population, and not limited to a specific region or centre. 
Studies carried out to understand women's knowledge about cervical cancer symptoms, 
and their attitudes towards early diagnostic testing, have so far been limited to single 
hospitals, universities or regions. Representative cross-sectional studies to compare 
levels of awareness between regions would probably help elucidate the persistence of 
delayed diagnosis in the peripheral regions. Further, exploring barriers to both early 
diagnosis and effective treatment is essential. Efforts are already under way to encourage 
women to undergo cervical screening, but ensuring timely referral and adequate treatment 
for women who screen positive is the ultimate goal of early diagnosis. 
The population-based cancer registry provides a unique opportunity for exploring patterns 
of patient movement between regions, cities and hospitals, as well as differences between 
Saudis and non-Saudis in referral for diagnosis and treatment. Using larger datasets for 
more common cancers, such as breast or colorectal cancer, would be more appropriate 
for this purpose. 
Data quality recommendations 
ID numbers were missing for many women, and of those for whom they were available, a 




to men. The Saudi Cancer Registry (SCR) is working to build its own programme for 
tumour registration. Incorporating ID verification in the programme would be the most 
effective way to ensure correct recording of ID numbers during abstraction. The Saudi ID 
number contains a check digit (a digit added to the end of a string of numbers that is 
computed from the other digits in the string). This characteristic could be utilised to verify 
the correctness of each ID number at data entry. As a minimal requirement, the cancer 
registry programme should only accept complete 10-digit ID numbers. While CanReg is 
still being used, verifying ID numbers at the time of carrying out other regular quality checks 
centrally could allow for routine correction of ID numbers along with other variables. 
"Yakeen" is a new service launched by Elm, a company that manages the government’s 
digital security. It allows instant verification of identity, matching ID numbers with official 
records, and it could therefore be used by the registry for this purpose. Data from Saudi 
Arabia could not be used in the third cycle of the CONCORD programme, due to the large 
proportion of records for which linkage to the individual's vital status, based on their ID 
number and date of birth, had failed. Verifying ID numbers should rely on matching names, 
not dates of birth, which often differ between hospital records and government records. 
Since four names are recorded in official records (first name, father's name, grandfather's 
name, and family name), and women do not take their husband’s names after marriage, 
names are in most instances highly reliable. A downside to using names is that they need 
to be manually cross-checked, since names are recorded in Latin letters in CanReg but in 
Arabic in government records.    
Obtaining follow-up for the vital status of registered cancer patients from the National 
Information Centre (NIC) is a lengthy process. Unfortunately, it is likely to become even 
more difficult, because the NIC has recently been transferred to the Presidency of State 
Security. The SCR has succeeded in ensuring statutory access to all cancer patients' 
records, and has since treated these with confidentiality and shared data responsibly. 
Similar legislation to allow continuous updates of the vital status of registered cancer 
patients, in addition to the residency status for non-Saudis, would enable timely monitoring 
of survival patterns. This would be especially effective when the reporting of deaths in 
hospital becomes automated. 
In a survey of population-based cancer registries in the Eastern Mediterranean Region in 
2020, led by the International Agency for Research on Cancer, the SCR did not provide 




indicates a disconnect between registry staff, researchers and policymakers.200 Utilising 
the full potential of the SCR data would produce policy-relevant research, bring clinicians' 
attention to the existence of the registry and encourage them to make use of the available 
data. This would also attract political recognition of the importance of maintaining and 
improving the registry, which currently suffers a perennial shortage of staff and resources. 
Periodic assessment and transparent reporting of quality indicators could identify areas 
for improvement, and it would be expected to increase confidence in the registry data. 
After ensuring high completeness and quality of the data currently collected by the SCR, 
expanding the scope of the data to include variables such as dates of referral and start of 
treatment, as well as the type of treatment, could be valuable in monitoring the quality of 
cancer care. These variables could also be used in more detailed analyses of the patterns 
of care and survival. Looking beyond survival, these data could support the establishment 
of survivorship research, which is essential to evaluate the full scope of cancer services.  
Cause-specific mortality is an important metric to assess the burden of disease and to 
monitor progress in public health interventions. Mortality data have so far been of very low 
completeness and quality in Saudi Arabia. This weakness should be addressed by 
expanding the coverage of mortality data collection to non-MOH hospitals, training 
physicians to assign the cause of death appropriately, and making these data publicly 
accessible. 
Constructing regional life tables for Saudi Arabia from population and death counts may 
more accurately reflect the background mortality for each region, and therefore improve 
the reliability and public health utility of net survival estimates. This would require 
facilitating access to vital registration data. Access to data from various government 
sectors has been a challenge throughout this project. 
In its global strategy for the elimination of cervical cancer as a public health problem, WHO 
has emphasised the need for high-quality population-based surveillance systems, to 
evaluate progress towards this goal. It highlights the role of population-based cancer 
registries in monitoring cervical cancer incidence and survival by stage at diagnosis, and 
stresses the importance of these metrics for planning cancer services and evaluating the 
delivery of cancer care, through comparison of survival estimates between regions and 




to monitor cervical cancer mortality trends, which enable the evaluation of screening 
programmes.9  
The current elimination goal is to reduce cervical cancer incidence to below 4 per 100,000 
women per year in all countries, through defined targets for HPV vaccination, screening 
and treatment of precancerous lesions. But in countries such as Saudi Arabia, where 
incidence is already below the WHO target, the strategy may need to be redefined 
according to their context. Given the high priority the elimination of cervical cancer has 
been accorded on the global health agenda, it is crucial for Saudi Arabia to join the effort 
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Appendix A. Registrable neoplasms in the SCR 
Site ICD-10  Site ICD-10 
Mouth C01-C02  Cervix uteri C53 
Salivary Glands C07-C8  Corpus uteri C54 
Tonsil C09  Uterus unspecified C55 
Other oropharynx C10  Ovary C56 
Nasopharynx C11  Other female genital C57 
Hypopharynx C12-C13  Placenta C58 
Pharynx Unspecified C14  Penis C60 
Oesophagus C15  Prostate C61 
Stomach C16  Testis C62 
Small intestine C17  Other male genital C63 
Colon C18  Kidney C64 
Rectum C19-C20  Renal pelvis C65 
Anus C21  Ureter C66 
Liver C22  Bladder C67 
Gall bladder C23-24  Other urinary organs C68 
Pancreas C25  Eye C69 
Nose, sinuses, etc. C30-31  Brain, Nervous system C70-C72 
Larynx C32  Thyroid C73 
Lung C33-C34  Adrenal gland C74 
Other thoracic organs  C37-C38  Other endocrine C75 
Bone C40-C41  Hodgkin Disease C81 
Melanoma of skin  C43  Non-Hodgkin lymphoma  C82-C85; C96 
Other skin C44  Immunoproliferative dis. C88 
Mesothelioma  C45  Multiple Myeloma C90 
Kaposi sarcoma C46  Lymphoid Leukaemia C91 
Connective, Soft tissue  C47; C49  Myeloid Leukaemia C92-C94 
Breast C50  Leukaemia unspecified C95 
Vulva  C51  Other & unspecified other 
Vagina C52    
Appendix B. Data quality control by calendar period of diagnosis 
Annex table 1: The number and proportion of Saudi women diagnosed with cervical cancer between 2005 and 2016 and are ineligible for, or excluded from survival 
analysis, and reasons for exclusion. 
   2005-2010  2010-2016  All periods 2005-2016 
   Records Patients %  Records Patients %  Records Patients % 
Total submitted   669 669 100.0  801 801 100.0  1470 1470 100.0 
              
Incomplete date(s)   0 0 0.0  0 0 0.0  0 0 0.0 
In situ neoplasm    113  113  16.9   107  107  13.4   220  220  15.0 
Benign or uncertain behaviour    0  0  0.0   0  0  0.0   0  0  0.0 
Metastatic from another primary site    0  0  0.0   0  0  0.0   0  0  0.0 
Ineligible morphology    1  1  0.1   3  3  0.4   4  4  0.3 
Ineligible topography    -  -  -   -  -  -   -  -  - 
Age at diagnosis <15 or 100+ years    4  4  0.6   0  0  0.0   4  4  0.3 
Not eligible     118  17.7    110  13.7    228  15.5 
              
Patients who are eligible for survival analysis    551 100.0   691 100.0   1242 100.0 
Vital status unknown   0  0  0.0  0  0  0.0  0  0  0.0 
Sex unknown    0  0  0.0   0  0  0.0   0  0  0.0 
Sex-site error    0  0  0.0   0  0  0.0   0  0  0.0 
Site-morphology mismatch    61  2  0.4   67  6  0.9   128  8  0.6 
Age-site mismatch    2  0  0.0   0  0  0.0   2  0  0.0 
Age-morphology mismatch    0  0  0.0   0  0  0.0   0  0  0.0 
Age-site-morphology mismatch    -  -  -   -  -  -   -  -  - 
Invalid date(s) or date sequence    0  0  0.0   1  1  0.1   1  1  0.1 
Death certificate only    10  10  1.8   4  4  0.6   14  14  1.1 
Autopsy only    0  0  0.0   0  0  0.0   0  0  0.0 
Duplicate registration    0  0  0.0   0  0  0.0   0  0  0.0 
Synchronous tumours    0  0  0.0   0  0  0.0   0  0  0.0 
Multiple primary same site    1  0  0.0   0  0  0.0   1  0  0.0 
Total exclusions     12  2.2    11  1.6    23  1.9 
              
Patients included in analyses     539 97.8   680 98.4   1219 98.1 
 
 
Annex table 2: The number and proportion of Saudi women diagnosed with cervical cancer between 2005 
and 2016 to be included in survival analysis for which the tumour was microscopically verified, of non-
specific morphology; the patient was lost to follow-up; or follow-up was censored within 5 years of 
diagnosis. 
  No. % 
  
  
Patients included in analyses 1219 100 
Microscopically verified  1215 99.7 
Non-specific morphology 15 1.2 
Censored within 5 years of diagnosis     
   Diagnosed 2005-10  130 24.1 
   Diagnosed 2011-16* 284 41.7 
Death within 30 days 24 2 
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Appendix figure 1: Distribution of the day and the month of the dates of birth, diagnosis and last known vital 
status 
Appendix C. Articles included in literature review 
Table 1: Literature review 1: Geographic differences in cervical cancer incidence, mortality or survival. 
 First author Year Title Region Notes 
1 Bray 2005 Trends in cervical squamous cell 
carcinoma incidence in 13 European 
countries: changing risk and the effects 
of screening 
Europe • Effectiveness of cervical cancer screening against the 
background of changing risk in 13 European countries with 
incidence data from 1953-2000.  
• Changing risk trends in Europe have been affected by 
screening and sexual behaviours, responsible for the decline in 
period risk and increase in cohort risk, respectively. 
• The decline in several European countries is a consequence of 
screening programmes, organised programmes in Nordic 
countries and UK having the clearest effect.  
• Cohort related increase in risk especially in younger 
generations with unmet screening-related decline. 
2 Ferlay J 2013 GLOBOCAN 2012 v1.0, Cancer 
Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. 
International Age standardised incidence and mortality rates. 
3 Gustafsson 1997 International incidence rates of 
invasive cervical cancer before 
cytological screening 
International • Data from 28 populations (CI5).  
• Pre-screening incidence rates up to 16-fold higher than recent 
post-screening rates but same age curve shape: rapid increase, 
peak, slower decline/plateau.  
• Shift towards younger age with time was seen in some 
countries. 
4 Levi 1999 Cancer mortality in Europe, 1990-1994, 
and an overview of trends from 1955 to 
1994 
Europe • Decline in uterine including cervical cancer mortality trend 
during 1955-1994, most probably due to introduction of cervical 
cancer screening. 
5 Qualters 1992 Breast and cervical cancer 
surveillance, United States, 1973-1987 
USA Decline in cc incidence and mortality 1973-87. 1987 incidence 
was 8.2/100000 and mortality 3/100000.   
6 Mokdad 2017 Trends and patterns of disparities in 
cancer mortality among US Counties, 
1980-2014 
USA • Population attributable factor for risk factor (HPV )=1, (second is 
lung 0.9) 
• Though mortality rate has steadily gone down, cervical cancer 




 First author Year Title Region Notes 
• large differences in county level mortality rate (range 0.6 - 
5.2/100000) 
7 Vos 2017 Global, regional, and national 
incidence, prevalence, and years lived 
with disability for 328 diseases and 
injuries for 195 countries, 1990-2016: A 
systematic analysis for the Global 
Burden of Disease Study 2016 
international • GBD from 195 countries. 
• Estimated 186,000 YLDs due to cervical cancer in 2016, with 
9.4% increase in number despite 11.3 % decrease in ASR 
between 2006 and 2016. 
8 Fidler 2016 A global view on cancer incidence and 
national levels of the human 
development index 
international •  Cervical cancer one of 3 cancers with ASR negatively 
associated with HDI with a clear trend across the 4 HDI 
categories (along with kaposi sacrcoma and other pharynx in 
women).  
• A substantial decrease in cervical cancer was observed across 
HDI level, decreasing from 30.0 to 8.6 per 100,000 in low to very 
high HDI regions, respectively.  
• ASRs were very scattered within Low and Medium HDI 
countries (very low in Yemen). 
9 Soerjomataram 2012 Global burden of cancer in 2008: a 
systematic analysis of disability-
adjusted life-years in 12 world regions 
international • Age adjusted DALYs due to cc was estimated at 82/100,000 in 
MENA, which is only slightly higher than that of north America 
and western Europe and very close that of Very high HDI 
countries.  
• Inversely related to HDI. 
• Premature death (YLL) was the overwhelming contributor to 
age adjusted DALYS due to cc. it contributed to more premature 
deaths than breast cancer in 23 countries. 
10 Torre 2015 Global cancer statistics, 2012 international Incidence and mortality in world regions and more and less 
developed countries. 
11 Allemani 2015 Global surveillance of cancer survival 
1995-2009: analysis of individual data 
for 25,676,887 patients from 279 
population-based registries in 67 
countries (CONCORD-2) 




 First author Year Title Region Notes 
12 Allemani 2018 Global surveillance of trends in cancer 
survival 2000–14 (CONCORD-3): 
analysis of individual records for 37 
513 025 patients diagnosed with one of 
18 cancers from 322 population-based 
registries in 71 countries 
international • Wide differences in cervical cancer survival. 
• Slight improvement in survival over the past 20 years. 
13 Laara 1987 Trends in mortality from cervical cancer 
in the Nordic countries: association 




Direct association between screening coverage and mortality 
reduction witnessed in the 20th century. 
14 Senno 2015 Spatial Distribution and 
Sociodemographic Composition of 





• The incidence of HGCL has significantly declined from 2009-
2013 in the 20-29 age group (14.6% in 20-24 and 2.8% in 25-29) 
but not in the older age group reflecting effect of vaccination. 
15 Jong 2004 Remoteness of residence and survival 




• Survival analysis 
• Diagnosed 1992-1996.  
• Relative excess risk of death over 5 years for the most 
geographically remote category (vs highly accessible category) 
was highest for cervical cancer (crude RER 3.22 (95% CI, 1.54–
6.75) adjusted 2.25 (95% CI, 1.06–4.77), probably reflecting 
contribution of screening and treatability of early detected 
tumours. 
16 Mengersen 2011 Identification of area-level influences 
on regions of high cancer incidence in 






• 1998-2007, n = 186,075. 
• Area-level factors mostly associated with cancer incidence. 
• Cervical cancer had higher incidence in remote areas (only 
cancer besides male lung) and most disadvantaged areas.  
• Interaction with areas with high indigenous population. 
17 Lynge 1984 Regional differences in smear-taking 
activity and cervical cancer incidence 
in Denmark 1943-1982 
Denmark • Previous geographic differences in cc incidence between 
Copenhagen and Western Jutland have disappeared. This is 




 First author Year Title Region Notes 
18 Melan 2017 Epidemiology and survival of cervical 
cancer in the French West-Indies: Data 





• Population based cancer registry. 2002-11, n=1253 (947 in situ, 
306 ICC). 
• ASIR, mortality, and survival 
• 5-year OS=55%, median survival 6.5 y. HR of death for stage 3 
and 4 vs 1 and 2 was 4 ,  
• survival was related mostly to stage (HR=3.53), then SES and 
location (north vs centre-south) (HR 1.5) 
19 Levêque 1999 Atlas of 'avoidable mortality' in Belgium 
1985-1989 
Belgium • 1985-89 
• Among 20 causes of avoidable deaths, no statistically 
significant heterogeneity in SMR for cervical cancer (and body of 
uterus) between 43 districts. 
20 Treurniet 1999 Variations in 'avoidable' mortality: A 
reflection of variations in incidence? 
Netherlands • 1984-1994. 
• Significant regional mortality variations were found for cervical 
cancer (RR=0.82-1.32). 
•  Of 16 causes of avoidable death, cervical cancer was the only 
disease where regional variation in avoidable mortality was fully 
explained by variation in incidence (regional differences in 
mortality disappeared after adjusting for incidence). 
21 Zhan 2014 Racial/Ethnic, Socioeconomic, and 
Geographic Disparities of Cervical 





• Found geographic clustering of advanced cervical cancer.  
• Could be explained by age, race/ethnicity, SES, and the 
percentage of African Americans in a census tract.  
• Differences in spatial access did not explain racial/ethnic and 
contextual-level SES disparities of cervical cancer advanced 
stage diagnosis in this study. 
22 Seamon 2011 Cervical cancer survival for patients 




• 2001-2010.  
• Prognostic factors influencing cervical cancer survival in 
patients referred to the University of Kentucky (complete or partial 




 First author Year Title Region Notes 
• Race, residence (Appalachian region), insurance status, 
months between last normal cervical cytology and diagnosis, 
histology, tumour grade, and location of primary radiation 
treatment (Appalachian/non-Appalachian) showed no association 
with survival.  
• Stage, comorbid risk factors and unemployment was correlated 
with overall survival.  
• Conclusions: Residence and location of treatment centre are 
not an important factor in cervical cancer survival when a tertiary 
cancer centre can oversee and coordinate care. 
23 Aponte-Gonzalez 2012 The impact of under-recording on 
cervical cancer-related mortality rates 
in Colombia: an equity analysis 
involving comparison by provenance 
Columbia 
 
Cervical cancer mortality was found to be higher in urban areas, 
but underreporting was inversely correlated with mortality. 
24 Vatanasapt 1995 Cancer Incidence in Thailand, 1988-
1991 
Thailand Cervical cancer most common cancer in females with little 
regional variation 
25 Brewer 2009 Demographic differences in stage at 
diagnosis and cervical cancer survival 
in New Zealand, 1994-2005 
New 
Zealand. 
• 1994-2005,1594 cases  
• NZ has an organized population wide screening program. 
• little evidence of geographic (urban vs rural) differences in 
stage at diagnosis (OR 1.02, 95% CI 0.671.53) and HR of death 
from cervical cancer over 5 years (Cox proportional hazard)(1.03, 
95% CI 0.70–1.50)  
• Adjustment for age, year of diagnosis, stage ethnicity and SES 
did not change outcome. 
27 Lin 2015 Racial/ethnic, area socioeconomic, and 
geographic disparities of cervical 
cancer survival in Texas 
USA, Texas • 1995-2005, 11,212 women with cervical cancer 
• Cervical cancer specific overall 5-year survival using passive 
follow up. 
• Individual level factors: race/ethnicity, age at diagnosis, year of 
diagnosis, grade, stage and treatment. 
• Contextual (census tract level variables): demographics, health 
insurance expenditure, behavioural factors, urbanisation, spatial 




 First author Year Title Region Notes 
• Race/ethnicity, SES and geography associated with survival. 
• OS was slightly lower (54% vs 58%) in the higher vs lower 
spatial access to quartile. 
• Geographic clusters HR only decreased slightly after adjusting 
for all the covariates.   
28 Walters 2011 Geographical variation in cancer 
survival in England, 1991-2006: An 
analysis by cancer network 
UK, 
England 
• Compares selected cancers relative survival (1991-2006) 
across UK cancer networks. 
• Geographic inequalities in survival (north worse than south), but 
some reduction in survival inequality between networks over time 
periods. 
• Age adjusted 1-year survival (adjusted for age, sex, region and 
deprivation using life tables) improved by up to 10 percentage 
points for all cancers analysed over the period 1991-2006, with 
the exception of cervical cancer. This may be explained stage 
migration: over 85% screening coverage achieved since 1998, 
leading to dramatic decline in incidence. Most tumours happen in 
women who haven’t been screened or are particularly 
aggressive.  
29 Brewer 2012 Travel time and distance to health care 
only partially account for the ethnic 
inequalities in cervical cancer stage at 
diagnosis and mortality in New Zealand 
New 
Zealand 
• Diagnosed 1994-2005, follow up until end of 2005? 
• Travel time and distance to nearest GP were only weakly 
associated stage at diagnosis HR 1.67 (0.95-2.94) and 1.37 
(0.78-2.40) for the highest quartile, respectively; and cc mortality 
1.32 (0.79-2.19) and not associated with cervical cancer 
screening. 
30 Barrington 2016 Distance from a Comprehensive 
Cancer Center: A proxy for poor 
cervical cancer outcomes? 
USA 
(Alabama) 
• Retrospective cohort of patients treated at a single centre.  
• Those living >100 miles away had lower median OS (66 vs 99 
months), worse OS by Cox PH. (HR=1.68, 95% CI 1.11–
2.54).(not clear whether it was adjusted for age, BMI, race, 




 First author Year Title Region Notes 
• Received less radiotherapy and more "other" may be due to 
delays in treatment due to transportation problems. 
31 Eggleston 2006 Cervical Cancer Survival by 
Socioeconomic Status, Race/Ethnicity, 




• 7232 cc cases, Texas cancer registry, 1995-2001. 
• Cox PH model by stage. 
• Zip-code level rural residence was not associated with cervical 
cancer specific survival in any stage. 
• Stage adjusted zip-code level SES was associated with survival 
(adjusted HR=2 in lowest vs highest quintile) 
32 Minelli 2007 Urban-rural differences in 
gynaecological cancer occurrence in a 




Incidence of cervical cancer was higher in urban regions in the 
period 1978-82 then similar afterwards, author explains this by 
more wide spread screening later. Mortality was higher (non-
significant) in rural. 
33 Moss 2017 Urban/Rural Differences in Breast and 
Cervical Cancer Incidence: The 
Mediating Roles of Socioeconomic 
Status and Provider Density 
USA • 2009-13 
• Data source: SEER data (SES), 2010 census (ethnicity), 2010 
Area Health Resource File (PCP concentration), Small Area 
Estimates for Cancer Risk Factors & Screening Behaviours 
(screening), USDA (9 point urbanicity score for each county).  
• Method: Ecological mediation analyses.  
• As urbanicity increased, age standardised cervical cancer 
incidence rates decreased. 
• SES and PCP density were significant mediators, changing the 
main effect by 82 and 32% respectively.  
• Percentage whites and pap screening levels did not contribute 
to the relationship (pap history was a mediator in the preliminary 
but not complex mediation analysis). After controlling for all 4 
variables, the relationship between urbanicity and cervical cancer 
incidence was weaker but remained significant. 
34 Australian Institute 
of Health and 
Welfare & 
Australasian 




 First author Year Title Region Notes 
Association of 
Cancer Registries. 
• Preventable cancers such as cervical cancer have higher 
incidence in rural and remote areas: by 20%, 35%, and 26%, in 
outer regional, remote and very remote areas respectively. 
35 Schouten 1996 Urban-rural differences in cancer 
incidence in the Netherlands, 1989-
1991 
Netherlands • 1989-1991.  
• Excess in cervical cancer incidence in urban areas (RR=1.69 CI 
1.47, 1.94) with linear trend. Potential reasons: tobacco, sexual 
patterns, migration to urban centres. 
36 Sharp 2014 Risk of Several Cancers is Higher in 
Urban Areas after Adjusting for 
Socioeconomic Status. Results from a 
Two-Country Population-Based Study 
of 18 Common Cancers 
Ireland • 1995-2007 
• RR for cervical cancer incidence 1.48 (1.35–1.62) for urban vs 
rural after adjusting for SES. 
• Organised cervical screening has been in place since the 
1980s.  
• There is no difference in screening uptake between urban and 
rural areas in the UK and it is mostly done by a GP. 
• Urban–rural variations could also arise as a result of people 
with cancer moving to urban areas to seek management in 
specialised centres, smoking (20% higher in urban) and HPV 
patterns. 
37 Singh 2012 Rural-urban trends and patterns in 
cervical cancer mortality, incidence, 




• Disparities between metropolitan and non-metropolitan areas in 
cervical cancer. 
• Mortality rates 1950 - 2007. 
• Incidence, stage and survival for 2000-2008. 
•  Sharp overall decline in incidence and mortality.  
• Non-metropolitan had higher mortality in small urban (15%) and 
rural areas (20%) vs metropolitan. Non-metropolitan had a higher 
likelihood of advanced stage at dx (non-significant) 
• Blacks had double the mortality.   
• Higher incidence in small urban (6%) and rural (15%) areas. 
• 5-y survival: 51% non-metropolitan black, 60% for metropolitan 




 First author Year Title Region Notes 
• Worse mortality and survival persisted after controlling for 
stage.  
38 Benard 2007 Cervical cancer incidence in the United 
States by area of residence, 1998-
2001 
USA • 1998-2001. 39,946 cases (SEER). 
• Rural had higher rates than suburban or metropolitan across 
ethnic, SE groups and within localized stage, despite age and 
race interaction. No area difference was seen in those over 45.  
• Increase among younger women. 
• Peak at 40-44 years. 
• No differences in stage at diagnosis were seen between urban 
and rural areas (but were seen for race) 
39 Hopenhayn 2008 Variability of cervical cancer rates 
across 5 Appalachian States, 1998-
2003 
USA • 1998-2003 
• Among Appalachian states, rural counties were at higher risk of 
cervical cancer.  
40 Blake 2017 Making the case for investment in rural 
cancer control: An analysis of rural 
cancer incidence, mortality, and 
funding trends 
USA • SEER 
• 14% and 13% higher incidence and mortality in rural vs 
metropolitan counties, respectively. 
• No consensus on definition of rurality within USA. 
41 Chen 2016 Cancer Statistics in China, 2015 China  
 
• Data source: national cancer registry of china (combined data 
from 72 registries). Covers 6.5% of population.  
• Data from 2009-11 was used for incidence and mortality 
estimation for 2015. A subset of longer standing registries was 
used for trends (2000-11). 
• Strong increase in incidence (annual percentage change (APC) 
15.6 for 2000-2007) and slower increase in mortality (APC 5.9).  
• Incidence higher in urban areas. Estimated for 2015: 53200 vs 
45700 new cases in 2015) but mortality higher in rural (urban 
13600 rural 16900). No ASR 




 First author Year Title Region Notes 
42 Herrmann 2015 40 years of progress in female cancer 
death risk: A Bayesian Spatio-temporal 
mapping analysis in Switzerland 
Switzerland • Mortality rate dropped drastically during 1969-2010 (up to 6 
time reduction) with no appreciable regional differences with 
respect to urban and rural or geographic access to care. 
Switzerland is an affluent country with universal access despite 




2016 The role of socio-demographic factors 
in premature cervical cancer mortality 
in Colombia 
Colombia • Cervical cancer deaths 2005-13 obtained from National 
Administrative Department of Statistics by year. 
• Risk factors including rural/urban residence extracted from 
mortality record  
• Age 20-49 selected (n=5093), stratified by 5 y age groups. 
Outcome: age group specific cervical cancer death counts. 
• IRR for cervical cancer mortality was higher for urban than in 
rural areas after accounting for the effects of age, region of 
residence, and type of insurance or educational level.  
• May be explained by those diagnosed moving to larger cities 
and dying there (or lower incidence, only provide mortality and no 
survival data). 
44 Baldwin 2012 Receipt of Recommended Radiation 




• Adjusted rates of radiation therapy receipt were similar for rural 
and urban patients overall (66.1% vs 68.2%; difference not 
significant), and for each stage of cervical cancer (urban/rural: 
91/90% for stage I, 85/86% for stage II, 80/71% for stage IV) 
 
Table 2: literature review 2: Cervical cancer incidence, mortality or survival, Saudi Arabia. 
 Author Year Title Category Notes 
1 Al-Ahmadi 2013 Spatial autocorrelation of 




• Studying the clustering of cancers: cervical cancer was clustered in the 
eastern region. 
• Spatial association between various cancers: 
• The weakest association was between cervical and other common types of 




 Author Year Title Category Notes 
• The strongest association was between cervical and lung cancer.  
• Other: Cancer management is offered free of charge to all Saudi patients, 
including those who may need further treatment abroad. It is therefore 
unlikely for a Saudi citizen to seek treatment outside the national healthcare 
system.   
• Although major cancer treatment centres are located in the major regions 
(Riyadh, Makkah, and Eastern regions), cancer detection and diagnosis is 
usually made at the secondary healthcare centres, which are widely spread 
to cover all geographic regions of the country. 
• While inequitable access to an advanced healthcare system for cancer 
patients from remote areas is expected, authors believe that this would have 
negative impacts on the treatment outcome rather than on cancer detection. 
2 Sebai 1989 Cancer in Saudi Arabia Cervical cancer 
epidemiology 
• Cervical cancer was the 6th most seen cancer in females in KFSH in 
1979-84 in terms of crude relative frequency (4.6% of female cancers) 
• Breast cancer patients presented relatively late. On average 6 months 
after start of symptoms.  
• General attitude of fatalism 




• Cervical cancer ranked 7th overall. 4.2% (42/1000 cancer cases)  
• Ranked 2nd after breast in females in life threatening malignancies. 
4 Taylor 1963 Cancer in Saudi Arabia Cervical cancer 
epidemiology 
• Very low incidence of gynaecological tumours may reflect women’s 
resistance to examination. 
5 Al Nsour 2012 Breast and cervical cancer 
screening among women in 
Jordan: Findings from the 
behavioural risk factor 




• Data from the third Jordan Behavioural Risk Factor Surveillance System 
(2007) among a nationally representative sample of Jordanian women aged 
>35 years (n=1,157).  
• Mean age 50. 
• Association between cervical cancer screening and socio-demographic 
characteristics was assessed by logistic regression.  
• Income had the strongest association with screening followed by 
geography, age and working status. 




 Author Year Title Category Notes 
• Highest in 35-44 year olds lowest in 65+, and higher in women with higher 
income (OR increased with income up to 4, strongest predictor) education, 
and who worked (NS).  
• Primary source of health was private sector (OR 1.5).  
• Women in the south were significantly less likely to undergo screening 
compared to north and middle (OR=0.43).  
6 Dajani 1995 Cervical intraepithelial 






• 10,659 females attending obstetrics and gynaecology clinics in Jordan. 
4,048 (38%) were for routine check-up, 3519 (33%) had gynaecologic 
complaint(s) and 3,092 (29%) had no specific reason stated. 
• Incidence of CIN much lower in those presenting for routine pap and vs 
total (49/100,000 vs 114/100,000). 





• Data: Gulf Centre for Cancer Registration (GCCR). 1998-2001, active and 
passive population based cancer registration of nationals. Health surveys 
(Family Health Survey): smoking and reproductive factors.  
• Incidence: crude and ASR (world standard population), population 
estimated at 1 Jan 2000 by 5-year age category.  
• Cancer in males more than females in Saudi Arabia and Oman , ASR 
highest in Qatar and Bahrain for males and females and lowest in Saudi 
Arabia and UAE. 
• Bahrain and Kuwait have the highest smoking. 
• Between 3% and 12% of women aged 40–44 years had their first child 
before the age of 15 years, compared to only around 2% of those aged 15–
19 years.  
• Saudi has the youngest population.  
• Incomplete registration of the elderly?  
• Bahrain X7 lung cancer compared to Saudi (long smoking history and 
higher rates) 
8 Ben Khaial 2014 Cervical cancer in north-
eastern Libya: 2000-2008 
comparable 
countries 
• Data source: major oncology clinic. 74 cases cervical cancer over 9 years.  
• Mean age 53.  




 Author Year Title Category Notes 
• 83% and 13% were positive for HPV-16 and 18 respectively.  
• Highest incidence was observed in the 45–54 
9 Kapila 2006 Changing spectrum of 
squamous cell abnormalities 
observed on Papanicolaou 
smears in Mubarak Al-
Kabeer Hospital, Kuwait, 
over a 13-year period 
comparable 
countries 
• Source: Mubarak Alkabeer hospital (tertiary hospital serving 25 hospitals 
and 17 clinics). 1992-2004.  
• Age and nationality retrieved for those with abnormalities diagnosed 2000-
2004 for age specific analysis and was restricted to Kuwaitis. 
• Results: 86,434 smears over a 13-year period.  
• 4.3% abnormal. (96% satisfactory, ASCUS 2.2%, AGUS 0.8%, LSIL 1%, 
HSIL 0.2%, cc 0.1%, slightly over half of them SSC with a mean age of 48 
(28-80).  
• Increase in ASCUS and AGUS % over the period. Reduction in LSIL and 
HSIL. 
LSIL highest in 25-34 year olds. peak age for HSIL 25-34 
10 Kulhánová 2017 Profile of cancer in the 
Eastern Mediterranean 
region: The need for action 
comparable 
countries 
• GLOBOCAN 2012 data were used to estimate cancer incidence and 
mortality by country, cancer type, sex and age in 22 EMR countries. 
• Cervical cancer ranks second or third after breast in 10 of 22 countries. 
• 100% increase in cancer expected over the coming 2 decades. The 
highest in WHO regions. 
11 Sengul 2014 Population-based cervical 
screening outcomes in turkey 
over a period of 
approximately nine and a half 
years with emphasis on 




• frequency of cervical cytological abnormalities January 2001- April 2010 at 
the Early Cancer Screening, Diagnosing and Education Center Giresun 
Prof. Dr. A. İlhan Ozdemir State Hospital, Turkey. 
• Department of pathology reports and corresponding patient records.  
• Results: of 32,578 pap-smears, 95.7% were satisfactory.  
• cervical cytological abnormality was 1.83% (n=598), with ASCUS in 
1.18%, LSIL in 0.39, HSIL in 0.16%, AGUS in 0.07%, squamous cell 
carcinoma in 0.02%, and adenocarcinoma in 0.006%.  
• 9.5% of abnormal findings were in women aged 30-34 (n=57) (but not 
highest age specific rates) which would have been missed according to old 
guidelines of starting at age 35. mean age ± SD of women having the 




 Author Year Title Category Notes 
12 Sharkas 2017 Trends in the Incidence of 




•  2000-2013, Jordan Cancer registry. 
• ASR= 2/100,000. Mean age 50. 
• Decreased after 2006 but remained constant 2008-13. 
13 Zaabi 2015 Age specific cytological 
abnormalities in women 
screened for cervical cancer 
in the Emirate of Abu Dhabi 
comparable 
countries 
• Aim: prevalence of cervical abnormalities in the year of introduction of 
screening programme, using liquid based cytology, and age specific 
abnormalities. 
• Data: retrospective SKMC hospital (public referral centre where all 
collected samples are sent), Abu Dhabi, Jan-Dec 2013 and electronic health 
records.  
• Results: total screened=4,593, mean age =39.5. 97% satisfactory, with 
225 (4.89%) abnormal smears, (ASCUS) 114 (2.48% of total), ASC-H 
(0.1%), LSIL (1.56%) HSIL (0.58%) cancer (0.04%), glandular (0.1%). 
abnormalities highest in the >61 age group. mean age for cervical cancer 
was 45. 
14 Al-Badawi 2011 Detection and genotyping of 
human papilloma virus in 
cervical cancer specimens 
from Saudi patients 
HPV in cervical 
cancer 
• 1997-2007.  
• 100 cervical cancer and CIS specimens randomly selected from pathology 
department at KFSHRC, Riyadh. HPV detected with PCR.  
• Results: 90 cases analysed. HPV detected in 95.5%. HPV-16 (63.4%), 
followed by HPV18 (11.1%), HPV45 (4.5%), HPV33 (3.3%), and HPV-31, 
HPV52, HPV53, HPV58, HPV59, and HPV66 (2.2%) 
15 Alsbeih 2013 HPV prevalence and genetic 
predisposition to cervical 
cancer in Saudi Arabia 
HPV in cervical 
cancer 
100 cervical cancer patients, 82 were HPV positive. Mean age 49. Most 
common genotypes were HPV16 (71%), 31 (7%), and 18, 45, 73 (4% each) 
16 Alsbeih 2011 Prevalence and genotypes' 
distribution of human 
papillomavirus in invasive 
cervical cancer in Saudi 
Arabia 
HPV in cervical 
cancer 
• 100 paraffin-embedded cervical tumours at KFSHRC, Riyadh 
• 89% HPV+. The most common genotypes were 16 (65.2%), 31 (7.9%), 45 
(6.7%), 18 (3.4%. but 10% when considering double infection). 16+18 
formed 79% of infections. 
• Only 40% from central region. Rest referred mainly from eastern region 
(30%). 




 Author Year Title Category Notes 
17 Abdullah 2007 2007 Pattern of abnormal 
Pap smears in developing 
countries: a report from a 
large referral hospital in 
Saudi Arabia using the 




• 5590 smears between 1995 and 2005, 77% negative, 4.6 % had cervical 
epithelial abnormalities, 0.37% SCC, 0.25% adenocarcinoma.  
• Referral centre most probably leading to higher results than even 
opportunistic screening.  
• Only Saudis. Usually as part of post-partum follow up or gynaecological 
complaint.  
• Mean age for SCC was 59, younger for lower grade lesions. 
18 Al-Jaroudi 2010 Prevalence of abnormal 
cervical cytology among 
subfertile Saudi women 
Abnormal 
cytology 
• 241 sub-fertile women in tertiary centre, mean age 40 (49% participation). 
• 2.9% epithelial cell abnormality. ASCUS 42.8%, ACS-H 14.3% LSIL 28.5% 
AGS 14.3% ;  
19 Al-Kadri 2015 Prevalence and 
characteristics of abnormal 
Papanicolaou smear in 
Central Saudi Arabia 
Abnormal 
cytology 
• Case control, department of obstetrics and gynaecology and 
histopathology, Riyadh, 2008-2011. 
• All pap-smears reviewed according to Bethesda 2001.  
• Abnormal cytology in 841 of 19,650 (4.3%) 
20 el Dosoky 1995 Preinvasive cervical 
carcinoma in Saudi Arabia 
Abnormal 
cytology 
• 1,515 cervical smears taken between 1985 and 1994 at KKNGH, Jeddah.  
• 25-60 years, routine on request or minor complaints (% not given). 
• 14 ICC detected, all in late stage (age 35-80), none had previous smear. 
• 2 severe, 4 moderate, 8 mild dysplasia (total 1.26%). 
21 Jamal 2003 Profile of Pap smear cytology 




• Retrospective, KAAUH, 1984-2000,. 
•  22,089 pap smears. 
• 1.7% abnormal pap. 0.28% CIN1 0.2% CIN2 0.12% CIN3 0.09% 
malignancy, 0.39 ASCUS. 0.16 AGUS, 1.17 SCC, 0.03% adenocarcinoma. 
(mean ages for each given) 
22 Nasser 2017 Eleven-year review of data 
on Pap smears in Saudi 
Arabia: We need more focus 
on glandular abnormalities! 
Abnormal 
cytology 
• 2006-16, n= 19,759 
• Riyadh Regional Laboratory at King Saud Medical City. 
• 1.98% abnormal pap. mean age 39 




 Author Year Title Category Notes 
23 Altaf 2001 Pattern of cervical smear 
cytology in the western 
region of Saudi Arabia 
Abnormal 
cytology 
• King Khalid NGH retrospective 1990-1997 pap-smears; 3,088 samples 
•  3.14% abnormal.  
• HSIL: 17 (0.55%) 
•  Invasive squamous cell: 4 (0.13%) 
24 Altaf 2012 Pattern of cervical smear 
abnormalities using the 
revised Bethesda system in a 
tertiary care hospital in 
Western Saudi Arabia 
Abnormal 
cytology 
• Jeddah, KAUH and Alkhadrah lab, all smears 2005-2009, n=7,297  
• Retrospectively reviewed and reclassified (Bethesda) 
• Epithelial cell abnormalities: 17.3%, ASCUS: 9.3% (mean age 40), ASC-H: 
0.8% (42) LSIL: 2.7% (47), HSIL: 0.9% (45), SCC: 0.06% (46) AGSUG: 
3.20%, GC favouring neoplasm: 0.10%, endometrial favouring neoplasm: 
0.08%. 
Repeat pap within short interval excluded. 
25 Balaha 2011 Cytological pattern of cervical 
Papanicolaou smear in 




• 2003-2012, n=1,171. Retrospective. 
• maternity hospital, eastern region (Alahsa)  
• ECA: 4.95%, ASCUS: 2.99% (45), ASC-H: 0.60%, LSIL: 0.09%, HSIL: 
0.68%, SCC: 0.34%, AGCUS: 0.09%. 
26 El. Mahalli 2015 Incidence and risk factors of 
abnormal cervical cytology in 




• Case-control. 2004–2013.  
• University hospital Al-khobar.  
• Cases=63 (Saudi women with positive result and contact data), 
controls=375. Mean age for cases was 45.97 ± 8. 
• Over 10 years, 1.8% (129) had abnormal results (CIS, ASCUS, AGUS, 
and ICC). 
• Higher risk in: IUD, older age, repeated pregnancies. Lower risk: condom 
use, previous pap. 
27 Elhakeem 2005 Cytopathological pattern of 
cervical Pap smear 
according to the Bethesda 




• 1994-2003, n=2,100. Retrospective 
• King Fahad Hospital, Albaha (the major referral hospital).  
• ECA: 7.90%, ASCUS: 2.8% (age peak incidence 30-39), ASC-H: 0.19 (40-
49), LSIL: 1.3% (50-59), HSIL: 0.7% (40-49), SCC: 0.3% (50-59), 




 Author Year Title Category Notes 
28 Haroon 2012 Role of pap smear in early 
diagnosis of cervical cancer- 




• 1/2009-1/2011, n=1475, prospective?  
• King Abdulaziz hospital and Oncology Centre, Jeddah. 
• ECA: 2.57%, ASCUS: 0.27%, LSIL: 1.02%, HSIL: 0.88%, SCC: 0.20% 
• First pap-smear for 83%, 79% of smears were done when presenting for 
gynaecological complaint. 
• Methods not clear.  
• All performed by the same physician. 
29 Mufti 2014 Changing pattern of epithelial 
cell abnormalities using 
revised Bethesda system 
Abnormal 
cytology 
•  1/2000-10/2012, n=15,805. Retrospective.  
• KAUH, Jeddah.  
• ECA: 14.50%, ASCUS7.1%(39), ASC-H: 1.08%(43), LSIL2.2%(45), 
HSIL0.86%(46) SCC: 0.05%(45), AGCUS: 2.4%(46), GC favouring 
neoplasm: 0.09%(53), endometrial favouring neoplasm: 0.01% (56)  
30 Jabbar 1988 Prevalence of carcinoma in 
situ and squamous dysplasia 
of the uterine cervix in 
Riyadh, Saudi Arabia 
Abnormal 
cytology 
• 1983-1986, 2,476 Saudi women. Mean age 28.Prospective. 
• KKUH gynaecology department.  
• 97.6% normal cytology. 
• Atypical squamous cells were detected in 2.4%. 
• 1.9% mild dysplasia, 0.2% moderate, 0.1% severe. No CIS or CC. 
• Low-income group of women had a slightly larger number of atypical 
squamous cells as compared to other income groups, smokers had higher 
risk.  
31 Al-Shahrani 2017 Cancer Incidence Report 




• Incidence by age and region. 
32 Saudi Health 
Council 
2002 Cancer Incidence Report 




• Cervical cancer 8th for Saudi females of all ages. 4th among non-Saudi 
females 
• Morphology distribution, incidence by region, highest: Tabuk, Najran, 
Qassim, Eastern.  
• mean age 51 (youngest 20)  





 Author Year Title Category Notes 
33 Saudi Health 
Council 
2011 Cancer Incidence Report Saudi cancer 
incidence 
reports 
• Incidence by age and region. 
34 Alhamlan 2016 Sociodemographic 
characteristics and sexual 
behaviour as risk factors for 
human papillomavirus 




• 400 Women attending family medicine and gynaecology departments for 
cervical examination at KFSHRC 2013-2015. Excluded those who did not 
complete the questionnaire. 
• HPV type distribution varied with age, and declined with age, associated 
with smoking, number of lifetime sexual partners.  
• 17% were HPV positive. 16% in those with 1 lifetime sexual partner. 
• 30% smokers. 
• Average age of first intercourse was 21.5 and median 20.  
• 12% had more than 1 lifetime sexual partner. 
35 Saudi Health 
Council 
2007 Cancer Incidence and 
Survival Report, Saudi 
Arabia 2007 
survival  • SCR has started collecting death certificates for cancer cases in 2005  
• 5-year overall survival 1994-2004 for Saudis for the 14 most common 
cancers: Breast, Colorectal, Non Hodgkin Lymphoma (NHL), Thyroid, 
Leukaemia, Liver, Lung, Hodgkin Disease, Stomach, Skin, Prostate, Urinary 
Bladder, Corpus Uteri, and Ovary. 
• Record linkage of 10 digit national number with the National Information 
Centre (NIC), Ministry of Interior through Al-Elm Information Security 
Company. 
Out of 15,484 case, Al-Elm company were able to match 5,141 patients 
whose names in Arabic correlated exactly with the 10-digit national ID 
number. 
36 Manji 1999 Carcinoma of cervix, the King 
Faisal Specialist Hospital & 
Research Center experience-
-the need for screening for 




• Retrospective, cervical cancer cases diagnosed April 1975-december 
1993 at KFSHRC, Riyadh. 
• Ages 20-90 (median 50).  
• Of 504 patients, 410 received treatment with curative intent (radical 
surgery, radiation or both). 
• Overall 5-year survival was 55%, and 61% for those treated with curative 
intent. 




 Author Year Title Category Notes 
• 75% stage I ,70% stage II , 41% stage III, 11 % stage IV (4 years)  
Stage specific survival was similar to developed countries but 2/3 presented 
in advanced stage.  
37 El Sayed 2017 Outcome of cervix uteri 
cancer patients: Clinical 
treatment results and toxicity 
profile in a retrospective 
study from Saudi Arabia 
cervical cancer 
survival  
• 2004-2010, N=60. 
• King Faisal Specialist Hospital and Research Center, Jeddah and King 
Abdulaziz University Hospital, Jeddah. Retrospective chart review.  
• 69% presented in stage IIB, 23% higher (15% III, 3% IV) and 8 % lower 
(5% IB, 3% IIA) 
• 78% received Cisplatin + radiotherapy. 
• Median follow-up period was 24 months (range: 6–77 months). 
• Mean survival time 65 months. 
• The 2- and 4-year overall survival (OS) was 82% and 79%. Disease free 
survival: 80% and 69%. 
Treatment and complication results and predictors of survival given. 
38 Al Asiri 2013 Five-year outcome of 
concurrent radiotherapy and 
chemotherapy in Saudi 





• 2007-2012, retrospective. King Fahad Medical City , Riyadh  
• 74 patients with histologically proven locally advanced cervical cancer (IIB-
IVA) receiving three-dimensional conformal radiotherapy with concurrent 
chemotherapy followed by high dose rate brachytherapy. 
• Median follow-up period = 60 months (range, 8-66). 
• Median age of = 52.3 years (32-78). 
• 66% stage IIB. 
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